Detailed Schedule - Sunday, April 6

Transcription

11_14AM_Sun_Layout 1 3/11/14 12:35 PM Page 189
SUNDAY, APRIL 6
AT-A-GLANCE
All sessions eligible for CME credit
unless otherwise noted.
7:00 a.m.-8:00 a.m.
Meet-the-Expert Sessions
191-194
7:00 a.m.-8:00 a.m.
NCI/NIH-Sponsored Session
195
8:15 a.m.-9:15 a.m.
Opening Ceremony and
Award Presentations
196-207
9:15 a.m.-12:15 p.m.
Opening Plenary Session
208-209
12:45 p.m.-2:00 p.m.
210
1:00 p.m.-3:00 p.m.
Current Concepts in Diagnostics
and Therapeutics Research
211-212
1:00 p.m.-3:00 p.m.
Current Concepts in Epidemiology
and Prevention Research
213
1:00 p.m.-3:00 p.m.
Current Concepts in Organ Site Research
214
1:00 p.m.-3:00 p.m.
Drug Development Track: Special Session
215
1:00 p.m.-3:00 p.m.
Major Symposia
216-220
1:00 p.m.-3:00 p.m.
Science Policy Session
221
1:00 p.m.-5:00 p.m.
Poster Sessions
222-255
1:00 p.m.-5:00 p.m.
Late-Breaking Poster Sessions
256
1:15 p.m.-1:45 p.m.
Meet the Research Icon
257
1:30 p.m.-3:00 p.m.
MICR Meet and Greet
258
2:00 p.m.-4:00 p.m.
AMC Meet and Greet
259
2:00 p.m.-4:00 p.m.
WICR Meet and Greet
260
2:15 p.m.-3:00 p..m
261
3:15 p.m.-4:30 p.m.
Jane Cooke Wright Memorial Lectureship
262
3:15 p.m.-4:45 p.m.
263
3:15 p.m.-5:15 p.m.
Clinical Trials Symposium
264
April 5-9, 2014 • San Diego, CA
189
SUNDAY, APRIL 6
AT-A-GLANCE
All sessions eligible for CME credit
unless otherwise noted.
3:15 p.m.-5:15 p.m.
Drug Development Track: Special Session
265
3:15 p.m.-5:15 p.m.
Minisymposia
266-271
3:30 p.m.-4:30 p.m.
Meet and Greet
272
3:45 p.m.-5:15 p.m.
Special Session
273
4:00 p.m.-5:00 p.m.
Meet the Pancreatic Cancer Research Icon
274
4:15 p.m.-4:45 p.m.
Meet the Research Icon
275
4:30 p.m.-5:30 p.m.
Pezcoller Foundation-AACR Lecture
276
5:30 p.m.-6:30 p.m.
Presidential Address
277
6:00 p.m.-7:30 p.m.
MEG Town Meeting
278
6:30 p.m.-8:30 p.m.
PCWG Town Meeting
279
6:30 p.m.-8:30 p.m.
TME Town Meeting
280
9:00 p.m.-12:00 a.m.
Annual Reception
281
190
AACR ANNUAL MEETING 2014
MEET-THE-EXPERT SESSIONS
Room 7, San Diego Convention Center
Cellular Senescence – A Flawed Tumor
Suppressor Mechanism?
Peter D. Adams, University of Glasgow, Glasgow, United
Kingdom
In recent years, a substantial body of evidence has
accumulated to support the idea that cellular
senescence functions as a tumor suppressor
mechanism. As a result, senescence has increasingly
been viewed as a programmed and efficient tumor
suppressor process. However, more recent molecular
analyses of senescent cells have challenged this view:
While senescent cells do have tumor suppressive
capability, for example in benign human nevi, some
features of senescent cells, for example their secretory
program and epigenomes, appear to predispose these
cells to malignancy. A better understanding of the
conflict played out in senescent cells – tumor
suppression vs. progression – is critical for risk
assessment, early detection, and chemoprevention
strategies targeted towards premalignant senescent
cells, as well as for therapies towards malignant cancer
cells.
Room 28A-C, San Diego Convention Center
The Dominant Immune Suppressive
Process in a Model of Pancreatic Ductal
Adenocarcinoma: A Therapeutic Target
Douglas T. Fearon, Cancer Research UK Cambridge
Research Institute, Cambridge, United Kingdom
Human pancreatic ductal adenocarcinoma (PDA) is
resistant to therapy with T cell checkpoint antagonists,
suggesting either that the tumors are not immunogenic,
or that another immune suppressive process exists. This
session will discuss recent studies (Kraman M, et al.
Science 2010; and Feig C, et al., PNAS 2013) that
provide evidence for the immune suppressive role of the
carcinoma-associated fibroblast (CAF) that expresses
fibroblast activation protein (FAP). Depleting FAP+ CAFs
from PDA tumors of the KPC mice (Hingorani and
Tuveson, Cancer Cell 2005) allows immune control of
tumor growth. Immune suppression by the FAP+ CAF is
mediated by its biosynthesis of the chemokine, CXCL12,
which physically associates with PDA cancer cells and
prevents the accumulation of T cells. Treating mice with
Sunday, 7:00 a.m.-8:00 a.m.
AMD3100, an antagonist of the CXCL12 receptor,
CXCR4, causes the rapid appearance of intratumoral T
cells, unveils PDA sensitivity to antibody to PD-L1, and
eliminates cancer cells. Since many studies have shown
that the KPC model of PDA replicates the human
disease in many respects, these findings have prompted
plans for assessing the effect of blockade of CXCR4 in
human PDA.
Room 6A, San Diego Convention Center
Enhancing the Impact of Targeted
Therapy Through Drug Combinations
Robert Schlegel, Novartis Institutes for BioMedical
Research, Cambridge, MA
Therapies targeting specific genetic and pathway lesions
in tumors have provided exciting new approaches to
cancer treatment. While there have been remarkable
clinical responses to these agents, there still remain
significant areas for improvement. For example, it is
often unclear why some tumors that harbor the genetic
lesion being targeted respond while others do not. In
addition, tumors that undergo complete or partial
responses often relapse within months or years. Efforts
to improve both initial response rates and durability of
response have led to increasing interest in the discovery
and clinical application of combination therapies. This
presentation and ensuing discussion will help define the
unmet medical need driving the use of combination
therapy, outline major research approaches used to
identify the most promising combinations, and give
examples of recent combination discoveries and their
clinical efficacy.
191
Genetic Dissection of the Tumor
Microenvironment using RNAi Whole
Genome Screens in C. Elegans
Gustavo Leone, Ohio State University Comprehensive
Cancer Center, Columbus, OH
Stromal fibroblasts are co-opted by epithelial tumor cells
early in carcinogenesis, but the identification of stromal
signaling networks that potentiate progression remains a
major challenge. We exploited conserved developmental
pathways in C. elegans vulval development, stromaspecific RNAi, and a cancer-like sensitized worm strain
to discover 39 novel stromal factors that suppress tumor
cell proliferation. Strikingly, stromal candidates “hit”
different components of the same protein complex
and/or conserved pathway with functions in chromatin
dynamics, cytoplasmic polyadenylation, and translation
control. An expression signature of the 31 stromal
human orthologues distinguished normal- from tumorstroma in triple-negative breast cancer patients, and
their depletion from stromal fibroblasts accelerated
tumor cell proliferation in co-culture assays. This work
identifies stromal pathways with unanticipated cell nonautonomous tumor suppressor function and highlights
the exquisite specificity and conservation of tumorstroma communication.
Room 6CF, San Diego Convention Center
The LKB1-AMPK Tumor Suppressor
Pathway: Metabolic Reprogramming
and Therapeutic Targeting
Reuben J. Shaw, The Salk Institute, La Jolla, CA
The serine/threonine kinase LKB1 is a tumor suppressor
gene mutated in the familial cancer condition PeutzJeghers syndrome, as well as in 30% of non-small cell
lung cancer (NSCLC). One of the critical substrates of
LKB1 is AMPK, a highly conserved sensor of cellular
energy status that restores metabolic homeostasis
following stress. Thus LKB1 is a unique energy-state
sensitive regulator of growth and metabolic
reprogramming via its effects on AMPK. Our laboratory
has performed a three-pronged screen to identify novel
substrates of AMPK and related kinases that may
mediate LKB1 effects on tumor suppression, metabolism,
and metastasis. These findings have also spurred
192
examination of whether compounds that activate AMPK
may exhibit anticancer activities. Notably, the most widely
used type 2 diabetes therapeutic in the U.S. and
worldwide, metformin, is a mitochondrial OXPHOS
inhibitor that activates AMPK. We have therefore
examined the potential anticancer effects of metformin
and compounds against other metabolic targets.
Molecular Genetics of Diffuse Large B
Cell Lymphoma
Riccardo Dalla-Favera, Columbia University Institute for
Cancer Genetics, New York, NY
Diffuse large B cell lymphoma (DLBCL) represents the
most common form of B cell derived non-Hodgkin
lymphoma (B-NHL), accounting for ~30% of the de novo
diagnoses and also arising as a frequent clinical
evolution of follicular lymphoma (FL), the second most
common type of B-NHL. DLBCL and FL derived from
B cells at different stages of germinal center (GC)
development. In order to identify the genetic lesions
associated with DLBCL pathogenesis, we have
integrated whole-exome sequencing analysis and copy
number variation analysis for a comprehensive definition
of the DLBCL coding genome. The results have
identified a novel set of recurrent genetic lesions, which,
in turn, identify mutant genes regulating important
pathways involved in GC development, including those
involved in chromatin remodeling, transcriptional control
of apoptosis and differentiation, and immune escape.
The normal role of the DLBCL-associated mutant genes,
as well as their role in tumor initiation and progression,
has been investigated in GC-directed conditional
transgenic mice.
Sunday, 7:00 a.m.-8:00 a.m.
Room 6B, San Diego Convention Center
Molecular-Driven Therapies for
Colorectal Tumors
NextGen Cancer Research: Why the
Existing Siloed, Guild-Like System Will
Soon Be Less Relevant
Alberto Bardelli, IRCC - University of Turin, Medical
School, Candiolo, Italy
It is now evident that colorectal cancers (CRC)
indistinguishable by light microscopy are actually distinct
diseases requiring unique therapeutic approaches.
Tissue and liquid biopsies can be used to define CRC
molecular subtypes and to monitor response and
resistance to therapy. Using these approaches, CRC
patients were found to respond selectively to targeted
agents interfering with oncogenic nodes of the EGFR
signaling pathway. Notably, the patient-specific
responses can be recapitulated and paralleled in cellular
and mouse clinical proxies (CRC-avatars). The inevitable
development of acquired resistance to inhibitors of the
EGFR signaling pathway presently limits further clinical
advances. Strategies to prevent or overcome resistance
are therefore essential to design the next generation of
molecularly driven clinical trials for CRC patients.
Room 29A-D, San Diego Convention Center
New Insights into Targeted Therapies
for Myeloma
Kenneth C. Anderson, Dana-Farber Cancer Institute,
Boston, MA
This session will describe advances in genomics and
biology of myeloma that have and will translate to novel
therapies for myeloma. It will review current treatment
paradigms and ongoing clinical trials, as well as describe
promising targeted small molecule and immune
therapies, combination therapies, and the impact of
genomics on personalized medicine in myeloma.
Stephen H. Friend, Sage Bionetworks, Seattle, WA
After working in academia (DFCI, FHCRC), building a
biotech (Rosetta Inpharmatics), and leading Oncology
Discovery at Merck, I chose five years ago to pull out of
the formal system to set up a non-profit called “Sage
Bionetworks” in Seattle. At Sage Bionetworks we believe
that the advances needed for carrying out “precision
medicine” will be best harnessed when individuals and
groups can collaborate openly on discoveries, with a
fundamental shift in the traditional roles and rewards for
individuals and organizations involved. We have been
working to redefine how complex biological data are
gathered, shared, and used through the adoption of
open systems and new incentive strategies. We
challenge the traditional roles of patients, postdocs, and
PIs. Our work includes building platforms and services
and undertaking research to develop predictors related
to health. We collaborate with a network of partners and
individuals to accelerate and enhance the impact
biomedical research has on improving health. This past
year we have seen the power of providing credit to
scientists for not just sharing their ideas but also their
insights in real time. We have been fortunate to work
with communities interested in conditions ranging from
colon cancer and AML to schizophrenia. We have seen
the benefit of open collaborations on breast cancer,
toxicogenomics, and base-pair calling in tumor samples.
We will discuss alternatives to the current closed, siloed,
first author- / H Factor-driven treadmill that looks more
and more irrelevant. Come if you think that you are
courageous enough to contemplate alternative incentive
strategies for scientists to conduct open, collaborative
research.
193
Sunday, 7:00 a.m.-8:00 a.m.
Ballroom 20D, San Diego Convention Center
p53 and Normal Tissue Injury
by Radiation
Targeting the Epigenome to
Treat Cancer
David G. Kirsch, Duke University Medical Center,
Durham, NC
Ricky W. Johnstone, Peter MacCallum Cancer Center,
Melbourne, Australia
The tumor suppressor p53 not only plays an important
role in tumor development, but also mediates the
response of some normal tissues to radiation therapy.
Activation by p53 can induce cell death or promote cell
cycle arrest in a cell-type dependent manner. Although
inhibiting p53 protects some tissues from radiation, loss
of p53 can sensitize other tissues to radiation. These
preclinical results will be reviewed and implications for
combining p53 inhibitors with radiation therapy will
be discussed.
Altered expression, function, or localization of epigenetic
enzymes and/or their partner proteins can play a crucial
role in cancer onset and progression. Histone writers
and erasers that regulate histone acetylation or
methylation, or histone readers that recognize specific
histone marks, play important roles in tightly regulating
gene expression through the remodeling of chromatin
and these proteins are promising targets for therapeutic
interventions intended to reverse aberrant epigenetic
states associated with cancer. I will outline our current
understanding of altered epigenetic regulation in cancer
onset and progression, the development of small
molecule inhibitors of epigenetic enzymes and/or key
partner proteins, and the molecular, biological, and
clinical consequences of inhibiting these proteins.
Primary Xenografts to Model Cure of
Hematologic Neoplasms
David M. Weinstock, Dana-Farber Cancer Institute,
Boston, MA
The increasing availability of primary leukemia,
lymphoma, and myeloma xenografts has made it
possible to assay efficacy, mechanism of action, and
resistance for experimental therapeutics using human
samples in vivo. Approaches that model clinical
heterogeneity across panels of primary xenografts (akin
to murine phase II trials) can guide patient selection and
the development of biomarkers. A broad range of
targeted inhibitors, with or without conventional
chemotherapy, can induce complete responses in
hematologic malignancy xenografts. This creates a
unique opportunity to model and interrogate minimal
residual disease (MRD), the obstacle between response
and cure for many patients.
194
NCI/NIH-SPONSORED SESSION
Sunday, 7:00 a.m.-8:00 a.m.
(not eligible for CME credit)
Room 28D-E, San Diego Convention Center
NIH Grants Session: Changes in Review, Funding, and Funding
Opportunities at the NCI
Chairperson: Suresh Mohla, National Cancer Institute-DCB, Rockville, MD
This session, held at every AACR annual meeting since the early 1990s, is primarily focused on
familiarizing new applicants with the NIH grants submission, review, and funding processes. The
session is predominantly focused on R01/R21 type grant applications since there are other NCI
sessions focusing primarily on training and mentoring grant applications. Traditionally, this is a
team effort between NCI and CSR. The one-hour session will include presentations from an SRO
and an NCI Program Director, after which there will be an opportunity for questions. The session
has been very popular with new, junior, and senior investigators because the speakers present
new policies, procedures, and funding opportunities that are available to applicants.
The major theme of this session is how to be proactive in preparing grant applications. A variety of
topics are discussed including how applicants can self-refer their applications, and issues related
to “grantsmanship” such as the common mistakes made in research applications and how to
avoid them. It is a great opportunity for applicants to meet with NCI Program Staff, and with CSR
and NCI Scientific Review Officers. The NCI and CSR staff will be available to meet either
immediately after the session or in the NCI Resource Room for the duration of the meeting.
Overall, this has been a successful forum to provide an overview of NCI paylines, plans and
programs, funding opportunities, changes in grant submissions process, and other significant
changes in review at CSR and NCI.
Speaker: Angela Y. Ng, National Institutes of Health-CSR, Bethesda, MD
NCI Resource Room
The NCI Grants Resource Room, located in Room 10 of the San Diego Convention Center,
provides information and handouts related to new research initiatives and information on the grant
application process, including Program and Review staff contacts. Program and Review staff of
the NCI as well as Review staff from CSR will be available at the Resource Room for discussions
and consultation throughout the meeting. A list with details of specific NCI and CSR staff
availability will be posted in the room. Conferences can be scheduled to discuss individual
grant/review questions. Interested members of the scientific community are encouraged to meet
with Program or Review staff to clarify specific issues or other items of interest. New investigators
are especially encouraged to meet with Program staff handling grant portfolios in their area of
scientific interest. The Resource Room will be open from 9:00 a.m. to 5:00 p.m. Sunday through
Tuesday, and from 9:00 a.m. until 12:00 p.m. on Wednesday.
195
OPENING CEREMONY
Join us on Sunday for the Annual Meeting Opening Ceremony, a
yearly tradition marking the start of four days filled with
outstanding and innovative science.
AACR CEO Margaret Foti, PhD, MD (h.c.), will address attendees
and discuss the immense progress the AACR has made over the
past year.
AACR President Charles L. Sawyers, MD, will highlight the
dramatic advances in cancer research and today’s challenges to
the cancer field.
The Opening Ceremony will also feature the presentation of some
of the AACR’s most prestigious awards, including:
• The Eighth Annual AACR Team Science Award
• The Eleventh Annual AACR Award for Lifetime Achievement in
Cancer Research
• Recognition of the 2014 Class of Fellows of the AACR Academy
• Presentation of the Young Champion in Cancer Research Award
to Elena Simon
• The Eighth Annual AACR Margaret Foti Award for Leadership
and Extraordinary Achievements in Cancer Research
Don’t miss this exciting event, which leads
directly into the opening plenary session!
196
Sunday, 8:15 a.m.-9:15 a.m.
Hall F-G, San Diego Convention Center
Eighth Annual AACR Team
Science Award
2014 The Duke, Hopkins, National
Cancer Institute Malignant Brain
Tumor Team
NCI
Darell D. Bigner, Duke University Medical Center,
Durham, NC
Bert Vogelstein, Johns Hopkins Kimmel Comprehensive
Cancer Center, Baltimore, MD
Ira H. Pastan, National Cancer Institute, Bethesda, MD
Duke University
Daniel Barboriak, Duke University Medical Center, Durham, NC
Oren J. Becher, Duke University Medical Center, Durham, NC
Thomas J. Cummings, Duke University Medical Center, Durham, NC
Johns Hopkins
Annick Desjardins, Duke University Medical Center, Durham, NC
Luis A. Diaz, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD
Allan H. Friedman, Duke University Medical Center, Durham, NC
Henry S. Friedman, Duke University Medical Center, Durham, NC
Matthias Gromeier, Duke University Medical Center, Durham, NC
Sridharan Gururangan, Duke University Medical Center, Durham, NC
Yiping He, Duke University Medical Center, Durham, NC
Kenneth W. Kinzler, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD
Chien-Tsun Kuan, Duke University Medical Center, Durham, NC
Roger E. McLendon, Duke University Medical Center, Durham, NC
Nickolas Papadopoulos, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD
Katherine B. Peters, Duke University Medical Center, Durham, NC
Tulika Ranjan, Duke University Medical Center, Durham, NC
B. K. Ahmed Rasheed, Duke University Medical Center, Durham, NC
John H. Sampson, Duke University Medical Center, Durham, NC
Victor E. Velculescu, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD
Gordana Vlahovic, Duke University Medical Center, Durham, NC
Jason A. Watts, Duke University Medical Center, Durham, NC
Hai Yan, Duke University Medical Center, Durham, NC
Michael R. Zalutsky, Duke University Medical Center, Durham, NC
197
OPENING CEREMONY (not eligible for CME credit)
Team Science Award (cont’d)
The AACR Team Science Award has been established by the American Association for Cancer
Research and Eli Lilly and Company to acknowledge and catalyze the growing importance of
interdisciplinary teams to the understanding of cancer and/or the translation of research
discoveries into clinical cancer applications.
The AACR Team Science Award recognizes an outstanding interdisciplinary research team for its
innovative and meritorious science that has advanced or likely will advance our fundamental
knowledge of cancer or a team that has applied existing knowledge to advance the detection,
diagnosis, prevention, or treatment of cancer.
The Duke, Hopkins, National Cancer Institute Malignant Brain Tumor Team is an interdisciplinary
team that includes faculty from Duke, Johns Hopkins, and the NCI. Their findings have informed
both the basic science and clinical communities in managing diagnosis, prognosis, and treatment
of brain tumors.
Working together against this cancer, the team identified several major genetic aberrations in GBM
tumors that provided novel insights. One of their first discoveries was the amplification of a gene
called GLI in GBMs. This gene has since been found to be a critical component of the Hedgehog
signaling pathway and continues to be subject of intense research in both cancer and
developmental biology.
Their next major discovery was a deletion mutant of EGFR called EGFRvIII that is exclusively
found in GBMs. The team developed, and continues to develop, novel therapeutics targeting
these drivers. One of these is an EGFRvIII therapeutic vaccine currently being tested in an
international phase III clinical trial. Additionally, they have developed immunotoxins that target
both of these drivers. The first clinical trial involving one of these immunotoxins showed that it was
safe and that some patients benefited.
They were the first to describe the genomic landscapes of GBMs, reporting the sequence, copy
number, and expression of every gene in the human genome in more than 20 cancers. In addition
to providing the basic outline of GBM genomics, this work revealed that a gene called IDH1 was
mutated in a subgroup of GBMs. They went on to discover that mutations in IDH1, or the related
gene IDH2, were mutated in a large fraction of gliomas of various types. IDH1 was the first novel
cancer gene to be discovered through unbiased genome-wide sequencing and has had a plethora
of diagnostic and therapeutic implications.
One of their latest discoveries was that of mutations in genes (ATRX or TERT) controlling telomere
maintenance in both GBMs and lower grade gliomas. In addition to illuminating the biology of
these tumors and their potential relationship to normal stem cells, these mutations provide a
remarkably simple approach to the diagnostic classification of gliomas based on genetic rather
than histopathologic features.
The team also used their molecular analyses of GBM tumors as a foundation to unravel some of
the biologic abnormalities that characterize these cancers. This information led them to develop a
genetically modified poliovirus that has lost the ability to kill nerve cells and cause poliomyelitis,
but retains the ability to kill tumor cells. Early results of a phase I trial testing this oncolytic
poliovirus are promising.
The development of new methods of brain tumor diagnosis and treatment requires integration of
basic, translational, and clinical research from a multidisciplinary team of experts. This team’s
collaborative efforts have undoubtedly enhanced the scientific field and ultimately will improve the
lives of those with brain tumors.
198
Sunday, 8:15 a.m.-9:15 a.m.
Hall F-H, San Diego Convention Center
Eleventh Annual AACR Award for Lifetime Achievement in
Cancer Research
Douglas Hanahan, PhD
Director, Swiss Institute for Experimental Cancer Research (ISREC)
Professor, Swiss Federal Institute of Technology Lausanne (EPFL)
Vice-Director, Swiss Cancer Center Lausanne
Lausanne, Switzerland
The American Association for Cancer Research Award for Lifetime Achievement in Cancer
Research was first established in 2004 to honor individuals who have made significant
fundamental contributions to cancer research, either through a single scientific discovery or a
collective body of work. These contributions, whether they have been in research, leadership, or
mentorship, must have had a lasting impact on the cancer field and must have demonstrated a
lifetime commitment to progress against cancer.
Dr. Douglas Hanahan has made numerous seminal contributions to cancer research, both in terms
of his research and the tools he developed, as well as in his broad influence and impact in the
community. Dr. Hanahan has a keen ability to integrate multiple subareas of cancer research from
genomics and oncogenes to tumor microenvironment to immune modulation, attesting to his
incredibly broad bandwidth and ability to seamlessly integrate ideas from traditionally separate
areas of cancer research.
As a graduate student, Dr. Hanahan developed new procedures for plasmid transformation and
DNA cloning that vastly improved efficiency, in turn facilitating molecular genetics research as a
whole. He then went on to engineer some of the first transgenic mouse models of cancer,
including a pancreatic tumor model that has proved to be a valuable prototype of multistage
tumorigenesis, widely used to this day. He worked closely with Judah Folkman, and together they
discovered the “angiogenic switch” using his mouse cancer models. Subsequent research helped
identify mediators of tumor angiogenesis, and promoted the field of antiangiogenic therapy. His
involvement and contributions to the field of tumor angiogenesis continue to this day. More than
20 years ago he began using genetically engineered mouse models of cancer to evaluate
mechanism-guided therapies aimed at tumor angiogenesis and other tumor phenotypes; his
efforts helped incentivize clinical trials that changed the standard of care for human pancreatic
neuroendocrine cancer.
Dr. Hanahan broadly explored the potential of using transgenic models as probes into complex
mammalian systems; for example he also made significant contributions to understanding
autoimmunity towards the insulin-producing islet beta cells. He provided one of the first
demonstrations that self-tolerance and autoimmunity could be modeled by transgenic introduction
of neoantigens into mouse germlines, which in turn revealed the existence of rare peripheral
antigen-expressing cells in the thymus involved in induction of self-tolerance. His work
documenting insulin gene expression in the thymus helped establish the now well-accepted
199
Lifetime Achievement in Cancer Research Award (cont’d)
concept that “ectopic” gene expression by cells in the thymus were involved in establishing selftolerance to rare self-antigens. His lab went on to develop other transgenic mouse models for
immunology research, including T cell receptor transgenic mice that were informative about the
limited capacity of islet beta cells to tolerize self-reactive T cells.
Dr. Hanahan’s multidisciplinary expertise also allowed him to contribute to the understanding of
the tumor microenvironment. He was among the first to show that the tumor microenvironment
was actually a barrier to antitumor cytotoxic T cell attack, a concept that is now well-accepted. He
also helped establish the concept that inflammation could be tumor-promoting, exploring
interactions between tumor-infiltrating immune cells, cancer-associated fibroblasts, tumorassociated vascular cells, and extracellular matrix proteases, which through their interactions with
cancer cells influence tumor development and progression. His recent and ongoing work includes
studies on genetic signatures and physical cues in the microenvironment that modulate tumor
invasion and metastasis, with promise to further advance knowledge of cancer mechanisms and
therapeutic applications.
While his scientific contributions are unquestionable, his impact on the field extends in many other
ways. Dr. Hanahan trained and promoted the careers of a growing cadre of prominent young
cancer researchers. He co-authored with Robert Weinberg a highly cited perspective, “The
Hallmarks of Cancer,” which presented an organizing principle that has served to conceptually
integrate the vast complexity of cancer. Currently, Dr. Hanahan is a professor in the Swiss Institute
for Experimental Cancer Research at EPFL. His colleagues credit him with transforming the cancer
research community in Lausanne by recruiting exciting talent and helping bring together clinical
and basic cancer researchers, and inspiring new directions in integrative cancer research, in
particular the creation of the new multi-institutional Swiss Cancer Center Lausanne (SCCL), which
seeks to become the first comprehensive cancer center in Switzerland. Thus continuation of his
contributions to cancer science and medicine can be anticipated.
200
Sunday, 8:15 a.m.-9:15 a.m.
Fellows of the AACR Academy
Class of 2014
The AACR Academy serves to recognize and
honor distinguished scientists whose major
scientific contributions have propelled significant
innovation and progess against cancer. These
Fellows have been selected through a rigorous
peer review process that evaluates individuals on
the basis of their stellar scientific achievements in
cancer research. The AACR Academy is proud to
have inducted its second class of illustrious
Fellows at the 2014 Annual Meeting.
Congratulations to
the Class of 2014!
201
Fellows of the AACR Academy Award (cont’d)
Jerry Adams, PhD
James P. Allison, PhD
Mariano Barbacid, PhD
José Baselga, MD, PhD
Stephen Baylin, MD
Günter Blobel, PhD
David Botstein, PhD
202
Joan S. Brugge, PhD
Sunday, 8:15 a.m.-9:15 a.m.
Lewis C. Cantley, PhD
Pierre Chambon, MD
Hans Clevers, PhD
James E. Darnell Jr., MD
Titia de Lange, PhD
Vincent T. DeVita, Jr., MD
Lawrence H. Einhorn, MD
Stephen J. Elledge, PhD
203
OPENING CEREMONY
Ronald M. Evans, PhD
Andrew Z. Fire, PhD
Emil J Freireich, DSc, MD
Robert C. Gallo, MD
Douglas Hanahan, PhD
Richard O. Hynes, PhD
William G. Kaelin Jr., MD
204
Kenneth W. Kinzler, PhD
Sunday, 8:15 a.m.-9:15 a.m.
Richard D. Kolodner, PhD
Ronald Levy, MD
Frederick P. Li, MD
David M. Livingston, MD
Paul A. Marks, MD
Peter C. Nowell, MD
Christiane Nüsslein-Volhard, PhD
205
OPENING CEREMONY
Sir Richard Peto, FRS
Axel Ullrich, PhD
Charles L. Sawyers, MD
Sir Michael R. Stratton, MBBS, PhD, FRS
Inder M. Verma, PhD
Irving L. Weissman, MD
Owen N. Witte, MD
206
Sunday, 8:15 a.m.-9:15 a.m.
Eighth Annual AACR Margaret Foti Award for Leadership
and Extraordinary Achievements in Cancer Research
Webster K. Cavenee, PhD
Director, Ludwig Institute for Cancer Research, San Diego
Distinguished Professor, University of California at San Diego
La Jolla, CA
The American Association for Cancer Research
established this Award in 2007 in honor of Margaret Foti,
PhD, MD (h.c.) for her exemplary leadership of the AACR
as its Chief Executive Officer; for her sustained,
outstanding work in fostering research, scholarly
communications, education and training, science policy,
and public education; and for her extraordinary
dedication and contributions to the conquest of cancer.
The Award recognizes a true champion of cancer
research, an individual who embodies the sustained
commitment of Margaret Foti to the prevention and cure
of cancer. The Award is given to an individual whose
leadership and extraordinary achievements in cancer
research or in support of cancer research have made a
major impact on the field. Such achievements may
include scientific contributions to the acceleration of
progress against cancer, significant accomplishments in
the national or international awareness of the importance
of cancer research, or other ways demonstrating a
sustained extraordinary commitment to cancer research.
Dr. Webster K. Cavenee, Director of the Ludwig Institute
for Cancer Research, San Diego, and distinguished
professor at the University of California, San Diego, is
being recognized for his pioneering work in cancer
genetics, his leadership in the global fight against one of
the most lethal cancers, glioblastoma multiforme, and
his service to the AACR for more than 25 years.
Much of Dr. Cavenee’s career has been spent unraveling
the inherited genetic changes that predispose individuals
to cancer. His pioneering work in retinoblastoma
provided the first indisputable genetic evidence for the
existence of tumor suppressor genes in humans and
confirmed the “two-hit” hypothesis, which had been
proposed more than a decade earlier. He went on to
identify other recessive genetic lesions that predispose
individuals to Wilm’s tumor, osteosarcoma, and
rhabdomyosarcoma, and established the concept of loss
of heterozygosity, which is now known to contribute to
multiple cancers, both spontaneous and hereditary.
Dr. Cavenee has also made key contributions to
understanding of the biology of glioblastoma multiforme.
His research in this area has helped illuminate the
molecular mechanisms that drive the growth, migration,
and survival of glioblastoma multiforme cells and
identified potential new therapeutic approaches.
In addition to his extraordinary research
accomplishments, Dr. Cavenee is an active leader in the
global fight against glioblastoma multiforme. As a
member of the Strategic Scientific Advisory Council of
the Defeat GBM Research Collaborative, he is playing a
key role in developing initiatives that aim to double the
five-year survival rate for glioblastoma multiforme
patients in just five years.
Dr. Cavenee was named among the inaugural class of
Fellows of the AACR Academy in 2013. In addition, he
has been recognized with numerous other awards
throughout his career, including the AACR Princess
Takamatsu Memorial Lectureship, the Albert Szent
Gyorgyi Award from the National Foundation for Cancer
Research, the Anthony Dipple Award from the European
Association for Cancer Research, and the Farber Prize
from the American Association of Neurological
Surgeons. He is also an elected member of the National
Academy of Science of the United States of America and
the Institute of Medicine of the National Academies.
Dr. Cavenee received his undergraduate degree from
Kansas State University in Manhattan, Kan., and his
doctorate from the University of Kansas Medical School
in Kansas City. After completing postdoctoral work at the
Jackson Laboratory and the University of Utah, Dr.
Cavenee held professorships at the University of
Cincinnati in Ohio and McGill University in Montreal,
Quebec, Canada. He has been director of the Ludwig
Institute for Cancer Research, San Diego, since 1991.
207
OPENING PLENARY SESSION
Harnessing Breakthroughs, Targeting Cures
Chairperson: Scott W. Lowe, Memorial Sloan-Kettering Cancer Center, New York, NY
9:15 a.m.
Transcriptional and epigenetic
control of tumor cells
Richard A. Young
MIT Whitehead Institute for
Biomedical Research
Cambridge, MA
9:45 a.m.
The two faces of p53: Tumor
suppressor and oncogene
Carol L. Prives
Columbia University
New York, NY
10:15 a.m.
Final results of a randomized phase 2 study of
PD 0332991, a cyclin-dependent kinase (CDK)
4/6 inhibitor, in combination with letrozole vs.
letrozole alone for first-line treatment of ER+
HER2- advanced breast cancer (PALOMA-1,
TRIO-18)
Richard S. Finn
University of California
Los Angeles, CA
10:35 a.m.
Discussant
José Baselga
Memorial Sloan-Kettering Cancer Center
New York, NY
208
Sunday, 9:15 a.m.-12:15 p.m.
10:45 a.m.
New lymphoma therapies
based on functional and
structural genomics
Louis M. Staudt
National Cancer Institute-CCR
Bethesda, MD
11:15 a.m.
Diet and cancer:
Status report in 2014
Walter C. Willett
Harvard School of Public Health
Boston, MA
11:45 p.m.
Tumor-specific immune activation:
Immuno-oncology comes of age
Roger M. Perlmutter
Merck Research Laboratories
Rahway, NJ
209
Sunday, 12:45 p.m.-2:00 p.m.
NCI Training Workshop: Fellowships, Career Development Awards,
and Transitioning to Independence
Chairperson: Ming Lei, National Cancer Institute-CCT, Bethesda, MD
The National Cancer Institute provides numerous opportunities for the training the next generation
of cancer scientists. These include fellowships within the walls of the NCI in the intramural
research program studying all aspects of cancer including AIDS, behavioral research,
epidemiology, clinical sciences, basic cancer biology, and translational research. The NCI also
funds training at universities and other extramural institutions across the nation. These funding
mechanisms include institutional support, individual career development awards, and fellowships
to individuals. This first half of this session will provide a broad overview of this wide range of
opportunities to support training. Presentations will describe the extramural funding mechanisms
managed by the Cancer Training Branch, as well as training opportunities in NCI’s three intramural
research programs. The second part of this workshop will provide expert advice to career
development (K) awardees about how to obtain the first R01 award. Two former NCI K awardees
will share with participants their scientific paths and experiences in successfully competing for
R01 awards. Four NCI program directors who manage R01 awards will provide advice and answer
questions in a panel discussion session.
Training opportunities in the NCI intramural programs
Jonathan S. Wiest, National Cancer Institute-CCT, Bethesda, MD
Fellowships
Sonia B. Jakowlew, National Cancer Institute-CCT, Bethesda, MD
Career development awards
Susan Perkins, National Cancer Institute-CCT, Bethesda, MD
Transitioning to independence awards
Michael Schmidt, National Cancer Institute-CCT, Bethesda, MD
210
CURRENT CONCEPTS IN DIAGNOSTICS
AND THERAPEUTICS RESEARCH
Sunday, 1:00 p.m.-3:00 p.m.
Applications of Nanotechnology for
Cancer Diagnosis, Treatment,
and Prevention
Preclinical Models of NeurofibromatosisAssociated Tumors as Platforms for
Testing Inhibitors of Aberrant Ras
Signaling in Vivo
Chairperson: Chad A. Mirkin, Northwestern University,
Evanston, IL
Nanomaterials have the potential to be used to solve
some of the most pressing issues in cancer diagnosis,
treatment, and prevention today. Specifically, due to their
unique chemical and physical properties that stem from
their size, shape, and composition, nanomaterials could
enable the development of systems that can be used to
detect cancer earlier and more accurately and treat
cancer more effectively and cheaply without causing
harmful side effects. In particular, novel nanostructures
like spherical nucleic acids (SNAs), carbon nanotubes,
and iron oxide nanoparticles may be able to be used to
improve patient outcomes. In this session, leaders in the
field will discuss the current state of the art and research
directions for the future.
1:00 p.m.
Spherical nucleic acids for the treatment
of glioblastoma multiforme
Chad A. Mirkin, Northwestern University,
Evanston, IL
1:20 p.m.
Discussion
1:25 p.m.
Nanotube x-rays for cancer imaging
and therapy
Otto Zhou, UNC Lineberger Comprehensive
Cancer Center, Chapel Hill, NC
1:45 p.m.
Discussion
1:50 p.m.
Synthetic high-density lipoprotein
nanoparticles as cancer therapy
C. Shad Thaxton, Northwestern University,
Chicago, IL
2:10 p.m.
Discussion
2:15 p.m.
Magnetic nanoparticle breast cancer
treatment: Material science to
clinical patients
P. Jack Hoopes, Dartmouth Medical
School, Hanover, NH
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
Chairperson: Kevin M. Shannon, University of
California, San Francisco, CA
Neurofibromatosis type 1 (NF1) is a multisystem
developmental disorder and familial cancer syndrome
caused by heterozygous germline loss of function
mutations in the NF1 tumor suppressor gene. Affected
persons are predisposed to specific benign and
malignant tumors. In addition, recent high-throughput
sequencing technologies have identified frequent
somatic NF1 mutations in glioblastoma and other
sporadic cancers. The NF1 gene encodes neurofibromin,
a GTPase activating protein that negatively regulates
Ras signaling. Genetically accurate mouse models of
NF1-associated tumors represent robust experimental
platforms for investigating how individual Ras effector
pathways drive aberrant growth, for testing preclinical
therapeutic strategies, and for translating these data into
mechanism-based human clinical trials. Preclinical
studies performed to date have identified an important
role of the microenvironment in tumorigenesis, and
showed that cell lineage and disease stage strongly
modulated Ras effector pathway dependencies for
tumor growth.
1:00 p.m.
Strategies to target the tumor
microenvironment and tumorigenic
cells in plexiform neurofibromas:
Results in preclinical models and phase
2 clinical trials
D. Wade Clapp, Indiana University School
of Medicine, Indianapolis, IN
1:20 p.m.
Discussion
1:25 p.m.
A novel system for identifying
therapeutic targets in NF1-associated
malignant peripheral nerve sheath
tumors
Lu Le, UT Southwestern Medical Center,
Dallas, TX
1:45 p.m.
Discussion
211
CURRENT CONCEPTS IN DIAGNOSTICS
AND THERAPEUTICS RESEARCH
1:50 p.m.
Targeted strategies to improve
outcomes in NF1-associated
brain tumors
David H. Gutmann, Washington University
School of Medicine, St. Louis, MO
2:10 p.m.
Discussion
2:15 p.m.
Mechanisms of response and resistance
to targeted inhibitors in NF1-deficient
hematologic cancers
Kevin M. Shannon, University of California,
San Francisco, CA
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
Sunday, 1:00 p.m.-3:00 p.m.
1:25 p.m.
Microsatellite instability in tumor
genomes
Peter J. Park, Children’s Hospital, Harvard
Medical School, Boston, MA
1:45 p.m.
Discussion
1:50 p.m.
The use of mutational signatures to
identify carcinogen exposure
Bin Tean Teh, National Cancer Centre
Singapore, Singapore, Singapore
2:10 p.m.
Discussion
2:15 p.m.
Mechanisms that maintain genome
stability
Andre Nussenzweig, National Cancer
Institute, Bethesda, MD
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
Unique Mutational Patterns in
Cancer Genomes
Chairperson: Michael R. Stratton, Wellcome Trust
Sanger Institute, Cambridge, United Kingdom
All cancers are believed to be caused by somatic
mutations. The repertoire of mutations that contribute to
cancer development includes base substitutions, small
insertions and deletions, and rearrangements. These
mutations may be acquired through the intrinsic low
somatic mutation rate of normal cells and/or by
exposures to exogenous or endogenous mutagens,
activity of DNA editing enzymes, and defects in DNA
maintenance. The genome sequences of thousands of
cancers are providing comprehensive overviews of the
patterns of mutations present in human cancer. These
are yielding insights into and questions about the
underlying mutational processes, leading to a
convergence of research endeavor in the areas of cancer
genomics, DNA damage and repair, epidemiology, and
others. In this session, mutational patterns and their
underlying processes and causes will be discussed.
1:00 p.m.
Mutational processes in cancer
Michael R. Stratton, Wellcome Trust Sanger
Institute, Cambridge, United Kingdom
1:20 p.m.
Discussion
212
CURRENT CONCEPTS IN EPIDEMIOLOGY
AND PREVENTION RESEARCH
Sunday, 1:00 p.m.-3:00 p.m.
Repurposing Aspirin and Metformin for
Cancer Prevention and Treatment
Chairperson: Eric J. Jacobs, American Cancer Society, Atlanta, GA
Metformin and aspirin are both inexpensive medications that have well-established safety profiles
and that are used by millions of people. Metformin, used in the treatment of diabetes, influences
biological pathways that are likely to be important in cancer etiology and progression.
Randomized trials are currently assessing the effects of metformin on progression in cancer
patients and on potential markers of cancer risk. Aspirin, commonly used to reduce risk of
cardiovascular events, is now known to also reduce risk of developing colorectal cancer. Recent
research has strengthened the evidence that aspirin could contribute to the prevention or
treatment of other cancers. Speakers in this session will discuss a broad range of current evidence
from biological, clinical, and epidemiologic studies relevant to the potential use of aspirin and
metformin for cancer prevention or treatment.
1:00 p.m.
Contributions and challenges of observational studies of metformin and cancer
Jeffrey Johnson, University of Alberta, Edmonton, AB, Canada
1:20 p.m.
Discussion
1:25 p.m.
Metformin as a potential anticancer agent
Pamela J. Goodwin, University of Toronto Mount Sinai Hospital, Toronto, ON,
Canada
1:45 p.m.
Discussion
1:50 p.m.
Aspirin and colorectal cancer: Mechanistic insights from human studies
Andrew T. Chan, Massachusetts General Hospital, Boston, MA
2:10 p.m.
Discussion
2:15 p.m.
Beyond colorectal cancer: Aspirin and other cancers and overall risks
and benefits
Eric J. Jacobs, American Cancer Society, Atlanta, GA
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
213
CURRENT CONCEPTS IN
ORGAN SITE RESEARCH
Sunday, 1:00 p.m.-3:00 p.m.
Breast Cancer: Progress in Basic and Translational Research
Chairperson: Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN
This session will include four presentations that will cover the spectrum of bench to bedside and
back to bench investigation of high relevance to breast cancer biology, genomics, and
mechanism-based clinical investigation. Topics will include use of genetically engineered mouse
models for therapeutic research, aspects of tumor heterogeneity and plasticity, genomic profiling
of mouse and human breast cancers, and the latest on the clinical development of PI3K/TOR
pathway inhibitors for patients with breast cancer.
1:00 p.m.
Unraveling therapy resistance in mouse models of breast cancer
Jos Jonkers, Netherlands Cancer Institute, Amsterdam, The Netherlands
1:20 p.m.
Discussion
1:25 p.m.
Cellular plasticity and lineage infidelity drive breast cancer heterogeneity
Charlotte Kuperwasser, Tufts University School of Medicine, Boston, MA
1:45 p.m.
Discussion
1:50 p.m.
Genomic and genetic analysis of human and murine mammary cancers
Charles M. Perou, University of North Carolina at Chapel Hill, Chapel Hill, NC
2:10 p.m.
Discussion
2:15 p.m.
PI3K/TOR pathway: Role in breast cancer progression and as a
therapeutic target
Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN
2:35 p.m.
Discussion
2:40 p.m.
Blockade of EGFR and HER3 enhances PI3K/Akt antitumor activity in triplenegative breast cancer
*Maurizio Scaltriti, Memorial Sloan-Kettering Cancer Center, New York, NY
2:55 p.m.
Discussion
*NextGen Star, selected to give a talk by the AACR President and Annual Meeting Program Chairperson
through a competitive application process designed to bring more visibility to early-career scientists. Abstract
can be found in the Invited Abstracts: NextGen Stars section of the Proceedings.
214
DRUG DEVELOPMENT TRACK:
SPECIAL SESSION
Sunday, 1:00 p.m.-3:00 p.m.
New Drugs on the Horizon 1
Co-Chairpersons: Lori S. Friedman, Genentech, Inc., South San Francisco, CA, and Simon
Bailey, Pfizer, Inc., San Diego, CA
Advances in the understanding of the molecular basis of cancer have led to the identification of
key pathways involved in tumor initiation and progression, and translating this innovative science
into the next generation of therapeutic agents remains one of the major hurdles to meaningful
improvements in cancer treatment. While clinical successes remain extremely challenging to
achieve, increasing numbers of targeted agents are emerging through clinical trials and making
differences in the lives of patients. This symposium will provide the first disclosure of several new
clinical agents that continue the drive for successful targeted therapies.
1:00 p.m.
Discovery of CGM097 as a novel HDM2 inhibitor
Keiichi Masuya, Novartis Institutes for BioMedical Research, Basel, Switzerland
1:25 p.m.
Discussion
1:30 p.m.
Discovery, preclinical, and early clinical evaluation of volitinib: A potent and
selective c-Met kinase inhibitor
Weiguo Su, Hutchison MediPharma, Ltd., Shanghai, China
1:55 p.m.
Discussion
2:00 p.m.
Discovery and preclinical pharmacology of JNJ-61186372: A novel bispecific
antibody targeting EGFR and cMET
Sheri L. Moores, Janssen Research and Development, LLC, Spring House, PA
2:25 p.m.
Discussion
2:30 p.m.
SGN-CD19A: A novel anti-CD19 antibody drug conjugate
Tina M. Albertson, Seattle Genetics, Inc., Bothell, WA
2:55 p.m.
Discussion
215
MAJOR SYMPOSIA
2:25 p.m.
Mapping genetic interactions in
cancer pathways
Michael Boutros, German Cancer Research
Center, Heidelberg, Germany
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
Beyond Big Data: Empowering Cancer
Omics with Regulatory Models
Chairperson: Andrea Califano, Columbia University,
New York, NY
Despite massive efforts in tumor profiling, the number of
heritable variants and somatic alterations that are
pharmacologically actionable or that constitute robust
biomarkers remains small. Achieving the next level of
understanding of this complex class of diseases will thus
require the assembly of genome-wide, context-specific
molecular interaction networks (interactomes) and their
use as models to help elucidate causal effectors and
integrators downstream of these aberrant events.
Indeed, use of regulatory networks in the study of cancer
phenotypes has been transformative over the last five
years, leading to elucidation of both individual and
synergistic drivers of tumorigenesis, progression, and
chemosensitivity as candidate therapeutic targets and
biomarkers. This symposium describes the latest
advances in the study of cancer regulatory models. Its
goal is to motivate the research community toward a
global community effort to exploit big data and novel
high-throughput technologies to assemble accurate and
comprehensive maps representing transcriptional, posttranscriptional, post-translational, and metabolic
interactions in tumor-specific fashion.
1:00 p.m.
Introduction
1:10 p.m.
Reverse engineering regulatory
perturbations in cancer
Saeed Tavazoie, Columbia University,
New York, NY
1:30 p.m.
Discussion
1:35 p.m.
De novo assembly and interrogation of
regulatory networks reveals mechanisms
of tumorigenesis and chemosensitivity
Andrea Califano, Columbia University,
New York, NY
1:55 p.m.
Discussion
2:00 p.m.
Interactome networks and human
disease
Marc Vidal, Dana-Farber Cancer Institute,
Boston, MA
2:20 p.m.
Discussion
216
The Dependency of Cancers on
Oncogenic Transcription Factors:
An Addiction to Transcription
Chairperson: Gerard I. Evan, University of Cambridge,
Cambridge, United Kingdom
The Myc oncoprotein is functionally deregulated in
almost all human cancers, sometimes by direct mutation
but more often indirectly through its incessant and
constitutive induction by upstream oncogenic signals.
However, despite the clear implications of its causal role
in multiple cancer types, enthusiasm for its utility as a
cancer therapeutic target has been blunted by several
concerns: first, like most other transcription factors it is a
difficult molecule to target pharmacologically; second, as
a key mediator of cell proliferation, its inhibition would be
expected to arrest, but not kill, cancer cells; and third, its
obligate role in the proliferation of all normal cells raises
the specter that systemic Myc inhibition would elicit
unacceptably severe side effects. However, using
switchable genetic mouse models in which endogenous
Myc function can be systemically and reversibly inhibited
in normal and tumor tissues in vivo, we have
demonstrated that inhibiting Myc has a remarkably
efficacious and durable therapeutic impact on multiple
cancer types, including cancers of lung, brain, pancreas,
and mammary epithelium, while eliciting only mild,
reversible, and noncytotoxic side effects in normal
tissues. Moreover, in keeping with the nonredundant
nature of Myc in proliferation, we never see the
emergence of resistant clones since the requirement for
Myc cannot be circumvented. A comprehensive
understanding of the molecular means by which Myc
inhibition triggers tumor regression remains unclear but it
involves multiple mechanisms that act in both tumor cell
autonomous and nonautonomous ways.
Sunday, 1:00 p.m.-3:00 p.m.
1:00 p.m.
Introduction
1:00 p.m.
Introduction
1:10 p.m.
Redeployment of Myc and E2f3 drives
cancer-like cell cycles
Gustavo W. Leone, Ohio State University
Comprehensive Cancer Center,
Columbus, OH
1:10 p.m.
HIPPO signaling in development
and cancer
Duojia D. J. Pan, Johns Hopkins Medical
Institutions, Baltimore, MD
1:30 p.m.
Discussion
1:30 p.m.
Discussion
1:35 p.m.
1:35 p.m.
The essential role that deregulated Myc
plays in maintaining cancers
Gerard I. Evan, University of Cambridge,
Cambridge, United Kingdom
Parallels between nerve regeneration
and cancer
Alison C. Lloyd, University College London,
London, United Kingdom
1:55 p.m.
Discussion
1:55 p.m.
Discussion
2:00 p.m.
2:00 p.m.
Revisiting the STATs of cancer:
Emergence of stem-like cancer cells
Richard Jove, Vaccine and Gene Therapy
Institute of Florida, Port Saint Lucie, FL
Overlapping mechanisms in CNS
development and gliomagenesis
David H. Rowitch, University of California,
San Francisco, CA
2:20 p.m.
Discussion
2:25 p.m.
A cell “ground state” for cancer
Richard J. Gilbertson, St. Jude Children’s
Research Hospital, Memphis, TN
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
2:20 p.m.
Discussion
2:25 p.m.
Regulation of cancer cell proliferation
and survival by NF-κB
Neil Perkins, Newcastle University Medical
School, New Castle, United Kingdom
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
Development, Regeneration,
and Cancer
Chairperson: Alison C. Lloyd, University College
London, London, United Kingdom
The recapitulation of developmental and tissue
regenerative processes occurs frequently during tumor
development. This contributes to multiple characteristics
of tumor biology, including inappropriate proliferation,
migration into surrounding tissues, and interactions with
inflammatory cells. In this session, we will discuss how
novel insights into these processes increase our
understanding of how and why the reinitiation of these
normal cell behaviors can have such disastrous
consequences. We will also discuss how the identification
of the signaling pathways involved in mediating these
complex cell behaviors offers new therapeutic targets and
approaches for the treatment of tumors.
217
MAJOR SYMPOSIA
Ballroom 20A-C, San Diego Convention Center
IDH Mutations in Cancer
Microbiota, Inflammation, and Cancer
Chairperson: Tak W. Mak, Campbell Family Institute for
Breast Cancer Research, Toronto, ON, Canada
Chairperson: Johanna Wyss Lampe, Fred Hutchinson
Cancer Research Center, Seattle, WA
Several types of cancers, including acute myeloid
leukemia and glioma, show high frequencies of
heterozygous mutations in isocitrate dehydrogenases 1
and 2 (IDH1/2). These alterations occur in the catalytic
arginine residues of these enzymes and cause them to
acquire a neomorphic activity that converts αketoglutarate (α-KG) to D-2-hydroxyglutarate (D2HG).
D2HG is normally a rare metabolite but accumulates to
high levels in cells and tissues expressing mutant
IDH1/2. In vitro, D2HG inhibits α-KG-dependent
enzymes involved in intracellular signaling, epigenetic
regulation, and collagen synthesis. D2HG may thus act
as an “oncometabolite” promoting tumorigenesis. This
symposium will highlight the latest results emerging from
basic and clinical analyses of IDH1/2 mutations and
discuss their consequences.
We will address aspects of the inflammation-cancer
connection from etiology to improving therapeutic
response. In a mouse model of inflammation-driven colon
cancer, Schloss shows that there are dramatic, continual
alterations in the gut microbiome, which are directly
responsible for tumor development. Bultman, also using a
mouse model of colon cancer, demonstrates that a highfiber diet is protective only when one of the gut bacteria
is a butyrate-producer, and that butyrate, a well-known
HDAC inhibitor, increases global histone acetylation in
tumors. Lampe discusses how other dietary bioactives,
such as lignans associated with high-fiber foods, may
modulate the human gut microbiome and influence
chronic inflammation and cancer risk. In relation to
therapy, Evans examines the role of the vitamin D
receptor (VDR) as a master transcriptional regulator of
pancreatic stellate cells, which drive the severe stromal
reaction characterizing pancreatic ductal
adenocarcinoma and provides a strategy through which
epigenomic reprogramming of pancreatic tumor stroma
improves chemotherapeutic response.
1:00 p.m.
Introduction
1:10 p.m.
The enigmatic mutations of isocitrate
dehydrogenases 1 and 2 in cancer
Tak W. Mak, Campbell Family Institute for
Breast Cancer Research, Toronto, ON,
Canada
1:00 p.m.
Introduction
1:10 p.m.
Dynamics of the gut microbiome in the
development of colorectal cancer
Patrick Schloss, University of Michigan,
Ann Arbor, MI
1:30 p.m.
Discussion
1:35 p.m.
Dietary fiber protects against colorectal
tumorigenesis in a microbiota- and
butyrate-dependent manner
Scott Bultman, University of North
Carolina, Chapel Hill, NC
1:30 p.m.
Discussion
1:35 p.m.
IDH mutations in glioma
Ingo K. Mellinghoff, Memorial SloanKettering Cancer Center, New York, NY
1:55 p.m.
Discussion
2:00 p.m.
Development of mutant Idh2 inhibitors:
From concept to patients
David P. Schenkein, Agios
Pharmaceuticals, Inc., Cambridge, MA
2:20 p.m.
Discussion
1:55 p.m.
Discussion
2:25 p.m.
IDH mutations in leukemogenesis:
Disrupting cytosine methylation
Maria Eugenia Figueroa, University of
Michigan, Ann Arbor, MI
2:00 p.m.
2:45 p.m.
Discussion
Gut microbiome-driven exposure to
anti-inflammatory dietary bioactives
in humans
Johanna Wyss Lampe, Fred Hutchinson
Cancer Research Center, Seattle, WA
2:50 p.m.
General Discussion
2:20 p.m.
Discussion
218
Sunday, 1:00 p.m.-3:00 p.m.
2:25 p.m.
Vitamin D receptor stromal
reprogramming suppresses pancreatitis
and enhances pancreatic cancer therapy
Ronald M. Evans, The Salk Institute,
La Jolla, CA
2:00 p.m.
Natural product-inspired peptide
drug discovery accelerated by the
RaPID system
Hiroaki Suga, The University of Tokyo,
Tokyo, Japan
2:45 p.m.
Discussion
2:20 p.m.
Discussion
2:50 p.m.
General Discussion
2:25 p.m.
Biological discovery and therapeutic
insight from DNA-templated macrocycle
libraries
David R. Liu, Harvard University,
Cambridge, MA
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
New Approaches for Accessing
Chemical Diversity
Chairperson: Jack M. Taunton, University of California,
San Francisco, CA
Drugs represent single points in an essentially infinite
chemical space. A major challenge at the earliest stages
of drug discovery is how to explore the vastness of
chemical space while maximizing the probability of
obtaining a molecule with the desired spectrum of
biological properties. This session will feature very
different yet complementary approaches to address this
challenge. David Liu and Hiroaki Suga will present
biology-inspired approaches that generate massive
chemical diversity and exploit the power of selection to
identify high-affinity ligands to challenging targets. Tom
Heightman and Jack Taunton will describe alternative
strategies, wherein smaller numbers of low-molecular
weight fragments are screened initially, followed by
structure-guided optimization of the fragments.
Applications of these approaches to the discovery of drug
candidates and useful chemical probes will be described.
1:00 p.m.
Introduction
1:10 p.m.
Fragment-based drug discovery:
Less is more
Tom D. Heightman, Astex Pharmaceuticals,
Inc., Cambridge, United Kingdom
1:30 p.m.
Discussion
1:35 p.m.
Targeting kinases with reversible
covalent fragments
Jack Taunton, University of California, San
Francisco, CA
1:55 p.m.
Discussion
219
MAJOR SYMPOSIUM
Sunday, 1:00 p.m.-3:00 p.m.
Wild Type and Mutant p53 Functions
Chairperson: Guillermina Lozano, The University of
Texas MD Anderson Cancer Center, Houston, TX
To better understand the mechanisms of p53 action in
tumor suppression, speakers in this session have
leveraged both mouse genetic and genomic approaches
to expand our understanding of the cellular
consequences of wild type and mutant p53 activities.
First, the role of p53 in metabolism will be discussed
followed by the use of p53 transactivation domain
mutant mice to define transcriptional programs involved
in p53 function in vivo. The last two talks will focus on
the activities of mutant p53 proteins, specifically how
these activities contribute to metastasis in vivo and
pediatric cancers in humans. Together, these
approaches will better define the environmental cues
and transcriptional networks important for p53 action in
tumor suppression.
1:00 p.m.
Introduction
1:10 p.m.
A role for p53 in adaptation to
metabolic stress
Karen H. Vousden, Beatson Institute for
Cancer Research, Glasgow, United
Kingdom
1:30 p.m.
Discussion
1:35 p.m.
Deconstructing p53 pathways in vivo
Laura D. Attardi, Stanford University School
of Medicine, Stanford, CA
1:55 p.m.
Discussion
2:00 p.m.
Gain-of-function activities of mutant p53
Guillermina Lozano, The University of Texas
MD Anderson Cancer Center, Houston, TX
2:20 p.m.
Discussion
2:25 p.m.
Germline p53 variants and childhood
malignancies
Gerard P. Zambetti, St. Jude Children’s
Research Hospital, Memphis, TN
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
220
SCIENCE POLICY SESSION
Sunday, 1:00 p.m.-3:00 p.m.
NIH and NCI Funding: How the AACR and Our Partners are
Taking a Stand against the Decades-Long Decline in Federal
Funding for Research and Development
Chairperson: George J. Weiner, Holden Comprehensive Cancer Center at the University of Iowa,
Iowa City, IA
Today, more than ever before, cancer researchers are maximizing the impact of the fundamental
discoveries emanating from investments at the National Cancer Institute (NCI) and the National
Institutes of Health (NIH). This progress is enabling us to accelerate our methods for translating
discoveries from the laboratory to the clinic, thereby resulting in improved ways for preventing,
diagnosing, and treating cancer. However, despite the unprecedented research opportunities that
exist today, our nation’s foremost sources of funding for our country’s most talented scientists and
clinical researchers—the NIH and NCI—are amidst a serious funding crisis. This crisis reached its
peak in early 2013 when NIH’s and NCI’s budgets were outright cut by 5% because of
sequestration. In addition, and even before this $1.6 billion cut, NIH’s budget has also declined by
more than 20% since 2003, when factoring in inflation. With the passage of the Consolidated
Appropriations Act of 2014 in January, some of these cuts were restored to the agency; however,
current funding still falls short of the levels seen prior to sequestration. Therefore, we are at a
pivotal moment, especially with an election only six months away, where we must urge Members
of Congress to recommit our country to making NIH and NCI national priorities. This special
session will arm cancer researchers with the knowledge needed to be effective advocates,
especially in the current, complex political and fiscal environments that exist in Washington, DC.
Mr. Bilbray will share his perspective as a former Member of Congress who was a champion for
NIH and medical research during his tenure in the U.S. House. As Vice-Chair of AACR’s Science
Policy and Government Affairs Committee, Dr. Weiner will describe how scientists can get more
involved in advocacy by discussing his experiences working with his respective Members of
Congress, as well as highlight his experiences as a participant in AACR advocacy events on
Capitol Hill. Ms. Ferris will discuss how not-for-profit cancer research organizations, such as
LUNGevity, are actively supporting cancer research and engaging their volunteers in advocacy
efforts. This session also will highlight how AACR is working with our nation’s policymakers and
the broader medical research advocacy community to sustain our investments in cancer research
and biomedical science. For example, key initiatives, such as the historic Rally for Medical
Research, which took place at during last year’s AACR Annual Meeting, as well as last
September’s Rally for Medical Research Hill Day will be discussed.
Speakers:
Brian Bilbray, former member, U.S. House of Representatives, San Diego, CA
George J. Weiner, Holden Comprehensive Cancer Center at the University of Iowa, Iowa City, IA
Andrea Ferris, LUNGevity Foundation, Potomac, MD
Jon G. Retzlaff, American Association for Cancer Research, Washington, DC
221
POSTER SESSION
Hall A-E, Poster Section 1 • Sunday, 1:00 p.m.-5:00 p.m.
Tumor Biology 1
Poster
Section
1
1
Angiogenesis 1: Molecular and Cellular Mechanisms
Poster Abstract
Board Number
1.
1 Interaction of prostate cancer cells with tumor
microenvironment promotes EMT and DTCs activation.
Junlin Shi, Yudui Xia, Qiong Song, Xiaolin Zhou, Atsushi
Mizokami, Evan Keller, Jian Zhang, Yi Lu.
2.
2 Paxillin enhances angiogenesis through
transcriptional regulation of Src in ovarian cancer. Hyun
Jin Choi, Seung-Wook Kim, Sunila Pradeep, Heather J.
Dalton, Rajesha Rupaimoole, Selanere Mangala, Gabriel
Lopez, Sood K. Anil.
3.
3 Imaging of stromal cells during hepatocellular
metastasis formation in the RFP-MUP-uPA mouse.
Atsushi Suetsugu, Hisanobu Ogata, Yukihiko Hiroshima,
Masashi Momiyama, Yosuke Osawa, Hisataka Moriwaki,
Shigetoyo Saji, Michael Karin, Robert M. Hoffman.
4.
4 WISP-1 increases angiogenesis and VEGF-A
expression in human oral squamous cell carcinomas.
Ching-Wen Tsao, Chih-Hsin Tang, Jing-Yuan Chuang.
5.
5 Real-time in vivo imaging of osteosarcoma
angiogenesis. Fuminari Uehara, Yasunori Tome, Hiroki
Maehara, Fuminori Kanaya, Shinji Miwa, Yukihiko Hiroshima,
Shuya Yano, Mako Yamamoto, Yasunori Matsumoto, Robert
M. Hoffman.
6.
6
Cancer stem cells and tumor angiogenesis in
epithelial ovarian cancer. S Krishna Priya, S Sneha, Rohit
P. Nagare, S Bindhya, C Sidhanth, P Manasa, Shirley
Sundar, D K. Vijaykumar, Trivadi S. Ganesan.
7.
8.
9.
10.
11.
12.
13.
14.
222
7
Assessment of FSH receptor expression in the
major molecular subtypes of breast cancer. François
Planeix, Mohammad-Ahsan Siraj, François-Clément Bidard,
Jean-Yves Pierga, Xavier Sastre, Martine Antoine, Nicolae
Ghinea.
8 The protein tyrosine phosphatase DEP-1/PTPRJ is
an essential promoter of vascular permeability,
angiogenesis and tumor progression. Patrick Fournier,
Sylvie Dussault, Alfredo Fusco, Alain Rivard, Isabelle Royal.
9
An angiogenic function for E-cadherin in ovarian
cancer. Maggie Kei Shuen Tang, Alice Sze Tsai Wong.
10
Characterization of CD45-/CD31ⴙ/CD105ⴙ
circulating cells in the peripheral blood of patients with
gynecological malignancies. Hyun-Kyung Yu, Ho-Jeong
Lee, Ha-Na Choi, Jin-Hyung Ahn, Ji-Young Choi, Eun-Jeong
Jeong, Hyun-Jeong Seok, Haengseok Song, Ki-Heon Lee,
Lee S. Yi, Sun Jin Kim, Tae Jin Kim, Jang-Seong Kim.
11
Absence of TGFBI favors tumor angiogenesis. JunYoung Seo, Hae Uk Jung, Hye-Nam Son, Soyoun Kim,
Eunsung Jun, Ju-Ock Nam, Jung-Eun Kim, In-San Kim.
12
Tumor macrophages in clinical breast cancers
transdifferentiate into lymphatic-like cells and
structurally contribute to lymphatic vasculature. Kelly
Hall, Lisa Volk-Draper, Sandeep Rajput, David DeNardo,
Sophia Ran.
13
Color-coded imaging of vessel anastomosis in
vivo using RFP and CFP transgenic mice. Fuminari
Uehara, Yasunori Tome, Hiroki Maehara, Kazuhiro Tanaka,
Fuminori Kanaya, Shinji Miwa, Yukihiko Hiroshima, Shuya
Yano, Mako Yamamoto, Yasunori Matsumoto, Robert M.
Hoffman.
14
Drug sensitivity of vascularized tumor tissue in
vitro. Seema M. Ehsan, Masahiro Inoue, Marian L.
Waterman, Christopher C. Hughes, Steven C. George.
Poster Abstract
Board Number
15.
15
Nucleolin-targeting NUCANT normalizes tumor
vasculature and inhibits tumor growth and metastasis
formation in mouse models of cancer. Maud-Emmanuelle
Gilles, Damien Destouches, Gilles Carpentier, Enrico Giraudo,
Federica Maione, José Courty, Ilaria Cascone.
16.
16
Immunomodulatory effects of VEGF on human
lymph node antigen-presenting and lymphoid cells.
Madeleine P. Strohl, Hallie Graor, Mei Zhang, Anthony
Visioni, John Ammori, Isabelle Rivers-McCue, Julian Kim.
17.
17
Hepatitis C virus (HCV) core protein potentiates
proangiogenic activity of hepatocellular carcinoma
(HCC) cells. Yu-Yun Shao, Chung-Yi Huang, Jun-Wei Chen,
Chih-Hung Hsu, Ann-Lii Cheng.
18.
18
MicroRNA-103 induces DNA damage and
radiosensitizes the tumor vasculature. Sudarshan Anand,
Sunil J. Advani, David A. Cheresh.
19.
19
PlGF/VEGFR-1 dependent activation of the Dll4Notch4/Ephrin B2 cascade contributes to liver vessel
anomalies in hepatocellular carcinoma. Annemilai TijerasRaballand, Armand de Gramont, Patricia Hainaud, JeanOlivier Contreres, Carole Le Hénaff, Marc Pocard, Evelyne
Dupuy.
20.
20
Adiponectin increases VEGF expression and
promotes angiogenesis in human chondrosarcoma.
Jhao-Sheng Shih, Chih-Hsin Tang.
21.
21
Stromal fibroblasts in breast carcinomas promote
angiogenisis through Adrenomedullin (AM)secretion.
zohra BENYAHIA.
22.
22
Interferon-␥ produced by tumor-infiltrating NK
cells and CD4ⴙ T cells downregulates TNFSF15
expression in endothelial cells. Xin Gu, Tao Cheng,
Luyuan Li.
23.
23
bFGF induced VEGF expression and angiogenesis
in human chondrosarcoma. Kai-Wei Lin, Chih-Hsin Tang.
24.
24
HFE genotype affects tumor progression and
macrophage behavior in a mouse model. Cody L. Weston,
Ahmed Alkhateeb, William Hund, James R. Connor.
25.
25
Targeting c-Myc in pediatric sarcoma xenografts
with the BET bromodomain inhibitor, JQ1, disrupts
angiogenesis. Hemant K. Bid, Doris A. Phelps, Linlin Xiao,
Laurence Baker, Jun Qi, Peter J. Houghton.
26.
26
MUC1 enhances neuropilin-1 signaling in
pancreatic ductal adenocarcinoma. Ru Zhou, Jennifer
Curry, Priyanka Grover, Lopamudra Das Roy, TinChung
Leung, Pinku Mukherjee.
27.
27
Label-free, real-time analysis of endothelial cell
morphogenesis using iPSC-derived endothelial cells.
David Mann, David Belair, Coby Carlson, Arne Thompson,
Yama Abassi, Jeff Irelan.
28.
28
The influence of PDGF and VEGF on tumor
proliferation in colon cancer. Romana Mönch, Tanja
Grimmig, Vinicius Kannen, Christoph T. Germer, Ana Maria
Waaga-Gasser, Martin Gasser.
29.
29
Myeloid cell and plasma cytokine and angiogenic
factor (CAF) dynamics in association with response to
VEGFR inhibitors cediranib and sunitinib. Alper Yetil, John
V. Heymach, Amado J. Zurita.
30.
30
Modulating the angiogenic potential of human
microvascular endothelial cells by an endogenous zinc
finger transcription factor, ZNF24. Di Jia, Lan Huang,
Joyce Bischoff, Marsha Moses.
POSTER SESSION
Tumor Biology 2
Biomarkers of Tumor Metastasis
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
7.
8.
9.
10.
11.
12.
13.
14.
15.
31
Phosphatidylserine-specific phospholipase
A1(PSPLA1) expression in colorectal cancer correlates
with tumor invasion and hematogenous metastasis.
Yuuki Iida, Eiji Sunami, Soichiro Ishihara, Hironori
Yamaguchi, Nelson H. Tsuno, Joji Kitayama, Toshiaki
Watanabe.
32
Heterogeneous expression of Her2, estrogen and
progesterone receptors in human breast cancer
metastasized to the brain. Morgan Labhart, Prema S. Rao,
Seshadri Thirumala, Subrahmanyeswara U. Rao.
33
In vitro functional study of Ang 2 in colorectal
cancer cell line and the significance of Ang 2
expression in colorectal cancer patients. Moo Jun Baek,
Dongjun Jeong, Chang-Jin Kim, Tae Hyun Kim, Han Jo Kim,
Tae Sung Ahn, Sang Byung Bae, Sang Han Lee.
34
The receptor for hyaluronan acid mediator motility
(RHAMM, CD168) expression in EMT-like cancer cells is
a predictor of tumor progression in colorectal cancer.
Valentina Mele, Viktor H. Koelzer, Bettina Huber, Manuele G.
Muraro, Dennis Pfaff, Giandomenica Iezzi, Luigi M.
Terracciano, Eva Karamitopoulou, Inti Zlobec, Alessandro
Lugli.
35
A universal marker for the detection of epithelialmesenchymal transitioned circulating tumor cells and
their prognostic relevance in epithelial cancers. Arun
Satelli, Zachary Brownlee, Scott Kopetz, Michael Overman,
Qing H. Meng, Shulin Li.
37
Bone metastases in renal cell carcinoma are
predicted by characteristics of the primary tumor. Elke
Schneider, Tobias Haber, Frederick C. Roos, Christian
Hampel, Kerstin Junker, Joachim W. Thüroff, Walburgis
Brenner.
38
Quantitative proteomic approaches to identify
biomarkers for oral cancer & targeting S100A7 by RNAmediated interference through NF kappa beta-mediated
pathway. Kaushik K. Dey, Mahitosh Mandal.
39
Expression of uPA-system members correlate with
the clinico-pathological parameters of PCa patients.
Omar Al-Janabi, Helge Taubert, Andrea Lohse-Fischer,
Michael Fröhner, Sven Wach, Robert Stöhr, Bastian Keck,
Max Burger, Wolf Wieland, Kati Erdmann, Manfred P. Wirth,
Bernd Wullich, Gustavo Baretton, Viktor Magdolen, Matthias
Kotzsch, Susanne Füssel.
40
Association of Interferon-induced protein with
tetratricopeptide repeats 1 and 3 expression with
regional metastasis and drug resistance in oral
squamous cell carcinoma. Ai-Hsin Yen, Ying-Chen Chen,
Vijaya Kumar Pidugu, Chung-Ji Liu, Te-Chang Lee.
41
47 kda CXCR4: A marker for highly invasive
neuroblastoma. Vipin Shankar, Lei Qi, Kentaro Kihira,
Yoshihiro Komada, Hiroki Hori.
42
TRPM7 expression predicts poor prognosis in
patients with nasopharyngeal carcinoma and correlates
with tumor metastasis. Jian-Peng Chen, Guiqin Sun, WeiBo Wang, Cai-Xia Wang.
43
Podoplanin in head and neck squamous cell
carcinoma: Prognostic value and clinicopathological
implications. Bon Seok Koo, Kyu Lim.
44
Monitoring of metastasis by detection of EGFR
mutation, T790M, with plasma using animal model for
metastasis of human lung cancer. Naoko Aragane, Akemi
Sato, Naomi Kobayashi, Yumi Nagano, Eisaburo Sueoka,
Seiji Okada, Shinya Kimura.
45
MACC1 expression and KRas13 mutation for
improved survival prognosis of colorectal cancer
patients. Katharina Ilm, Wolfgang Kemmner, Gudrun Koch,
Pia Herrmann, Marc Osterland, Senji Shirasawa, Takehiko
Sasazuki, Ulrike S. Stein.
April 5–9, 2014 • San Diego, CA
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
46
Loss of CADM1 expression is associated with
poor prognosis and brain metastasis in breast cancer
patients. Harriet Wikman, Laura Westphal, Felicitas Schmid,
Markus Glatzel, Jakob Matschke, Manfred Westphal, Sirkku
Pollari, Kristiina Iljin, Luigi Terracciani, Heini Huhtala, Anne
Kallioniemi, Guido Sauter, Volkmar Müller, Isabell Witzel,
Katrin Lamszus, Dirk Kemming, Klaus Pantel.
47
Y-box binding protein 1 is correlated with lymph
node metastasis in intestinal type of gastric cancer.
TianTian Guo, Yingnan Yu, George Wai-Cheong Yip, Gyeong
Hun Baeg, Aye Aye Thike, Puay-Hoon Tan, Ken Matsumoto,
Boon Huat Bay.
48
A novel method for live cell sorting based on RNA
expression levels of cancer biomarkers maintains
normal cellular function as confirmed by downstream
functional testing. Don Weldon, Victor Koong, Yuko
Williams.
49
Zinc finger protein 185 is a key molecule of liver
metastasis in colon cancer. Daisuke Furukawa, Tsuyoshi
Chijiwa, Masahiro Matsuyama, Masaya Mukai, Ei-ichi
Matsuo, Osamu Nishimura, Kenji Kawai, Hiroshi Suemizu,
Nobuyoshi Hiraoka, Toshio Nakagohri, Seiei Yasuda, Masato
Nakamura.
50
HOXB9 expression associate with lymphatic
invasion in superficial pharyngeal carcinoma. Hirofumi
Kawakubo, Mai Tsutsui, Rieko Nakamura, Tsunehiro
Takahashi, Norihito Wada, Yoshiro Saikawa, Tai Omori,
Hiroya Takeuchi, Yuko Kitagawa.
51
Elevated levels of E2F1, EZH2 and SUZ12 lead to
invasive progression of superficial bladder cancers. SeRa Lee, Yun-Gil Roh, Won-Tae Kim, Seon-Kyu Kim,
Jeonghoon Heo, In-Sun Chu, Sun-Hee Leem.
52
Identification of genomic alterations associated
with metastasis in clear cell renal cell carcinoma.
Venkata J. Thodima, Banumathy Gowrishankar, Ana Molina,
Murielle Georges, RSK Chaganti, Robert J. Motzer, Jane
Houldsworth.
53
Increased expression of L-selectin (CD62L) in high
grade bladder cancer: a potential biomarker for lymph
node metastasis. Dharamainder Choudhary, Poornima
Hegde, Shilpa Choudhary, Kevin Claffey, Pramod Srivastava,
Carol C. Pilbeam, John A. Taylor.
54
Differential plectin isoform expression correlates
with aggressive prostate cancer phenotypes. Tanya C.
Burch, Johng S. Rhim, Julius O. Nyalwidhe.
55
Separation of tetraspanin CD151 from its integrin
partner ␣3␤1 reflects an alter migratory state and
predicts prostate cancer progression. Trenis Palmer,
Carlos Martinez, Catalina Vasquez, Katie Hebron, Shanna
Arnold, Celestial Jones-Paris, Susanne Chan, Venu
Chalasani, Jose Gomez-Lemus, Andrew Williams, Joseph
Chin, Giovanna Giannico, Tatiana Ketova, John Lewis,
Andries Zijlstra.
56
Examining the role of nm23-H1 in the metastatic
profile of triple negative breast cancer (TNBC). Tanisha
Z. McGlothen, Rachel Tobin, Tiffanie Alcaide, LaTonia
Taliaferro-Smith, Tongrui Liu, Ruth O’Regan.
57
Blood parameters in renal cell carcinoma patients
can have prognostic impact and differ from those of
healthy blood donors. Steffen Goebel, Karen BluemkeAnbau, Wolfgang Altermann, Udo Bilkenroth, Axel Meye,
Susanne Fuessel, Christine Lautenschlaeger, Andres
Melchior, Hans Heynemann, Paolo Fornara, Helge Taubert.
2
2
223
POSTER SESSION
Tumor Biology 3
Poster
Section
3
3
Model Organisms of Cancer 1
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
224
58
Highly tractable stem cell-driven mouse model of
colonic neoplasia with features of familial adenomatous
polyposis. Anne E. Powell, Gregory Vlacich, Zhen-Yang
Zhao, Eliot McKinley, Rebekah Karns, Mary K. Washington,
Henry C. Manning, Bruce Aronow, Robert Coffey.
59
PDK1 in melanoma development and metastasis.
Marzia Scortegagna, Chelsea Ruller, Yongmei Feng, Rossitza
Lazova, Harriet Kluger, Jian-Liang Li, Surya K. De, Robert
Rickert, Maurizio Pellecchia, Marcus Bosenberg, Ze’ev
Ronai.
60
Mig-6 suppresses development and progression of
endometrial cancer by inhibiting ERK2 phosphorylation.
Jung-Yoon Yoo, Tae Hoon Kim, Hong Im Kim, Jane Li,
Gordon B. Mills, Russell R. Broaddus, John P. Lydon, HoGeun Yoon, Jae-Wook Jeong.
61
A mouse model for small round cell tumors
induced by the Ewing sarcoma oncogene EWS/FLI1.
Tahereh Javaheri, Barbara Sax, Harini Nivarthi, Eleni
Tomazou, Mario Mikula, Jan Pencik, Zahra Kazemi,
Maximilian Kauer, Marc Wiedner, Jan Tuckermann, Michaela
Schlederer, Lukas Kenner, Reinhold Erben, Malkolm Logan,
Christine Hartmann, Heinrich Kovar, Richard Moriggl.
62
Third hit genetic changes and clonal
heterogeneity in a genetically engineered mouse lung
cancer model. Sang-Won Um, Ping-Jie Xiao, David N.
Hayes, William Y. Kim, Scott H. Randell.
63
Driving brain tumorigenesis: Generation of a
mutant IDH1 mouse model of progressive glioma.
Christopher J. Pirozzi, Catherine Y. Wang, Austin B.
Carpenter, Huishan Zhu, Paula K. Greer, Roger E.
McLendon, Darell D. Bigner, Yiping He, Hai Yan.
64
A p53 activating mutation drives metastatic highgrade serous ovarian cancer arising from the ovary in
mice. Jaeyeon Kim, Donna M. Coffey, Lang Ma, Martin M.
Matzuk.
65
Ink4a/Arf locus drives gastric tumorigenesis
through induction of parietal cell loss. Ryo Seishima,
Takeyuki Wada, Hirotoshi Hasegawa, Yoshiyuki Ishii, Koji
Okabayashi, Masashi Tsuruta, Yuko Kitagawa, Hideyuki
Saya, Osamu Nagano.
66
p120 catenin: A novel regulator of PanIN epithelial
cell delamination in preinvasive pancreatic cancer.
Audrey M. Hendley, Jennifer M. Bailey, Janivette Alsina,
Christine Iacobuzio-Donahue, Anirban Maitra, Albert
Reynolds, Steven D. Leach.
67
Establishment and in-depth characterization of a
genetically engineered mouse model of metastatic
colorectal cancer. Sebastian Schölch, Linda Blickensdörfer,
Wilko Weichert, Michael Muders, Jürgen Weitz, Moritz Koch.
68
Tumor operational signaling pathways in an Nf1
mutant mouse model system. Steve Braunstein, Rana
Mroue, Brian Huang, Sourav Bandyopadhyay, Jean
Nakamura.
69
Characterization of an inducible transgenic p53/
Kras oncopig model for cancer. Laurie A. Rund, Tiago
Collares, Fabiana Seixas, Karine Begnini, Christopher M.
Counter, Lawrence B. Schook.
70
Mouse models of human lung adenocarcinoma:
identification of potential tumor suppressors by
functional in vivo shRNA screening. Narayana Yeddula,
Yifeng Xia, Inder Verma.
71
Investigating the sexually dimorphic susceptibility
to brain cancer in a glioblastoma model system. Tao
Sun, Nicole M. Warrington, Jingqin Luo, Michael Brooks,
Sonika Dahiya, Steven C. Snyder, Rajarshi Sengupta, Joshua
B. Rubin.
72
Analyzing the role of Astrocyte Elevated Gene-1
(AEG-1) in hepatocarcinogenesis using a knockout
mouse model. Chadia L. Robertson, Jyoti Srivastava,
Ayesha Siddiq, Rachel Gredler, Devaraja Rajasekaran,
Maaged Akiel, Xue-Ning Shen, Knarik Arkun, Shobha Ghosh,
Mark A. Subler, Jolene Windle, Paul B. Fisher, Devanand
Sarkar.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
73
Ewing’s sarcoma Ewsa protein regulates Sox9
during skeletogenesis in zebrafish. Chris Merkes, Timothy
K. Turkalo, Nicole Wilder, Hyewon Park, Mizuki Azuma.
74
Activation of Akt1 accelerates carcinogen-induced
tumorigenesis in mammary gland of virgin and postlactating transgenic mice. Yanyuan Wu, Juri Kim, Yayha
Elshimali, Jaydutt V. Vadgama.
75
PKR cooperates with an MDS driver mutation to
worsen cytopenias and promote acute leukemia. Michael
T. Byrne, Richard L. Bennett, Xiaodong Cheng, W. Stratford
May.
76
Liver receptor homologue-1 increases incidence of
DMBA-induced mammary tumors. Kyren A. Lazarus, Kristy
Brown, Morag Young, Jason Cain, Samantha Jayasekara,
Rhiannon Coulson, Neil Watkins, Colin Clyne, Ashwini
Chand.
77
bcl-xL protein overexpression enhances tumor
progression of human melanoma cells in zebrafish
xenograft model: Involvement of CXCL8 chemokine.
Chiara Gabellini, Elena Gómez, Sofia de Oliveira, Donatella
Del Bufalo, Victoriano Mulero.
78
A novel orthotopic mammary epithelial cell (MEC)
transplantation model of breast cancer formation. Zoltan
Szucs, Michael D. Prater, John Stingl, Kevin M. Brindle.
79
Deletion of STAT3 in a mouse model for
metastatic melanoma. Alexander Swoboda, Isabel J.
Sobieszek, Michaela Schlederer, Safia Zahma, Jelena
Marjanovic, Valeria Poli, Lukas Kenner, Markus
Hengstschläger, Mario Mikula, Richard Moriggl.
80
Activated SHP2 collaborates with MYCN in
neuroblastoma tumorigenesis. Xiaoling Zhang, Guang
Yang, A.Thomas Look, Benjamin G. Neel, Shizhen (Jane)
Zhu.
81
Deregulated expression of HDAC9 in B cells leads
to the development of lymphoproliferative disease and
lymphoma. Veronica S. Gil.
82
Development of the baboon as an animal model
for adult T-cell leukemia/lymphoma. Thushari
Alahapperuma, James N. Mubiru, Alice Yang, Maggie
Garcia-Forey, Edward J. Dick, Michael Owston, Robert E.
Shade.
83
Increased cyclooxygenase-2 and vascular
endothelial growth factor protein expression is
associated with canine prostatic carcionogenesis
process. Renée L. Amorim, Carlos E. Fonseca-Alves, Luis G.
Calderon, Andre A. Justo, Silvia R. Rogatto.
84
Functional evaluation of synchronous inactivation
of PTEN and P53 in a murine model of prostate cancer.
Hirotsugu Uemura, Yurie Kura, Naomi Ando, Emiko
Fukushima, Yuji Hatanaka, Yutaka Yamamoto, Nobutaka
Shimizu, Kazuhiro Yoshimura, Masahiro Nozawa, Kazuhiro
Yoshikawa, Kazuto Nishio, Marco A. De Velasco.
85
Prognostic stratification of naturally occurring
canine triple negative invasive mammary carcinoma
according to IGF1-R and AR expression. Laetitia
Jaillardon, Delphine Loussouarn, Jérome Abadie, Brigitte
Siliart, Mario Campone, Frédérique Nguyen.
86
Heterozygous expression of an oncogenic Pik3ca
mutation during murine development results in fatal
embryonic and extra-embryonic defects. Lauren M. Hare,
Quenten Schwarz, Rajendra Gurung, Karen G. Montgomery,
Christina Mitchell, Wayne A. Phillips.
87
Development of a novel six-month experimental
mouse model of hepatocellular carcinoma with
nonalcoholic steatohepatitis. Norihiro Kishida, Sachiko
Matsuda, Koichi Aiura, Osamu Itano, Yuko Kitagawa.
POSTER SESSION
Tumor Biology 4
Model Organisms of Cancer 2 / Imaging
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
88
Epithelial-mesenchymal transition occurs in pre
neoplastic and neoplastic lesions of canine prostate.
Carlos E. Fonseca-Alves, Igor S. Vicente, Luis G. Calderon,
Andre A. Justo, Silvia R. Rogatto, Renée Laufer-Amorim.
89
Development of preclinical lung adenocarcinoma
model. Young-Ah Suh, Minsuh Kim, Sun-Hye Lee, Chae Lim
Jung, Hye-Min Mun, Ju-Hee Oh, Eun Kyung Choi, Se Jin
Jang.
90
Development of a systemic Kasumi-3 acute
myeloid leukemia model in NSG mice. Diana Chin,
Christine Pietsch, Francis McCabe, Susan Chippari, Elizabeth
Kaiser, Rebecca Hanson, Mariusz Lubomirski.
91
Characterization of Tid1 conditional knockout
mice for preclinical testing of novel human head and
neck cancer therapeutics. Jeng-Fan Lo, Li-Hao Cheng.
92
Generating new syngeneic models for oral
squamous cell carcinoma metastasis study. Zonggao Shi,
Jeff Johnson, Yueying Liu, Sharon Stack.
93
Antagonizing pathways leading to differential
dynamics in colonic carcinogenesis in azoxymethane
(AOM)-treated Sgo1 (Shugoshin1)-haploinsufficient
chromosome instability (CIN) model mice. Chinthalapally
V. Rao, Saira Sanghera, Yuting Zhang, Laura Biddick, Stan
Lightfoot, Wei Dai, Hiroshi Y. Yamada.
94
The role of Pik3ca in uterine gland morphogenesis
and fertility in mice. Heesung Shin, Tae Hoon Kim, JungYoon Yoo, Jean J. Zhao, John P. Lydon, Un-Hwan Ha, JaeWook Jeong.
95
Depletion of mouse cells from human tumor
xenografts significantly reduces bias in molecular
analysis and improves culture of target cells. David
Agorku, Andreas Bosio, Olaf Hardt.
96
A novel in vivo preclinical model for the study of
human tumour angiogenesis with human vessels. Kirsty
A. Holden, Michael A. Batey, Martyn Bottomley, Catherine
Booth.
97
Establishment of a new in vivo model for human
T-cell lymphoblastic leukemia (T-ALL) suitable for
evaluation of the tumor stromal component. Mariana
Amorós, M. Florencia Cayrol, M. Celeste Díaz Flaque,
Luciana Gutiérrez, Osvaldo Podhjacer, Leandro Cerchietti,
Graciela Cremaschi, Marcela F. Bolontrade.
98
A novel mouse model for intestinal serrated
polyposis. Jennifer Cotton, He Huang, Mihir Rajurkar,
Junhao Mao.
99
Wnt signaling promotes tumor propagation in a
mouse model of lung adenocarcinoma. Tuomas Tammela,
Natanya Kerper, Wen Xue, Nikhil Joshi, Pekka Katajisto,
Tyler Jacks.
100
Establishment and characterization of allografts
derived from a genetically engineered mouse model of
non-small cell lung cancer (NSCLC). Damaris Kukuk,
Philipp Müller, Kerstin Klingner, Anne-Lise Peille, Alfred
Zipelius, Julia B. Schüler.
101
Surgical orthotopic implantation (SOI) lung
cancer model with 95% survival and 100% take rate for
spectral imaging. Yong Zhang, Nan Zhang, Ming A. Zhao,
Robert M. Hoffman.
102
A longitudinal, orthotopic mouse imaging model
using modified hNIS-A549 human lung adenocarcinoma
cells and SPECT/CT imaging. Amber A. McBride,
Dominique N. Price, Jeffrey P. Norenberg, Debra A.
MacKenzie, Todd A. Thompson, Pavan Muttil.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
103
64-Cu-NOTA-panitumumab F(ab’)2 fragments for
PET/CT imaging of pancreatic cancer. Amanda J. Boyle,
David W. Hedley, Sachdev S. Sidhu, Mitchell A. Winnik,
Raymond M. Reilly.
104
Preclinical microPET/CT imaging of 89Zr-Df-SGN35 in mice bearing xenografted CD30 expressing and
non-expressing tumors. Aaron Moss, Jean Gudas, Tina
Albertson, Nancy Whiting, Che-Leung Law.
105
Establishment of imaging-based orthotopic tumor
models for pharmacological evaluation of anticancer
agents. Ning Zhang, Wei Wang, Dan Meng, Jinjin Pan, Jing
Jin, Yanxia Fan, Wenhao Jin, Shuo Zhang, Ze Chen, Xueqin
Yang, Hongjun Wang.
106
A requirement for FADD and its phosphorylation
for KRAS-driven oncogenesis. Brittany M. Bowman,
Stefanie Galban, Benjamin A. Hoff, Kevin A. Heist, Jennifer
L. Boes, Craig J. Galban, Rajiv M. Patel, Jianke Zhang,
Brian D. Ross, Alnawaz Rehemtulla.
107
Lipid metabolism inhibitors enhance glycolysis
and FDG-PET imaging of prostate cancer tumors. Isabel
R. Schlaepfer, Colton T. Pac, Natalie J. Serkova, Gagan
Deep, Rajesh Agarwal, Scott D. Cramer, Robert H. Eckel, L.
Michael Glode.
108
Consequences of hepatic JAK2 deficiency for
liver metabolism and hepatocarcinogenesis. Madeleine
Themanns, Katrin Friedbichler, Sonja M. Kessler, Michaela
Schlederer, Lukas Kenner, Kay-Uwe Wagner, Johannes
Haybaeck, Richard Moriggl.
109
PET imaging of 89Zr-labeled Pertuzumab in
HER2-positive breast cancer xenografts. Bernadette V.
Marquez, Oluwatayo F. Ikotun, Brian Wright, Alexander
Zheleznyak, Pierce Richard, Suzanne E. Lapi.
110
Preclinical evaluation of 7-chloro-N,N,5-trimethyl
-4-oxo-3(6-[18F]fluoropyridin-2-yl)-3,5-dihydro-4Hpyridazino[4,5-b]indole-1-acetamide: A novel
pyridazinoindole ligand for PET imaging of TSPO in
cancer. Yiu-Yin Cheung, Jason R. Buck, Michael L. Nickels,
Dewei Tang, H. C. Manning.
111
In search of a lead fluorescent tracer for PSCAexpressing prostate cancer: A comprehensive analysis
of imaging agents and dyes. Ziyue Karen Jiang, Anna Wu,
Robert Reiter.
112
Synthesis and preclinical evaluation of
radiolabeled alisertib as an investigational aurora
kinase A PET tracer. Joost Verbeek, Jeroen A. Goos, Albert
A. Geldof, Annemieke C. Hiemstra, Otto S. Hoekstra, Gerrit
A. Meijer, Steven Stroud, Daniel Bradley, Remond J.
Fijneman, Albert D. Windhorst.
113
A comparative preclinical PET imaging study
between [11C]erlotinib and [18F]afatinib. Paul Slobbe,
Albert Windhorst, Marijke Stigter-van Walsum, Robert
Schuit, Egbert Smit, Heiko Niessen, Guus van Dongen, Alex
Poot.
114
The prediction of postoperative renal function
from renal cortex volumetry with preoperative
multidetector computed tomography. Shuji Isotani, Hiroshi
Shimoyama, Yasuhiro Noma, Keisuke Saito, Satoru Muto,
Hisamitsu Ide, Raizo Yamaguchi, Shigeo Horie.
115
Telomerase modulation in a human cancer stem
cell syndrome with loss of TGF-␤ signaling is a
promising treatment strategy in liver and
gastrointestinal cancers. Jian Chen, Jiun-Sheng Chen,
Zhixing Yao, Wilma Jogunoori, Bibhuti Mishra, Lopa Mishra.
4
4
225
POSTER SESSION
Tumor Biology 5
Poster
Section
5
5
Negative Modulators and Suppressors of Tumor Metastasis
Poster Abstract
Board Number
1.
116
ATF3 suppresses the invasion and metastasis of
esophageal squamous cell carcinoma cells by inducing
the MDM2-mediated degradation of MMP-2. Jianjun Xie,
Liyan Xu, Enmin Li.
2.
117
The transcription factor iroquois homeobox 2
(IRX2) is a candidate metastasis suppressor that acts
as regulator of cellular motility and chemokine
expression in breast cancer cells. Stefan Werner, Hauke
Stamm, Mutiha Pandjaitan, Dirk Kemming, Klaus Pantel,
Harriet Wikman.
3.
118
The cytoplasmic domain of ICAM-2 interacts
with ␣-actinin to confer a non-metastatic phenotype in
neuroblastoma cells. Joseph M. Feduska, Stephen G. Aller,
Stuart Cramer, Robert C. van Waardenburg, Karina J. Yoon.
4.
119
Overexpression SOCS-1 may inhibit invasion and
metastasis of cervical cancer. Moon-Hong Kim, Wonwoo
Kim, Miae Kang, Hyesil Seol, Jae-Hoon Jeong.
5.
120
Runx3 inhibited epithelial to mesenchymal
transition promotes motility and invasiveness of colon
cancer cells through reduction of ROS generation. Bo
Ram Kim, Myoung Hee Kang, Jung Lim Kim, Yoo Jin Jang,
Sun Il Lee, Jun Suk Kim, Sang Cheul Oh.
12.
127
Alternative transcription of the SLIT2/mir-218 –1
signaling axis mediates pancreatic cancer invasion
through the regulation of invadopodia. Brenna A.
Rheinheimer, Lukas Vrba, Bernard W. Futscher, Ronald L.
Heimark.
13.
128
Genetic and pharmacological proof-of-concept
studies imply profilin-1 as a potential target for
blocking metastatic colonization of breast cancer cells.
Zhijie Ding, Marion Joy, Laura Vollmer, Andrew Stern,
Andreas Vogt, Partha Roy.
14.
129
AIP1 suppresses tumor metastasis by regulating
tumor microenvironment and metastatic niche. Wang
Min.
15.
130
Deadly KISS, Kisspeptin10 interaction with
osteoblasts and breast cancer metastastic cells. Kaitlyn
E. Leahey, Danny R. Welch, Yu-Chi Chen, Karen M. Bussard,
Andrea M. Mastro.
16.
131
C-kit induces epithelial-mesenchymal transition
and contributes to salivary adenoid cystic cancer
progression. Xinhua Liang, Ya-ling Tang, Jian Jiang, Yunlong Fan.
17.
132
Investigating correlations of DARC underexpression (Duffy null phenotypes) with increased
breast cancer lymph node metastasis. Andrea Walens,
Brianna Bennett, Kauthar Mumin, Michael Lou, Rupali Hire,
Michele Monteil, Melissa Davis.
6.
121
Sulforaphene inhibited migration through downregulating the Hedgehog signaling in SUM159 human
breast cancer cells. Cheng Bao, Jaehoo Lee, Jiwon Ko,
Hyun-Chang Park, Hong jin Lee.
7.
122
15-lipoxygenase-1 regulation of HIF-1a and
angiogenesis. Yuanqing Wu, Fei Mao, Xiangsheng Zuo,
Micheline J. Moussalli, Elias Elias, Imad Shureiqi.
18.
123
The breast cancer metastasis suppressor RRP1B
modulates metastasis through regulation of histone
methylation. Minnkyong Lee, Amy M. Dworkin, Jens
Lichtenberg, Shashank J. Patel, Derek Gildea, David M.
Bodine, Nigel P. Crawford.
133
Role of Glypican-3 (GPC3) on tumor progression
of the human mammary gland. Lilian F. Castillo, Rocio S.
Tascon, Elisa Bal de Kier Joffé, Maria G. Peters.
19.
134
HNF4␣ inhibits liver cancer metastasis via
suppression of NF-кB activity. Bei-Fang Ning, Jiao Liu,
Wen-Ping Xu, Chuan Yin, Xin Zhang, Wei-Fen Xie.
20.
135
Phosphorylation and furin-mediated processing
are critical posttranslational modifications of the KISS1
metastasis suppressor. Sitaram Harihar, Kelsey R.
Hampton, Tomoo Iwakuma, Nabil G. Seidah, Danny R.
Welch.
21.
136
PTEN phosphatase inhibits metastasis through
negatively affecting Entpd5/IGF1R pathway. Yanlin Yu.
8.
9.
124
Effect of RKIP on MMP expression and regulation
of breast cancer metastasis. Ila J. Datar, Jingwei Feng,
Gang Ren, Zehui Li, Xiaoliang Qiu, Fahd Al-Mulla, Milad S.
Bitar, Miranda Yeung, Kam Yeung.
10.
125
A novel OSM inhibition of cancer metastasis and
epithelial᎑mesenchymal transition in lung
adenocarcinoma through STAT1᎑mediated suppression
of Slug. Chih᎑Ming Pan, Mong᎑Lien Wang, Cheng-Wen Wu.
11.
226
Poster Abstract
Board Number
126
The KISS1 metastasis suppressor appears to
integrate glycolysis, mitochondrial biogenesis and
metastasis via regulation of a PGC1␣ pathway. Wen Liu,
Benjamin Beck, Kedar S. Vaidya, Kevin T. Nash, Scott W.
Ballinger, Danny R. Welch.
POSTER SESSION
Tumor Biology 6
Pathway of Tumor Microenvironmental Modulation
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
16.
137
Tumor-associated ECM induces renal cell
carcinoma tumorigenic responses via ␣6␤1-integrin
regulation of ITPKA. Vivekanand Gupta, Janusz FrancoBarraza, Neelima Shah, Essel Dulaimi, Yan Zhou, Karthik
Devarajan, Kathy Q. Cai, Katherine R. Alpaugh, Robert G.
Uzzo, Edna Cukierman.
138
A role for Wnt signaling in regulation of Warburg
metabolism in colon cancer. George T. Chen, Mary Lee,
Kira Pate, Kehui Wang, Robert A. Edwards, John S.
Lowengrub, Marian L. Waterman.
139
Interaction between monocytes and bone
marrow microenvironment in pathogenesis of multiple
myeloma. Hiroshi Ikeda, Yuka Aoki, Toshiaki Hyayashi,
Yumiko Maruyama, Tadao Ishida, Takashi Tokino, Yasuhisa
Shinomura, Yasushi Sasaki.
140
The role of Abl kinases in breast cancer bone
metastasis. Jun Wang.
141
Impact of preoperative treatments on the
immune microenvironnement of colorectal liver
metastases. Frederic Bibeau, Hugo Gil, Florence Castan,
Magalie Pedot, François Quenet, Marc Ychou, Celine
Bouquet, Charrier Véronique, Vaios Karanikas, Michael
Cannarile, Solange Romagnoli, Fabien Gaire, Florence
Boissiere.
142
Sodium butyrate suppresses production of
chemokines in human U937 cells. Stephanie R. Pulliam,
Roland Cooper, Samuel E. Adunyah.
143
Non-canonical role of TAM receptors in breast
cancer. Shelly Hsieh, Khanh Q. Nguyen, Stanley Kimani,
Raymond B. Birge.
144
Leukemic exosomes stimulate cells from the
microenvironment to promote chronic lymphocytic
leukemia. Jerome Paggetti, Guy Berchem, Etienne
Moussay.
145
Fibulin-5 as a regulator of integrin-induced ROS
production and potential target for pancreatic cancer.
Mary Topalovski, Miao Wang, Rolf A. Brekken.
146
Combining molecular targeted drugs to inhibit
both cancer cells and activated stromal cells in colon
cancer. Ryo Yuge, Yasuhiko Kitadai, Kei Shinagawa, Mieko
Onoyama, Yuichiro Tanaka, Shinji Tanaka, Wataru Yasui,
Kazuaki Chayama.
147
Improving antitumor effects of a BRAF inhibitor
with a colony stimulating factor 1 receptor (CSF-1R)
inhibitor, PLX3397. Stephen Mok, Richard Koya, Jennifer
Tsoi, Lidia Robert, Jesse Zaretsky, Christopher Tsui, Thomas
Graeber, Antoni Ribas.
148
Release of the TNF-family member BAFF by NK
cells contributes to the resistance of chronic lymphoid
leukemia cells to direct and Rituximab-induced NK
reactivity. Julia Wild, Benjamin J. Schmiedel, Andreas
Maurer, Stefanie Raab, Pascal Schneider, Helmut R. Salih.
149
TF-FVIIa activates VEGF-A secretion in ovarian
epithelial cancer cell line via a PAR-2-dependent
mechanism. Alice Chanakira, John P. Sheehan.
150
Role of reactive oxygen species in doxorubicininduced apoptosis of myeloid-derived suppressor cells.
Darya Alizadeh, Emmanuel Katsanis, Nicolas Larmonier.
152
Galectin-7 increases the invasive behavior of
ovarian cancer cells and promotes tumor escape.
Marilyne Labrie, Maria C. Vladoiu, Andrée-Anne Grosset,
Louis Gaboury, Yves St-Pierre.
Poster Abstract
Board Number
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
153
High neuropilin-1 expression on monocytes is
positively associated with trastuzumab-mediated
antibody-dependent cellular cytotoxicity of the HER2overexpressing breast cancer cell line. Kosuke
Kawaguchi, Eiji Suzuki, Masao Kawashima, Masakazu Toi.
154
Immunological significance of p62/SQSTM1
accumulation in oral squamous cell carcinoma. Hideyuki
Takahashi, Koichi Sakakura, Kyoichi Kaira, Minoru Toyoda,
Tetsunari Oyama, Kazuaki Chikamatsu.
155
Expressions of autophagy-related proteins
positively correlate with infiltration of immune cells and
disease progression in oral squamous cell carcinoma.
Koichi Sakakura, Hideyuki Takahashi, Kyoichi Kaira, Minoru
Toyoda, Tetsunari Oyama, Kazuaki Chikamatsu.
156
Autophagic degradation of granzyme B impairs
NK-mediated killing of hypoxic tumor cells. Joanna
Baginska, Elodie Viry, Guy Berchem, Aurélie Poli,
Muhammad Zaeem Noman, Kris van Moer, Sandrine
Medves, Takouhie Mgrditchian, Jacques Zimmer, Anais
Oudin, Simone P. Niclou, R. Chris Bleackley, Salem Chouaib,
Bassam Janji.
157
Lapatinib induces IL-6 expression via MAPK
pathway in triple-negative breast cancer cells. Yu-Chun
Hsiao, Yun-Ju Chen, Chih-Hsin Tang, Wei-Chien Huang.
158
Sustained adrenergic signaling activates proinflammatory networks in ovarian carcinoma. Archana S.
Nagaraja, Guillermo Armaiz-Pena, Julie Allen, Nouara C.
Sadaoui, Behrouz Zand, Peiying Yang, Lin Tan, Steve Cole,
Susan Lutgendorf, Anil K. Sood.
159
CD90(ⴙ) intraperitoneal mesothelial-like cells
(MLC) promote peritoneal metastasis by forming a
tumor permissive microenvironment. Joji Kitayama,
Shiegenobu Emoto, Hironori Yamaguchi, Hironori Ishigami,
Toshiaki Watanabe.
160
CD8ⴙT cell-specific induction of NKG2D receptor
by doxorubicin plus interleukin-12 requires the
engagement of CD80 and CD28. Jiemiao Hu, Xueqing Xia,
Liangfang Zhang, Eugenie S. Kleinerman, Shulin Li.
161
Activation of mTOR pathway in myeloid-derived
suppressor cells with lysosomal acid lipase deficiency
stimulates cancer cell proliferation and metastasis. Ting
Zhao, Hong Du, Xinchun Ding, Katlin Walls, Cong Yan.
162
Immunomodulatory role of CRAMP (cathelicidinrelated antimicrobial peptide) in prostate cancer. HaRam Cha, Anandi Sawant, Jonathan Hensel, Carnella Lee,
Selvarangan Ponnazhagan.
163
Identification of a bone marrow-derived MDSC
subset that promotes the growth of colon carcinoma
liver metastases. Boram Ham.
164
Bone marrow myeloid cells promote multiple
myeloma chemoresistance by DNA mediated signaling.
Indu Ramachandran, Thomas Condamine, Dmitry
Gabrilovich, Yulia Nefedova.
165
Suppressed immunity and macrophages
characterize high risk high grade DCIS. Michael J.
Campbell, Rita Mukhtar, Ekene Obi-Okoye, Booyeon Han,
Vick Tandon, Sarah Zheng, Zelos Zhu, Max Endicott, Max
Wicha, Linda Lindstrom, Alfred Au, Frederick Baehner, Joe
Gray, Laura Esserman.
166
Transcriptional control of epithelial-mesenchymal
transition in the context of changing tumor
microenvironment. Kevin Tuttle, Adam Grant, Ryan Barlow,
Evan Johnson, Marc D. Hansen.
Poster
Section
6
6
227
POSTER SESSION
Tumor Biology 7
Poster
Section
7
7
Role of Tumor-associated Mesenchymes and Their Support of the Tumor
Microenvironment
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
9.
10.
11.
12.
13.
14.
15.
228
167
Roles of adipocytes and M2-macrophages in
high-fat diet-stimulated lymph node metastasis of
B16F10 melanoma. Han Jin Cho, Jae In Jung, Yoo Jin
Jung, Ki Won Lee, Mi-Kyung Sung, Jung Han Yoon Park.
168
Understanding the role of the carcinoid
associated fibroblasts in the neuroendocrine tumor
microenvironment. Michaela Bowden, Ewa Sicinska,
Matthew Kulke, Massimo Loda.
169
Maintenance of breast cancer stem cells in an
inert matrix is mediated by mesenchymal stem cells in
the tumor stroma. Samaneh K. Sarvestani, Danial Barati,
Esmaiel Jabbari.
170
Exosomes derived from mesenchymal stem cells
suppress angiogenesis by down-regulating VEGF
expression in breast cancer cells. Sae-Ra Park.
171
Adipose-derived mesenchymal stem cell (ADSC)
has the differentiation capacity towards cancer
associated fibroblast (CAF) and reproduce the
morphology of the clinical tumor stroma. Yuki Inagaki,
Tatsuya Oda, Tomohiro Kurokawa, Ryoichi Miyamoto,
Yasuyuki Kida, Nobuhiro Ohkohchi.
172
Adipocytes decrease daunorubicin concentration
in acute lymphoblastic leukemia cells. Xia Sheng,
Jonathan Tucci, James Behan, Steven D. Mittelman.
173
Tumor proximal mesenchymal stem cells initiate
a pro-metastatic microRNA regulatory network which
acts via convergent targeting of the speech-associated
transcriptional repressor FOXP2. Benjamin Cuiffo, Antoine
Campagne, George W. Bell, Evan Lien, Manoj K. Bhasin,
Odette Mariani, Anne Vincent-Salomon, Antoine Karnoub.
175
Carcinoma-associated fibroblasts promote breast
cancer cell invasion via IGF-1 and RhoA. Julien Daubriac,
Yves Boucher.
176
IL6 and CXCL1 induce senescent phenotype of
cancer-associated fibroblast via autocrine loops in oral
squamous cell carcinoma. Eun Kyoung Kim, Sook Moon,
Do Kyeong Kim, Jin Kim, Jung Yoon Bae.
177
Obesity promotes growth of ovarian cancer
through adipose stem cells. Yan Zhang, Travis Solley,
Karen Lu, Caimiao Wei, Alesandra Nowicka, Ann Klopp.
178
Stromal expression of long Pentraxin-3 impairs
tumor growth and metastasis. Arianna Giacomini,
Emanuela Di Salle, Daniela Coltrini, Mirella Belleri, Marco
Presta, Roberto Ronca.
179
Presence of primary cilia in cancer cells
correlates with prognosis of pancreatic ductal
adenocarcinoma. Katsura Emoto, Yohei Masugi, Ken
Yamazaki, Kathryn Effendi, Hanako Tsujikawa, Minoru
Kitago, Osamu Itano, Yuko Kitagawa, Michiie Sakamoto.
180
Interaction between bone marrow-derived
mesenchymal stem cells and tumor cells induces
expression of fibronectin in human colon cancer cells.
Kei Shinagawa, Yasuhiko Kitadai, Yuichiro Tanaka, Ryo
Yuge, Mieko Onoyama, Shinji Tanaka, Wataru Yasui, Kazuaki
Chayama.
181
Therapeutic approaches to metastasis induced
by mesenchymal stem cells in the tumor
microenvironment. Shrikanta Chattopadhyay, Cherrie
Huang, Siddhartha Mukherjee, Rushdia Z. Yusuf, Vasanthi
Viswanathan, Ben S. Wittner, Jeff Gentry, Alykhan Shamji,
Sridhar Ramaswamy, David T. Scadden, Stuart L. Schreiber.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
182
SPARC as a regulator of collagen signaling in
pancreatic cancer. Kristina Y. Aguilera, Courtney D.
Goldstein, Lee B. Rivera, Amy D. Bradshaw, Ke Ding, Rolf A.
Brekken.
183
Immune dysfunction cascades caused by
ALCAMⴙ mesenchymal stem cells toward tumor
progression. Chie Kudo-Saito, Takafumi Fuwa, Kouichi
Murakami.
184
DNA damage response in quiescent fibroblasts
elicits a distinct secretory program and confers
acquired resistance to cancer therapies. Yu Sun, Ilsa
Coleman, Stephen Plymate, Peter Nelson.
185
Cancer associated fibroblasts stimulates cancer
cell invasion through CXCL12-CXCR4 signaling in gastric
cancer. Daisuke Izumi, Takatsugu Ishimoto, Hietaka
Sugihara, Hiroshi Sawayama, Ryuichi Karashima, Satoshi
Ida, Yu Imamura, Shiro Iwagami, Yoshifumi Baba, Yasuo
Sakamoto, Yuji Miyamoto, Naoya Yoshida, Hideo Baba.
186
RHOA, RAC1 and PAK1 evaluation in paired
stromal fibroblasts of breast cancer primary and of
lymph node metastasis: Importance of these biomarkers
in lymph node invasion. Patricia B. Rozenchan, Fiorita G.
Mundim, Rosimeire A. Roela, Maria L. Katayama, Fatima S.
Pasini, Helena Brentani, Eduardo C. Lyra, Maria A. Folgueira,
Maria M. Brentani.
187
Absence of S100A9 confers survival advantage in
an aggressive de novo mouse model of glioblastoma
multiforme. Alexandra Calinescu, Hikmat Assi, Bradley Kolb,
Carl Koschmann, Pedro R. Lowenstein, John Ohlfest, Maria
G. Castro.
188
Stromal expression of suicide gene FCU1 affects
proliferation of tumor cells and depletes stromal cells in
co-culture models of pancreatic cancer. Marina
Kopantseva, Eugenia Usova, Maria Kostina, Olga Melekhina,
Vyacheslav Egorov, Eugene P. Kopantzev, Eugene D.
Sverdlov.
189
Stromal primary cultures from advanced human
prostate cancer obtained from needle biopsies revealed
distinctive gene expression pattern and functionality.
Javier Cerda-Infante, Paola F. Conejeros, Romina A.
Coronado, Ignacio F. San Francisco, Gary J. Smith,
Alejandro S. Godoy, Viviana P. Montecinos.
190
The anti-cancer potential of thrombospondin-1
by inhibiting angiogenesis and stroma reaction during
cervical carcinogenesis. Ming-Ping Wu, Li-Wha Wu,
Cheng-Yang Chou.
191
Desmoplasia in primary tumors and metastatic
lesions of pancreatic cancer. Clifford J. Whatcott, Aprill
Watanabe, Janine LoBello, Daniel Von Hoff, Haiyong Han.
192
Role of adipose tissue in bladder cancer
progression. Nisha Hariharan, Robert S. Svatek, Carolina B.
Livi, Jonathan A. Gelfond, Teresa L. Johnson-Pais, Robin J.
Leach.
193
Adipocytes, obesity and the multiple myeloma
microenvironment. Gervaise H. Henry, Nicholas J. Watson,
Rebecca C. O’Neill, Tracy Tabib, Erika M. Bullwinkle,
Kathleen L. DeCicco-Skinner.
POSTER SESSION
Tumor Biology 8
Stem Cell Expansion and Cancer Stem Cell Targeting
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
194
E-selectin mediates targeted delivery of
mesenchymal stem cells to tumor. Cuixia Yang, Danjuan
Li, Bo Wang, Omaida C. Velazquez, Zhao-Jun Liu.
195
CD44v9 expression in clinical pancreatic cancer
and the gemcitabine plus sulfasalazine therapy against
chemoresistant pancreatic cancer murine model.
Tomohiro Kurokawa, Tatsuya Oda, Yuki Inagaki, Ryoichi
Miyamoto, Yoshimasa Akashi, Nobuhiro Ohkohchi.
196
Targeting breast cancer stem cells with a panel
of potential ALDH1A3 inhibitors. Margaret L. Thomas,
Melissa Wallace, Carman Giacomantonio, Paola Marcato.
197
5-year survival for patients with metastatic
melanoma who had no evidence of disease at time of
treatment with patient specific tumor stem cell
vaccines. Robert O. Dillman, Carol DePriest, Robine Ellis,
Cristina de Leon.
198 Ex vivo expansion of hematopoietic stem cells in
nonhuman primate using optimal cytokine
combinations. Yu Zhang, Bin Shen, Zhihua Ren, Wei Dai,
Yupo Ma, Yongping Jiang.
199
Increased killing potential of ex vivo
differentiated human natural killer cells in the presence
of HOXB4. Salem Chouaib, Arash Nanbakhsh, Cécile
Pochon, Sophie Amsellem, Gianfranco Pittari, Jean-Henri
Bourhis.
200
DDX3X induces signal switching to stem cellspecific Wnt/␤-catenin signaling, resulting in EGFR-TKI
resistance in lung cancer cells harboring EGFR
activating mutation. Satoshi Shoji, Hiroshi Kagamu,
Koichiro Nozaki, Natsue Igarashi, Masaaki Okajima, Satoru
Miura, Satoshi Watanabe, Hrohisa Yoshizawa, Ichiei Narita.
201
The combination treatment of TNF-␣ and poly
(dA:dT) preactivated hMSCs with doxorubicin enhances
antitumorigenic activity. Nara Yoon, Min Sung Park, Grant
Peltier, John C. Reneau, Darwin J. Prockop, Darwin J.
Prockop, Ryang Hwa Lee.
202
p53 pathway restoring small molecule
Prodigiosin targets chemotherapy-resistant colorectal
cancer stem cells in vitro and in vivo via p73 activation.
Varun Vijay Prabhu, Bo Hong, Joshua E. Allen, Shengliang
Zhang, David T. Dicker, Wafik S. El-Deiry.
203
Inhibiting invasion and stemness in glioblastoma
by thymosin beta 4 gene silencing: a new therapeutic
target. Hans-Georg Wirsching, Shanmugarajan Krishnan,
Ana-Maria Florea, Karl Frei, Niklaus Krayenbühl, Kathy
Hasenbach, Guido Reifenberger, Michael Weller, Ghazaleh
Tabatabai.
204
Understanding breast cancer resistance to
chemotherapy: Characterization of cancer cell subpopulations in residual and relapsed tumors. Andrea
Aloia, Evgeniya Petrova, Olivier Deas, Sophie Banis, Enora
Le Ven, Andreas Bosio, Olaf Hardt, Stefano Cairo, JeanGabriel Judde.
205
Imatinib sensitizes endometrial cancer cells to
cisplatin by targeting CD117-positive growth-competent
cells. Mitsuhiro Nakamura, Satoru Kyo, Xiuzhi Zhang,
Masahiro Takakura, Yasunari Mizumoto, Yukiko Bono,
Toshiyuki Sasagawa, Hiroshi Fujiwara.
206
Depletion of ovarian cancer initiating cells by a
monoclonal antibody against ROR1. Suping Zhang, Bing
Cui, Hsien Lai, Grace Liu, Christina Wu, George Widhopf,
Rongrong Wu, Fitzgerlad Lao, Richard Schwab, Dennis
Carson, Thomas J. Kipps.
207
Dual targeting of DLL4 and VEGF signaling by a
novel bispecific antibody inhibits tumor growth and
reduces cancer stem cell frequency. Wan-Ching Yen,
Fumiko Axelrod, Chris Bond, Jennifer Cain, Cecile Chartier,
Marcus Fischer, Shirley Ma, Rene Meisner, Janak Raval,
Jalpa Shah, Austin Gurney, John Lewicki, Timothy Hoey.
208
Metformin represses stem cell properties and
induces apoptosis in human breast cancer cells and
mouse mammary epithelial cells. Eun Joo Kang, Jae Hong
Seo, Jun Suk Kim, Ji Young Kim.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
209
Pharmacological inhibition of protein kinase C
alpha (PKC␣) and all trans retinoic acid (ATRA)
synergize to inhibit the proliferation, migration and
cancer stem-like properties of a triple-negative
mammary cancer model. Damian E. Berardi, Maria I. Diaz
Bessone, Carolina Flumian, Stefano M. Cirigliano, Elisa D.
Bal de Kier Joffe, Alejandro J. Urtreger, Laura B. Todaro.
210
Id4 inhibition of twist1-mediated autocrine PDGF
signaling inhibits growth and promotes apoptosis of
glioblastoma-derived stem cell cultures. Gilbert J.
Rahme, Mark A. Israel.
211
Sulfasalazine (SSZ) works cancer stem-like cells
(CSCs) via inhibiting xCT signal pathway: Phase 1 study
in patients with gastric cancer (EPOC 1205). Kohei
Shitara, Shunji Takahashi, Takako Nakajima, Hironaka
Shuichi, Osamu Nagano, Chiyo Imamura, Taisei Mushiroda,
Yasuaki Einaga, Miki Fukunani, Akihiro Sato, Atsushi Ohtsu,
Hideyuki Saya, Toshihiko Doi.
212
Withaferin A in combination with cisplatin
targets CD44 and Oct4 positive cancer stem cells in
ovarian cancer. Sanjay K. Singh, J C. States, Sham S.
Kakar.
213
VS᎑5584 a dual mTORC1/2 and PI3K inhibitor has
anti-tumor activity in multiple in vivo xenograft tumor
models and enhanced efficacy in combination with
cisplatin or docetaxel. Anthony F. Trombino, Vihren N.
Kolev, Quentin G. Wright, Qunli Xu, Mahesh V. Padval.
214
Androgen resistance in prostate cancer is
associated with an enrichment of stem-like cells. Lisa Y.
Wu, Nitu Bansal, Tiancheng Liu, Clifford E. Berkman, Joseph
R. Bertino.
215
Aminoflavone exhibits in vivo efficacy on cancer
stem cells in a spontaneous estrogen-dependent breast
cancer murine model. Mariana Callero, Damian Berardi,
Laura Todaro, Marina Simian, Eileen J. Brantley, Ubaldo
Soto, Andrea Loaiza-Perez.
216
Attenuation of cancer-initiating cells stemness
properties by abrogating S100A4 calcium binding ability
in head and neck cancers. Li-Hao Cheng, Jeng-Fan Lo.
217
Salinomycin have antiproliferative and apoptotic
effects on ovarian cancer stem-like cell. So-Jin Shin,
Jin-Young Kim, Hyun-Gyo Lee, Eun-Ji Nam, Chi-Heum Cho.
218
MEOX-1 as a novel cancer stem cell target for
treatment of trastuzumab-resistant Her2ⴙ breast
cancers. Lichao Sun, Joseph P. Burnett, Mari Gasparyan,
Hasan Korkaya, Hui Jiang, Yajing Liu, Jamie Connarn, Max
Wicha, Duxin Sun.
219
Inhibition of CD133 expression induce the
chemoresistance to 5-fluorouracil in the colon cancer
cell line. Mi-Ra Lee, Sun-Young Ji, Khalilullah Mia-Jan,
Mee-Yon Cho.
220
Preclinical studies of EpCAM-targeted therapy for
human hepatocellular carcinoma with specific inhibition
of stem cell features. Shinji Tanaka, Kousuke Ogawa,
Ayano Murakata, Kaoru Mogushi, Satoshi Matsumura, Arihiro
Aihara, Daisuke Ban, Takanori Ochiai, Takumi Irie, Atsushi
Kudo, Noriaki Nakamura, Hiroshi Tanaka, Shigeki Arii,
Minoru Tanabe.
221
Annexin A3 is a therapeutic target for CD133ⴙ
liver cancer stem cells. Man Tong, Chun M. Fung, Xin Y.
Guan, Stephanie Ma.
222
Disulfiram targets glioblsatoma stem like cells
by modulating aldehyde dehydrogenase and hypoxiaNF-␬B pathway. Vinodh Kannappan, Peng Liu, Sarah
Brown, Xiuwu Bian, Tawari P. Erebi, Angel L. Armesilla,
John L. Darling, Weiguang Wang.
223
High-throughput drug discovery against breast
cancer stem cells. Sean P. McDermott, Fatou Ndaw,
Alexandra Fox, Steve R. Vander Roest, Martha J. Larsen,
Max S. Wicha.
Poster
Section
8
8
229
POSTER SESSION
Prevention Research 1
Poster
Section
10
10
Mechanisms of Chemoprevention
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
230
224
The role of Bmi-1 in benzyl isothiocyanatemediated suppression of breast cancer stem cell selfrenewal. Su-Hyeong Kim, Shivendra V. Singh.
225
Overexpression of truncated Ron augments
benzyl isothiocyanate-induced apoptosis in human
breast cancer cells. Anuradha Sehrawat, Shivendra V.
Singh.
226
Chemopreventive potential of curcumin in
prostate cancer. Hisamitsu Ide, Yan Lu, Raizo Yamaguchi,
Satoru Muto, Shigeo Horie.
227
Estrogen receptor-␣ and tumor initiating cells
are novel targets of diallyl trisulfide in breast cancer
cells. Eun-Ryeong Hahm, Su-Hyeong Kim, Shivendra V.
Singh.
228
Withaferin A downregulates tubulins and
covalently binds ␤-tubulin at cysteine-303 in human
breast cancer cells. Shivendra V. Singh, Marie L. Antony,
Joomin Lee, Eun-Ryeong Hahm, Su-Hyeong Kim, Guillermo
Romero, Adam I. Marcus, Zhen Yang, Vandana Kumari,
Xinhua Ji, Courtney L. Vowell, Peter Wipf, Guy T. Uechi,
Nathan A. Yates.
229
Restoring physiological levels of ascorbate
alleviates HIF-1 activation and reduces tumour growth
-/in Gulo mice. Elizabeth J. Campbell, Stephanie M.
Bozonet, Bridget A. Robinson, Margreet C. Vissers, Gabi U.
Dachs.
230
The inhibitory effects of an anthocyanin enriched
fraction of black raspberry (BRB), protocatechuic acid
and ferulic acid on DB[a,l]P-induced DNA adduct
formation in mouse oral tissues. Kun-Ming Chen,
Shangmin Zhang, Yuan-Wan Sun, Cesar Aliaga,
Krishnegowda Gowdahalli, Shantu Amin, Gary Stoner, Karam
El-Bayoumy.
231
Gene expression analysis of persistent and
regressive bronchial dysplasia identifies polo-like
kinase 1 (PLK1) and epoxide hydrolase 3 (EPHX3) as
potential mediators of malignant progression. Daniel T.
Merrick, Michael G. Edwards, Wilbur A. Franklin, Michio
Sugita, Micah Friedman, York E. Miller, Lori Dwyer-Nield,
Meredith Tennis, Kevin Choo, Greg Hickey, van Bokhoven
Adriaan, Lynn Heasley, Paul A. Bunn, Mark Geraci, Robert L.
Keith, Raphael Nemenoff.
232
Extracellular matrix components influence
prostate tumor cell sensitivity to cancer-preventive
agents selenium and green tea polyphenols. Rayudu
Gopalakrishna, Tiffany Fan, Ronald Deng, David Rayudu,
Zachary W. Chen, William S. Tzeng, Usha Gundimeda.
233
Prostacyclin analogs, iloprost and treprostinil,
differentially influence proliferation of lung tumor cells.
Lori D. Dwyer-Nield, Gregory Hickey, Meredith A. Tennis,
Kevin S. Choo, Donald S. Backos, Robert L. Keith.
234
Chemopreventive activity of BioBran/MGN-3, an
arabinoxylan from rice bran, against chemical induction
of gastric dysplasia and adenocarcinoma in rats.
Nariman K. Badr El-Din, Salma M. Abdel Fattah, Deyu Pan,
Lucilene Tolentino, Mamdooh Ghoneum.
235
Combination of the probiotic Lactobacillus
rhamnosus GG with grape antioxidant resveratrol for the
management of colorectal cancer. Chandra K. Singh,
Jasmine George, Megan Duster, Nasia Safdar, Nihal Ahmad.
236
Antiproliferative and proapoptotic effects of
(-)-epigallocatechin-3-gallate encapsulated in chitosan
nanoparticles on human prostate carcinoma cells.
Sameh M. Shabana, Imtiaz A. Siddiqui, Naghma Khan,
Vaqar M. Adhami, Qateeb A. Khan, Shaker A. Mousa,
Ahmed E. Hagras, Hasan Mukhtar, Mohamed A. Elmissiry.
237
Gene expression profiling identifies Sulindacresistant colon tumors. Matthew P. Hanley, Shingo
Miyamoto, Daniel Rosenberg.
238
Vitamin D sufficiency slows the progression of
dysplasic lesions in the NTCU mouse model of lung
squamous cell carcinoma. Sarah A. Mazzilli, Mary E. Reid,
Paul N. Bogner, Kristopher Attwood, Pamela A. Hershberger,
Donald L. Trump, Candace S. Johnson.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
239
Capsaicin may reduce the metastatic burden in
the transgenic adenocarcioma of the mouse prostate
(TRAMP) model. Natalie A. Venier, Toshihiro Yamamoto,
Linda Sugar, Neil Fleshner, Laurence Klotz, Vasundara
Venkateswaran.
240
Natural antioxidants exhibit chemopreventive
characteristics through the regulation of CNC-bZip
transcription factors in estrogen-induced breast
carcinogenesis. Anwesha Chatterjee, Amruta Ronghe,
Fatma Abdalla, Hari K. Bhat.
241
CHOP-deficiency promotes chronic inflammationinduced pancreatic fibrosis. Katsunobu Taki, Masaki
Ohmuraya, Kazuya Sakata, Daisuke Hashimoto, Shinya Abe,
Hidetoshi Nitta, Hiromitsu Hayashi, Akira Chikamoto, Toru
Beppu, Hideo Baba.
242
Dietary PUFA’s alter the visceral adipose
secretome, which modulates mammary stem cell selfrenewal. Ray Esper, Michael Dame, Djuric Zora, William
Smith, Wicha Max, Dean Brenner.
243
Tocopherols inhibit oxidative and nitrosative
stress in estrogen-induced early mammary hyperplasia
in ACI rats. Soumyasri Das Gupta, Jae Young So, Joseph
Wahler, Mao-Jung Lee, Chung S. Yang, Nanjoo Suh.
244
SPINK1 insufficiency induces impaired autophagy
resulting in chronic pancreatitis. Kazuya Sakata, Masaki
Ohmuraya, Katsunobu Taki, Daisuke Hashimoto, Satoshi Ida,
Hidetoshi Nitta, Hiromitu Hayashi, Akira Chikamoto, Tooru
Beppu, Hideo Baba.
245
Consumption of a high-fat diet abrogates
inhibitory effects of selenium on spontaneous
metastasis of Lewis lung carcinoma in mice. Lin Yan.
246
Mammary cancer preventive activity of an
extract of withania somnifera roots. kamel F. Khazal,
Donald Hill, Clinton J. Grubbs.
247
CtBP1 is implicated in prostate tumor
development in a metabolic syndrome-like disease in
vivo model. Cristian P. Moiola, Paola De Luca, Florencia
Zalazar, Santiago Rodriguez Segui, Javier Cotignola, Roberto
Meiss, Elba Vazquez, Nicolas Dalton, Estefania Labanca,
Kevin Gardner, Adriana De Siervi.
248
Vitamin D deficiency promotes hepatocellular
carcinoma tumor growth in TGF-␤ impaired mice by
Smad3 heterozygous deletion. Nina M. Muñoz, Lior H.
Katz, Keigo Machida, Hidekazu Tsukamoto, Kirty Shetty,
Aiwu R. He, Lynt B. Johnson, Asif Rashid, Sang Bae Kim,
Ju-Seog Lee, Lopa Mishra.
249
Carnosic acid effectively inhibits metastasis of
B16F10 melanoma cells. So Young Park, YooJin Jung, Ki
Won Lee, Mi-Kyung Sung, Jung Han Yoon Park.
250
Sulindac delayed and suppressed the tumor
progression, was not effective on inhibition of tumor
initiation in a human colorectal cancer mouse model
(CPC;Apc mouse). Tomohiro Adachi, Takao Hinoi, Yuu
Sasaki, Manabu Shimomura, Yasufumi Saito, Masashi
Miguchi, Hiroaki Niitsu, Yuusuke Sotomaru, Naohide Oue,
Wataru Yasui, Hideki Ohdan.
251
Aptamer conjugated prostate specific membrane
antigen (PSMA) targeting EGCG nanobioconjugate for
prostate cancer prevention and treatment. Imtiaz A.
Siddiqui, Dhruba J. Bharali, Minakshi Nihal, Vaqar M.
Adhami, Rahime Jashari, Shaker A. Mousa, Hasan Mukhtar.
252
Effects of black raspberry extract (BRB) and
related compounds on mutagenesis induced by the
tobacco carcinogen, dibenzo(a,l)pyrene and its
metabolites in cultured rat oral fibroblasts. Joseph B.
Guttenplan, Wieslawa Kosinska, Tianzhen Han, Kun-Ming
Chen, Shangmin Zhang, Krishnegowda Gowdahalli, Amin
Shantu, Gary Stoner, Karam El-Bayoumy.
253
Green tea polyphenol-mediated epigenetic
reactivation of TIMP-3 reduces invasiveness and
gelatinolytic activity in human breast cancer cells. Gauri
Deb, Vijay S. Thakur, Anil M. Limaye, Sanjay Gupta.
POSTER SESSION
Epidemiology 1
Cancer Risk: Exposures, Biomarkers, and Genetics
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
254
How can epidemiology become more effective in
reducing the burden of cancer in the 21st century? An
analysis of NCI-funded grants and the scientific
literature. Tram K. Lam, Christine Q. Chang, Scott D.
Rogers, Muin J. Khoury, Sheri D. Schully.
255
Addition of biologic therapy to traditional
disease-modifying anti-inflammatory drugs and the risk
of cancer in patients with rheumatoid arthritis: a
nationwide cohort study. Yi-Ju Chen, Chun-Ying Wu, DerYuan Chen, Jui-Lung Shen, Hsiu J. Ho, Han-Nan Liu, YunTing Chang, Ken-Nan Kuo.
256
Periodontal disease severity and incident cancer
in postmenopausal women: the Buffalo OsteoPerio
Study. Xiaodan Mai, Jo L. Freudenheim, Michael J.
LaMonte, Kathleen M. Hovey, Christopher A. Andrews,
Robert J. Genco, Jean Wactawski-Wende.
257
Circulating beta-2 microglobulin and risk of
cancer: the Atherosclerosis Risk in Communities (ARIC)
Study. Anna E. Prizment, Amy N. Linabery, Pamela Lutsey,
Heather H. Nelson, Aaron R. Folsom, Corinne Joshu,
Elizabeth A. Platz, Elizabeth Selvin.
258
Characterizing cancer gene mutations in nonsmall cell lung cancer from African American patients.
Aliccia Bollig-Fischer, Shirish Gadgeel, Wei Chen, Michele
Cote, Ann G. Schwartz, Gerold Bepler.
259
Analysis of Q356R polymorphism in BRCA1 gene
of Jamaican ovarian cancer patients. Aiyavu Chinnaiyan,
Colleen Salmon, Thiagarajan Venkatesan, Arkene Levy,
Sivanesan Dhandayuthapani, Appu Rathinavelu.
260
Integrative genomic analysis identifies epigenetic
marks that mediate genetic risk for epithelial ovarian
cancer. Devin C. Koestler, Prabhakar Chalise, Mine S.
Cicek, Julie M. Cunningham, Sebastian Armasu, Melissa C.
Larson, Jeremy Chien, Matthew Block, Kimberly R. Kalli,
Thomas A. Sellers, Ellen L. Goode, Brooke L. Fridley.
261
Implications of polygenic risk-stratified
screening for prostate cancer on overdiagnosis. Nora
Pashayan, Stephen W. Duffy, David E. Neal, Freddie Hamdy,
Jenny Donovan, Richard M. Martin, Patricia Harrington, Sara
Benlloch, Ali A. Al Olama, Mitul Shah, Zsofia Kote-Jarai,
Douglas F. Easton, Rosalind Eeles, Paul D. Pharoah.
262
The PROFILE feasibility study: genetic prostate
cancer risk stratification for targeted screening. Rosalind
Eeles, Zsofia Kote-Jarai, Antonis Antoniou, Pardeep Kumar,
Christos Mikropoulos, Tokhir Dadaev, Natalie Taylor,
Elizabeth Bancroft.
263
African American prostate cancer incidence
rates inside and outside of zinc zones. Jiro D. Mckinnis,
Hao Nguyen.
264
Breast cancer incidence and Gail risk in a
prospective study of women with benign breast disease.
Laura L. Reimers, Katherine D. Crew, Mary Beth Terry.
265
Early life exposure to air pollution and promoter
methylation in breast tumors in the Western New York
Exposures and Breast Cancer Study. Catherine Callahan,
Matthew Bonner, Peter Shields, Christine Ambrosone,
Daikwon Han, Jing Nie, Stephen Edge, Maurizio Trevisan, Jo
L. Freudenheim.
266
How many epidemiological types of breast
cancer: two, three, four, or more. William F. Anderson,
Philip S. Rosenberg, Aleix Prat, Charles M. Perou, Mark E.
Sherman.
267
Demographic differences in patients diagnosed
with breast neoplasms living in Arkansas counties that
have a history of a high percentage of crop land.
Rosalind B. Penney, Bryant Phelan, Amy M. Schrader, Page
Moore, Susan A. Kadlubar.
268
Absolute breast cancer risk according to three
risk prediction models: Inverse associations with risk of
death and poor prognostic features. Mark E. Sherman,
Laura Ichikawa, Diana Miglioretti, Pamela Vacek, Jeffrey
Tice, Ruth Pfeiffer, Karla Kerlikowske, Gretchen Gierach.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
269
Asymmetric laterality of breast tumors is
correlated with place of birth, but not race. Trevor
Sughue, James P. Brody.
270
The association between medical history and
breast cancer risk: A nationwide population-based
case-control study using claim data. Shu-Chun Chuang,
Guo-Jie Wu, Yen-Shen Lu, Ching-Hung Lin, Chao A. Hsiung.
271
Rising rates of acute lymphocytic leukemia in
Hispanic children: A review of trends in childhood
leukemia incidence from 1973–2010. Jessica BarringtonTrimis, Myles Cockburn, Catherine Metayer, W. James
Gauderman, Joseph Wiemels, Roberta McKean-Cowdin.
272
Evidence of decreased prevalence of the t(11;14)
translocation in black patients with multiple myeloma: A
multi-center study. Alexandra J. Greenberg, Sunita Philip,
Agne Paner, Sylvia Velinova, Ashraf Badros, Rosalind
Catchatorian, Dirk Larson, Rhett Ketterling, Robert A. Kyle,
Shaji Kumar, Celine M. Vachon, S. Vincent Rajkumar.
273
Commonly measured serum liver enzymes as
prospective predictors of hepatocellular carcinoma.
Magdalena Stepien, Veronika Fedirko, Talita Duarte-Salles,
Antonia Trichopoulou, Pagona Lagiou, Isabelle Romieu,
Mazda Jenab.
274
Occupational exposure to agricultural pesticides
and CLL risk. Emily J. Hallberg, Sara J. Achenbach, Kari G.
Rabe, Timothy G. Call, Cristine Allmer, Tait D. Shanafelt,
Mark Liebow, Neil E. Kay, James R. Cerhan, Susan L.
Slager.
275
Clinical and demographic comparison between
bladder cancer and upper urinary tract urothelial
carcinoma in Taiwan. Min-Che Tung, Hsin-An Chen, ChihMing Su, Ming-Te Huang, Hung-Yi Chiou, Yuan-Hung Wang.
276
Appalachian mountaintop mining particulate
matter induces malignant transformation and
tumorigenesis of human lung epithelial cells. Sudjit
Luanpitpong, Juhua Luo, Travis Kneuckles, Michael Hendryx,
Yon Rojanasakul.
277
Multiplex Epstein-Barr virus (EBV) serology in
EBV-positive and -negative gastric cancer. M. C.
Camargo, Angelika Michel, Kyoung-Mee Kim, Keitaro
Matsuo, Linda M. Liao, Javier Torres, Jovanny Zabaleta,
Margaret L. Gulley, Yasushi Yatabe, Isabel Alvarado-Cabrero,
Jolanta Lissowska, Sung Kim, Michael Pawlita, Charles S.
Rabkin.
278
Risk factors and prevalence of genital HPV
infection among adult females in US between 2003–
2010: Data from NHANES study. Srinivas S. Devarakonda,
Amarendra Neppalli, Lihong Liu, Ellen Friday, Runhua Shi.
279
Head and neck squamous cell carcinoma risk
among asphalt workers from the greater Boston area.
Scott M. Langevin, Melissa Eliot, Michael D. McClean, Karl
T. Kelsey.
280
Cancer risk in World Trade Center rescue and
recovery workers. Paolo Boffetta, Samara Solan, Sylvan
Wallenstein, Roberto Lucchini, Philip Landrigan.
281
Work history and cancer mortality risks in
90,268 United States radiologic technologists. Jason J.
Liu, Michele M. Doody, Mark P. Little, D M. Freedman,
Bruce H. Alexander, Cari M. Kitahara, Alice J. Sigurdson,
Terrence Lee, Preetha Rajaraman, Jeremy S. Miller, Diane
M. Kampa, Steven L. Simon, Dale L. Preston, Martha S.
Linet.
282
Smoking and increased age in hematuric
patients significantly confound the accuracy of
classifiers for the diagnosis of urothelial cancer. Kate E.
Williamson.
283
Biomarker search using gene expression
databases in a phase III, controlled clinical trial of
postoperative adjuvant chemotherapy for stage III colon
cancer (acts-cc): Correlation between gene expression
and DNA copy number. Hiroyuki Uetake, Toshiaki Ishikawa,
Megimi Ishiguro, Shigeyuki Matsui, Kenichi Sugihara, ACTSCC Study Group.
Poster
Section
11
11
231
POSTER SESSION
Epidemiology 2
Poster
Section
12
12
Epigenetic Biomarkers and Novel Approaches in Biomarker Research
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
232
284
Epigenome-wide study of sister study samples
replicates and extends cpg sites associated with
cigarette smoking. Sara S. Harlid, Zongli Xu, Vijayalakshmi
Panduri, Dale P. Sandler, Jack A. Taylor.
285
Integrative analyses of genome-wide expression
of miRNAs and DNA methylation patterns in
hepatocellular carcinoma to improve functional
biomarker identification. Jing Shen, Shuang Wang, Abby
B. Siegel, Helen Remotti, Qiao Wang, Iryna Sirosh, Regina
M. Santella.
286
Epigenome-wide association study of normal
lung tissues identifies hypomethylation of multiple CpG
sites associated with cigarette smoking. Wen-Qing Li,
Jianxin Shi, William Wheeler, Neil Caporaso, Ite LairdOffspringa, Maria Teresa Landi.
287
Characterizing the genetic basis of methylome
diversity in histologically normal human lung tissue.
Jianxin Shi, Crystal Marconett, Jubao Duan, Paula Hyland,
Peng Li, Zhaoming Wang, William Wheeler, Mihaela
Campan, Jing Huang, Weiyin Zhou, Tim Triche, Laufey
Amundadottir, Amy Hutchinson, Po-Han Chen, Beiyun Zhou,
Brian Chung, Pier Alberto Bertazzi, Andrew W. Bergen,
Mathew Freedman, Diane Lee, Kim Siegmund, Andrew Clay
Warner, Ben Berman, Angela C. Pesatori, Zea Borok, Dario
Consonni, Nilanjan Chatterjee, Margaret Tucker, Neil
Caporaso, Stephen J. Chanock, Ite A. Laird-Offringa, Maria
Teresa Landi.
288
DNA methylation patterns in peripheral blood
and the relationship with cancer susceptibility loci at
chromosome 8q24. Kathryn H. Barry, Lee Moore, Joshua
Sampson, Liying Yan, Ann Meyer, Charles C. Chung,
Meredith Yeager, Laufey Amundadottir, Sonja I. Berndt.
289
Aberrant DNA methylation of DLX4 and SIM1 is a
predictive marker for disease progression of uterine
cervical low-grade squamous intraepithelial lesion.
Junichi Sakane, Kiyomi Taniyama, Kazuaki Miyamoto,
Akihisa Saitou, Kazuya Kuraoka, Kazuhiro Sentani, Naohide
Ooue, Wataru Yasui.
290
Constitutional BRCA1 methylation is a major
predisposition factor for high-grade serous ovarian
cancer. Alexander Dobrovic, Thomas Mikeska, Kathryn
Alsop, Ida Candiloro, Joshy George, Gillian Mitchell, David
Bowtell.
291
Genomewide scale epigenetic profile and
prostate cancer recurrence. Hui-Yi Lin, Anders Berglund,
Thomas Sellers, Ardeshir Hakam, Hyun Park, Julio PowSang, Jong Y. Park.
292
Aberrant methylation of miR-34b as a potential
mechanism for increased shiftwork-mediated breast
cancer susceptibility. Daniel I. Jacobs, Ran Liu, Johnni
Hansen, Alan Fu, Richard G. Stevens, Yong Zhu.
293
High-throughput methylation sequencing of
targeted genes in breast cancer specimens using
nanofluidic PCR prepared libraries. Jun Wang, Zibo Li,
Yepeng Wu, Xinwu Guo, Shengyun Li, Zhi Xiao, Feiyu Chen,
Zhongping Deng, Lizhong Dai, Wenjun Yi, Lili Tang.
294
Blood lipids, colorectal adenomas, and nonadenomatous polyps: A comparison of associations from
clinical measurements and Mendelian randomization.
Michael N. Passarelli, Polly A. Newcomb, Karen W. Makar,
Andrea N. Burnett-Hartman, John D. Potter, Melissa P.
Upton, Lee-Ching Zhu, Michael E. Rosenfeld, Stephen M.
Schwartz, Carolyn M. Rutter.
295
Urine and serum biomarkers of pancreatic
cancer. Brian M. Nolen, William Grizzle, Randall Brand,
Anna E. Lokshin.
Poster Abstract
Board Number
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
296
Pre-treatment clinical laboratory tests indicative
of metabolic status are associated with survival in
patients with non-small cell lung cancer. Fanmao Zhang,
Qing H. Meng, Yuanqing Ye, Michelle A. Hildebrandt,
Maosheng Huang, Xifeng Wu.
297
Protein markers predict overall survival in
glioblastoma multiforme. Lindsay C. Stetson, Jill S.
Barnholtz-Sloan.
298
Serum MicroRNAs as biomarkers in early stage
non-small cell lung cancer. Yuanqing Ye, Yan Wang, Jack
Roth, Xifeng Wu.
299
Circulating microRNAs in association with
colorectal neoplasia. Scott V. Adams, Polly A. Newcomb,
Andrea N. Burnett-Hartman, Melissa P. Upton, Lee-Ching
Zhu, Margaret Mandelson, John D. Potter, Karen W. Makar.
300
Expression profiling of miRNA in asbestosrelated lung adenocarcinoma. Yasen Mahmut, Hironori
Ninomiya, Noriko Motoi, Satoru Itoh, Mutsunori Fujiwara,
Yuichi Ishikawa.
301
Application of RNA sequencing to detect fusion
transcripts in benzene-exposed workers. Nicholas K.
Akers, Qing Lan, Cliona M. McHale, Luoping Zhang, Reuben
Thomas, Alan E. Hubbard, Stephen M. Rappaport, Roel
Vermeulen, Guilan Li, Songnian Yin, Nathaniel Rothman,
Martyn T. Smith.
302
Novel implementation of cloud computing and
mobile technology to transform data collection and
management in cancer epidemiology. Jennifer L. Benbow,
Christina A. Clarke, Hannah L. Park, Christine N. Duffy,
Nadia T. Chung, Amy E. Brankin, Karen Angell-Mendez,
Argyrios Ziogas, Rich Pinder, Dennis Deapen, Hoda AntonCulver, Susan L. Neuhausen, Leslie Bernstein, Sophia S.
Wang, James V. Lacey.
303
Cell Slider: using crowd sourcing for the scoring
of molecular pathology. Paul D. Pharoah.
304
Feasibility study of next-generation sequencing
on residual formalin-fixed paraffin-embedded tissues.
Danielle M. Carrick, Sean Altekruse, Corrine Camalier,
Wendy Cozen, Brenda Hernandez, Charles Lynch, Paul
McGregor, Michele G. Mehaffey, Lisa McShane, JoyAnn
Phillips Rohan, Mickey Williams, Elizabeth M. Gillanders,
Leah E. Mechanic, Sheri Schully.
305
Ultra-low coverage exome sequencing of FFPE
tumor specimens identifies exposure to carcinogenic
aristolochic acid. Xavier Castells, Sandra Karanovic, Magali
Olivier, Maude Ardin, Florence Le Calvez-Kelm, Catherine
Voegele, James McKay, Damir Dittrich, Karla Medak Tomic,
Kathleen Dickman, Arthur P. Grollman, Bojan Jelakovic, Jiri
Zavadil.
306
DNA Repair Enzyme Signature of a cohort of 100
healthy individuals using peripheral blood mononuclear
cells: In the search of cancer susceptibility biomarkers.
Sylvie Sauvaigo, Lise Jacqueroux, Benoit Pitiot, Sylvain
Caillat, Nicolas Gonnet, Jean-Luc Cracowski.
307
The use of biospecimens in cancer population
science research. Danielle M. Carrick, Eliza Mette, Brittany
Hoyle, Scott D. Rogers, Elizabeth M. Gillanders, Sheri D.
Schully, Leah E. Mechanic.
308
Personal determinants of the human gut
microbiome. Christine Dominianni, Rashmi Sinha, James J.
Goedert, Zhiheng Pei, Liying Yang, Richard B. Hayes,
Jiyoung Ahn.
309
Replication of 50 high impact preclinical cancer
studies to examine rates of reproducibility. William Gunn,
Elizabeth J. Iorns.
POSTER SESSION
Molecular and Cellular Biology 1
Autophagy
Poster
Section
Poster Abstract
Board Number
1.
310
Identification of secreted proteins that reflect
intracellular autophagy dynamics in melanoma. Adam
Akl, Xiaowei Xu, Shengfu Piao, Ravi K. Amaravadi, David W.
Speicher.
2.
311
Autophagic pathways and activity in breast and
pancreatic cancer. Mar Egilsson, Ulfur Thoroddsen, Jon G.
Jonasson, Margret H. Ogmundsdottir, Helga M.
Ögmundsdottir.
3.
312
Autophagy mediates HIF2␣ degradation and
suppresses renal tumorigenesis. Xian-De Liu, Jun Yao,
Durga N. Tripathi, Zhiyong Ding, Yi Xu, Mianen Sun,
Jiangwei Zhang, Shanshan Bai, Peter German, Anh Hoang,
Lijun Zhou, Xuesong Zhang, Claudio J. Conti, Eleni
Efstathiou, Tony N. Eissa, Gordon B. Mills, Cheryl L. Walker,
Eric Jonasch.
4.
313
Essential role of ataxia telangiectasia in
mitochondrial autophagy in mantle cell lymphoma. Aloke
K. Sarkar, Kumudha Balakrishnan, Mary Ayres, Sattva S.
Neelapu, Varsha Gandhi.
5.
314
Low-dose NAMPT inhibition by FK866 initiates
autophagy to counteract cellular energy crisis, which is
overridden by apoptosis at higher drug concentrations.
Eric Bouchard, Iris Gehrke, Versha Banerji.
6.
315
Regulation of the transcription factor TFEB and
the autophagic/lysosomal network by GSK3 in
pancreatic cancer cells. Benoît Marchand, Alexandre
Raymond-Fleury, Marie-Josée Boucher.
7.
316
Modifying autophagy through combination
treatments as a potential therapeutic strategy in head
and neck squamous cell carcinoma (HNSCC). Omar G.
Ahmed, Wen-Liang Kuo, Tai-Fen Wei, Jeannette S. Messer,
Marina Sharifi, Madhavi Nagilla, Kay Macleod, Ezra E.
Cohen.
8.
317
Transcriptional repressor DAXX promotes
prostate cancer tumorigenicity via suppression of
autophagy. Lorena A. Puto, Tony Hunter.
9.
318
Specific role of Mieap ␣ in Mieap-induced
vacuole generation through an interaction with UVRAG.
Yasuyuki Nakamura, Hiroki Kamino, Yuri Saito, Noriaki
Kitamura, Hitoya Sano, Hirofumi Arakawa.
10.
319
Combination of miR-30e overexpression and
proanthocyanidin treatment inhibits autophagy and
induces apoptosis in human glioblastoma stem cells
and SNB19 cells. Mrinmay Chakrabarti, Swapan K. Ray.
Poster Abstract
Board Number
11.
320
Frequent inactivation of the Mieap-regulated
mitochondrial quality control in pancreatic and breast
cancer. Hiroki Kamino, Yasuyuki Nakamura, Hitoya Sano,
Ryuya Murai, Yuri Saito, Manabu Futamura, Kazuhiro
Yoshida, Nobuyoshi Hiraoka, Yae Kanai, Ryoji Kushima,
Toyomasa Katagiri, Hirofumi Arakawa.
12.
321
Autophagy is required for focal adhesion
turnover, tumor cell motility and metastasis. Marina N.
Sharifi, Christopher Collier, Lauren Drake, Hong Chen,
Stephanie Mui, Kay F. Macleod.
13.
322
The integrin ␣6A splice variant regulates Wnt/␤catenin and colorectal cancer cell proliferation through
autophagic degradation of DVL2. Jean-Francois Groulx,
Jean-Francois Beaulieu.
14.
323
Development of high throughput flow cytometry
assays to support target therapy/personalized medicine
in oncology drug discovery & development: Developing
and optimizing a flow cytometry-based autophagy
detection method/panel for oncology drug discovery &
development. Zheng Feng, Theodore Baginski, Michael
Donio, Diane Werth, Jacob Bode.
15.
324
Cytoprotective versus nonprotective autophagy
induced by radiation in head and neck cancer cells.
Duaa M. Bakhshwin, David Gewitz, Andrew Yeudall.
16.
325
TDP-43 promotes glioblalstoma cell survival
under nutrient deprivation condition via activating
autophagy. Yun-Ching Chang, Tzu-Wei Lin.
17.
326 ␤III-Tubulin and cell survival: Novel role in
endoplasmic reticulum stress and autophagy in nonsmall cell lung cancer. Amelia Parker, Joshua A.
McCarroll, Maria Kavallaris.
18.
327
Targeting autophagy overcomes enzalutamide
resistance in castrate-resistant prostate cancer cells
and improves therapeutic response in a xenograft
model. Joy C. Yang, Hao G. Nguyen, Hsing-Jien Kung, XuBao Shi, Derya Tilki, Ralph W. deVere White, Allen C. Gao,
Christopher P. Evans.
19.
328
Novel quantitative autophagy analysis by
organelle flow cytometry after cell sonication. Michael
Degtyarev, Mike Reichelt, Kui Lin.
20.
329
Rottlerin induced autophagy by targeting
multiple sites that leads to the apoptosis in cancer
stem cells. Dhruv Kumar.
14
14
233
POSTER SESSION
Poster
Section
15
15
Bcl-2 Family and Mitochondrial Pathway of Apoptosis
Poster Abstract
Board Number
1.
2.
331
Targeting mcl1 in npm1-mutant aml. Haitham
Qutob, Amina Abdul-Aziz, Amy Proudfoot, Martin Grundy,
Nigel H. Russell, Monica Pallis, Claire H. Seedhouse.
3.
332
Targeting BCL-2 in hypodiploid acute
lymphoblastic leukemia. Ernesto Diaz-Flores, Julie Weng,
Jon Akutagawa, Linda Holmfeldt, Triona Chonghaile,
Anthony Letai, Charles Mullighan, Benjamin Braun, Mignon
Loh.
4.
333
ZBP-89 downregulates histone deacetylase 3
(HDAC3) through inhibition of I kappa B in hepatocelluar
carcinoma (HCC). Paul B. Lai, Cai-Guo Ye, Liping Liu,
Ming-Liang He, Rocky Ho, George G. Chen.
12.
341
Imatinib induces expression of Bim and
apoptosis in chronic myelogenous leukemia cells via
p38/H2AX pathway. Min Xiong, Tianhui Niu, Yaqiong Dong,
Chengrong Lu.
13.
342
Telomerase-dependent oncolytic adenovirus
sensitizes human osteosarcoma cells to chemotherapy
through Mcl-1 downregulation. Shuhei Osaki, Toshinori
Omori, Hiroshi Tazawa, Joe Hasei, Yasuaki Yamakawa,
Tsuyoshi Sasaki, Toshiyuki Kunisada, Yasuo Urata,
Toshifumi Ozaki, Toshiyoshi Fujiwara.
14.
343
Targeting SF3B1 mediated splicing control of
Mcl-1 in chronic lymphocytic leukemia. Rong Chen,
Yuling Chen, Emanuela M. Ghia, Laura Rassenti, Thomas
Kipps, Michael J. Keating, William G. Wierda, William
Plunkett.
15.
344
Silencing RBBP6 (retinoblastoma binding protein
6) sensitizes breast cancer cells to staurosporine and
camptothecin-induced cell death. Lesetja R. Motadi,
Pontsho Moela, Mpho S. Choene.
5.
334
Mcl-1 protects prostate cancer cells from
chemotherapy-induced DNA damage. Carlos Perez-Stable,
Teresita Reiner, Alicia de las Pozas, Ricardo Parrondo.
16.
6.
335
Aspirin, di-aspirin and their toxicity to colorectal
cancer. Chandra S. Kankipati, Christopher J. Perry, Iain D.
Nicholl.
345
Sensitivity of human leukemic sup-t1 cells to
chemotherapeutic agents. Andrew D. Gisis, Rheem D.
Medh.
17.
7.
336
IL-6 primes melanoma cells from early stages to
statin induced apoptosis. Christoph Minichsdorfer,
Christine Wasinger, Martin Hohenegger.
8.
337
Carfilzomib synergistically enhances ABT-263induced apoptosis due to NOXA induction in KRAS wild
type and mutant colorectal cancer cell lines. Shengbing
Huang, Koichi Okamoto, Frank A. Sinicrope.
346
Differentiation induced apoptosis in AML cells:
The role of p73 in p53-independent versus p53mediated apoptosis. Michael Roberts, Rizwan Saffie,
Harold Salmons, Mansoor Ghoto, Juliana Schneider, Jeffrey
Forrester.
18.
347
Dasatinib accelerates valproic acid-induced
acute myeloid leukemia cells death by regulation of
differentiation capacity. Sook-Kyoung Heo, Eui-Kyu Noh,
Dong-Joon Yoon, Jae-Cheol Jo, Jae-Hoo Park, Hawk Kim.
19.
348
JMJD3 promotes the survival of diffuse large
B-cell lymphoma subtypes via distinct mechanisms. Yan
Zhang.
20.
349
mTOR complex 2 (mTORC2) positively regulates
Mcl-1 stability by suppressing GSK3-dependent and
FBXW7-mediated proteasomal degradation of Mcl-1.
Junghui Koo, Ping Yue, Fadlo R. Khuri, Shi-Yong Sun.
9.
234
330
The Wnt signal transcription factor TCF-4
directly regulates Bcl-xL expression in human
hepatocellular carcinoma cells. Hironori Koga, Miran Kim,
Anna Nakamura, Hirohisa Yano, Mitsuhiko Abe, Yu Ikezono,
Toru Nakamura, Takuji Torimura, Jack R. Wands, Michio
Sata.
Poster Abstract
Board Number
338
Mcl-1 mediates TWEAK/Fn14-induced non-small
cell lung cancer survival and therapeutic response.
Timothy G. Whitsett, Ian T. Mathews, Michael H. Cardone,
Ryan J. Lena, William E. Pierceall, Michael Bittner, Chao
Sima, Janine LoBello, Glen J. Weiss, Nhan L. Tran.
10.
339
Inhibition of NANOG/NANOGP8 downregulates
MCL-1 in colorectal cancer (CRC) cells, enhances the
efficacy of BH3 mimetics and inhibits clonogenicity.
Abid R. Mattoo, Jingyu Zhang, Luis A. Espinoza, Snorri S.
Thorgeirsson, J. M. Jessup.
11.
340
Mitochondrial priming of new targeted agents in
acute myeloid leukemia. Jo Ishizawa, Kensuke Kojima,
Seshagiri R. Duvvuri, Teresa McQueen, Vivian R. Ruvolo,
Graciela M. Nogueras-Gonzalez, Xuelin Huang, William
Pierceall, Michael Cardone, Ryan Lena, Camille Doykan,
Sharon Shacham, Michael Kauffman, Marina Konopleva,
Michael Andreeff.
POSTER SESSION
Cancer Systems Biology
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
350
Virtualization of drug testing by predictive
systems biology modeling for optimal drug treatment of
cancer cells and drug repositioning. Alexander Kuehn,
Felix Dreher, Svetlana Peycheva, Reha Yildiriman, Verena
Lehmann, Thomas Kessler, Christoph Wierling, Hans
Lehrach, Bodo M. Lange.
351
Comparative studies on SIRT6 and SIRT7
interactomes: implications of important roles in cancer
via associating with interacting partners. Namgyu Lee,
Jung-Hee Kwon, Sung Jin Park, Kwan Yong Choi.
352
Integrating transcriptomic data using metacore
pathway analysis to identify novel biomarkers of
bevacizumab target engagement. Chris D. Willis, Kyle
Lafferty-Whyte, Melinda Baker, Richard G. Pestell.
353
How highly purified lentiviral vectors matter
when it comes to genetically modifying your cells for
the generation of in vitro or in vivo predictive cancer
models. Adriana Georges, Régis Gayon, Christine Duthoit,
Yohann Moal, Raphael Sevrain, Nicolas Martin, Pascale
Bouillé.
Poster Abstract
Board Number
13.
362
Computational drug repositioning identifies
dexamethasone as potential ERG inhibitor. Kaitlyn
Gayvert, Cynthia Cheung, David Rickman, Olivier Elemento.
14.
363
Planar filtered gene regulatory networks in
breast cancer. Won-min Song, Tao Huang, Seungyeul Yoo,
EunJee Lee, Yongzhong Zhao, Li Wang, Zhidong Tu, Xudong
Dai, Hanna Irie, Jun Zhu, Bin Zhang.
15.
364
Mechanical properties of growing melanocytic
nevi and the progression to melanoma. Alessandro
Taloni, Alexander A. Alemi, Emilio Ciusani, James Sethna,
Stefano Zaperi, Caterina A. Laporta.
16.
365
Using radionuclear imaging and mechanistic
modeling to assess the therapeutic potential of
antibody-drug conjugates (ADCs). Shu-Wen Teng, Ozlem
Yardibi, Julie Zhang, Donna Cvet, Johnny Yang, Kelly Orcutt,
Melissa Gallery, Arijit Chakravarty, Wen Chyi Shyu, Jerome
Mettetal, Daniel Bradley, Petter Veiby.
17.
366
Translational modeling of docetaxel-thalidomide
combination treatment in metastatic, castrate-resistant
prostate cancer: predicting clinical response using
preclinical data. Eric Fernandez, Hitesh Mistry, Frances
Brightman, David Orrell, William L. Dahut, William D. Figg,
Wilfried D. Stein, Christophe Chassagnole.
5.
354
The replication stress response defect is
associated with tumor-initiating cell formation. Curtis
Chun-Jen Lin, Hui Dai, Shiaw-Yih Lin.
6.
355
The integrated analysis of multiple, highdimensional data types by joint matrix approximations
of rank-1 with applications to liver cancer and
glioblastoma. Gordon S. Okimoto.
18.
357
A systems biology approach for rational
molecular network inference. Megan E. Egbert, Michelle
L. Wynn, Zhi Fen Wu, Rabia A. Gilani, Santiago Schnell,
Sofia D. Merajver.
367
Tumorigenesis: an investigation by network
evolution and perturbations of somatic mutations in
cancer interactome. Feixiong Cheng, Peilin Jia, Quan
Wang, Chen-Ching Lin, Zhongming Zhao.
19.
358
Integrative pathway analysis of molecular
profiles of glioblastoma multiforme for predicting
patient survival. Arda Durmaz, Douglas Brubaker, Gurkan
Bebek.
368
Inferred regulatory interaction network from
prostate cancer reveals potential regulators coordinating
progression and metastasis. Xudong Dai, Yixuang Gong,
Matthew D. Galsky, Eric E. Schadt, William K. Oh, Jun Zhu.
20.
369
Network-based stratification of thyroid cancer.
Matan Hofree, John Paul Y. Shen, Trey Ideker.
21.
370
Modeling signaling networks in tumor
immunology. Trevor Clancy, Eivind Hovig.
22.
371
A Pareto efficiency model to explain hybrid
cellular behavior in tumor ecosystem. Ardeshir Kianercy,
Kenneth J. Pienta.
23.
372
Choosing the right schedule for progression free
survival: A systems pharmacology approach. Mayankbhai
Patel, Jerome Mettetal, Matthew Cohen, Santhosh Palani,
Keisuke Kuida, Mark Hixon, Joseph Bolen, Wen Chyi Shyu,
Dennis Noe, Arijit Chakravarty.
8.
9.
10.
11.
12.
359
An age-related 99-gene signature from
glioblastoma implicates differences in survival related
to RAS activation. Andrew D. Trister, Robert Rostomily,
Stephen H. Friend.
360
Thousands of published cancer signatures and
pathways can be collapsed into a handful of nonredundant gene programs: a TCGA pan-cancer analysis.
Denise M. Wolf, Cheng Fan, Katherine A. Hoadley, Christina
Yau, Artem Sokolov, TCGA Network, Josh Stuart, Charles
Perou, Laura van ’t Veer.
361
Illuminating the effects of tissue degradation to
improve the management of tissues used in cancer
research or clinical applications. Scott D. Jewell, Eric
Collins, John Beck, David Monsma, Dawna Dylewski,
Andrew Borgman, Mary Winn, Galen Hostetter.
16
16
235
POSTER SESSION
Poster
Section
17
17
Epigenetics 1
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
236
373
An siRNA screen identifies CHD4 as a target for
epigenetic therapy. Yasuyuki Okamoto, Jumpei Yamazaki,
Takahiro Sato, Matteo Cesaroni, Woonbok Chung, Judith
Garriga, Jaroslav Jelinek, Richard A Katz, Jean-Pierre Issa.
374
A novel sequencing method for genome-wide
profiling of 5-hydroxymethylcytosine with single-base
resolution. Xueguang Sun, Tzu-Hung Chung, Yap Ching
Chew, Darany Tan, Xi-Yu Jia.
375
A novel diagnostic assay for detection of
primate-specific RNA editing events in leukemia stem
cells. Leslie A. Crews, Qingfei Jiang, Maria A. Zipeto,
Angela C. Court, Christian L. Barrett, Marco A. Marra, Kelly
A. Frazer, Catriona H. Jamieson.
376
P-cadherin overexpression is associated with
poor prognosis in pancreatic carcinoma and is
regulated by its promoter hypomethylation. Keita
Sakamoto, Katsunori Imai, Shigeki Nakagawa, Hidetoshi
Nitta, Hiromitsu Hayashi, Akira Chikamoto, Takatoshi Ishiko,
Toru Beppu, Hideo BaBa.
377
SMYD2-dependent PARP1 methylation promotes
Poly(ADP-ribosyl)ation activity in cancer cells. Lianhua
Piao, Yusuke Nakamura, Ryuji Hamamoto.
378
Discovering potential epigenetic anti-cancer
drugs derived from natural compounds. Hanghang Zhang,
Noël J. RAYNAL, Marlene A. Jacobson, Jean-Pierre Issa.
379
TARBP1, a member of the SPOUT
methyltransferase family, is involved in human
carcinogenesis. Makoto Nakakido, Yusuke Nakamura, Ryuji
Hamamoto.
380
Discovery of new epigenetic drugs among FDAapproved drug libraries. Noël J. Raynal, Justin T. Lee,
Youjun Wang, Judith Garriga, Gabriel Malouf, Sarah Dumont,
Elisha J. Dettman, Vazganush Gharibyan, Saira Ahmed,
Woonbok Chung, Wayne E. Childers, Magid Abou-Gharbia,
Ryan A. Henry, Andrew Andrews, Jaroslav Jelinek, Ying Cui,
Stephen B. Baylin, Donald L. Gill, Jean-Pierre J. Issa.
381
Characterizing the role of heterochromatin
protein 1 gamma in normal intestinal homeostasis and
tumorigenesis. Ka Ian Lio, Alan Clarke, Karen Reed.
382
Inhibition of BET bromodomain proteins as a
therapeutic approach in prostate cancer. Anastasia Wyce,
Yan Degenhardt, Yuchen Bai, BaoChau Le, Susan
Korenchuk, Ming-Chih Crouthamel, Charles F. McHugh,
Robert Vessella, Caretha L. Creasy, Peter J. Tummino, Olena
Barbash.
383
Is loss of MGMT a therapeutic target in lung
cancer. Hongdo Do, Paul Mitchell, Alexander Dobrovic.
384
Epigenetic derangements in histone and cytosine
methylation are unique to diffuse intrinsic pontine
glioma (DIPG). Sama Ahsan, Eric Raabe, Michael C.
Haffner, Javad Nazarian, Katherine Warren, Leo Ballester,
Martha Quezado, Charles Eberhart, Fausto J. Rodriguez.
385
Tamoxifen-resistant breast cancer: DNA
methylation and expression of MAGED1. Rahul M.
Jawale, Krisitin Williams, Maxwell Lee, Howard H. Yang,
Jonine Figueroa, Mark Sherman, Christopher N. Otis,
Kathleen Arcaro.
386
Epigenome-wide association study to predict
breast cancer risk in European Prospective Investigation
into Cancer and Nutrition (EPIC) cohort. Srikant
Ambatipudi, Veronique Chajes, Florence Le Calvez-Kelm,
Cyrille Cuenin, Geoffroy Durand, Isabelle Romieu, Zdenko
Herceg.
387
Activating transcription factor 3 (ATF-3)
expression is a potential marker of tumor response to
the HDAC inhibitor Pracinostat. Dhanya Sooraj, Dakang
Xu, Jason Cain, Daniel Gold, Bryan R. Williams.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
388
Epigenome-wide profiling identified significant
differences in DNA methylation between AfricanAmerican and European-American men with prostate
cancer. Bernard Kwabi-Addo, Songping Wang, Joseph
Devaney.
389
Epigenetic and proteomic analysis of gastric
tumor and its histologically free proximal and distal
margins. Paulo C. Carvalho, Carlos Eduardo Carvalho,
Guilherme P. Bravo Neto, Juliana F. Carvalho, Thais Mac
Cormick, Priscila F. Aquino, Marcelo M. Silva, Maria da
Gloria D. Carvalho.
390
Impact of loss of IGF2 genomic imprinting on
IGF1R signaling and cancer stem cell-associated
biomarkers in gastric cancer. Teng Chen, Ronghua Zhao,
Qinsong Zuo, Chao Chen, Menfan Li, Dianxu Feng, Han Cai.
391
Identification of a novel tumor-suppressor gene
through methylome analysis in smoking-associated lung
adenocarcinoma. Issei Imoto.
392
Helicase-like transcription factor (HLTF)
expression and gene methylation in FFPE colon tumors.
Ludovic Dhont, Alisson Di Stefano, Angela Szucs, Fadi
Abdulsater, Isabelle Bar, Paul Delrée, Alexandra Belayew.
393
Genome-wide molecular characterization of CIMP
positive stage III colon cancer using cDNA microarray
analysis. Hongjae Jeon, Se H. Kim, Kyu H. Park, Hei-Cheul
Jeung, Nam K. Kim, Minkyu Jung, Kang Y. Lee, Chan H.
Park, Sun Y. Rha, Hyun C. Chung, Joong B. Ahn.
394
TET1, which act as an tumor suppressor gene, is
suppressed by DNA hypermethylation in gastric cancer.
Jong-Lyul Park, Oh-Hyung Kwon, Kyu Sang Song, SeonYoung Kim, Yong Sung Kim.
395
Evaluation of ZAR1 and SFRP4 promoter
methylation as potential biomarkers for detection of
cervical cancer in cytobrush and urine samples. Rene E.
Hoffstetter, Priscilla Brebi, Alejandra Andana, Carmen G. Ili,
Kurt L. Buchegger, Tamara Viscarra, Javier Retamal, Juan
C. Roa.
396
TET oxidase activity accumulated on methyl-CpG
sites extensively upregulates methylated genes through
DNA demethylation. Shinichi Fukushige, Yasuhiko
Mizuguchi, Akira Horii.
397
Transcriptional regulation of SPAG6 by DNA
methylation in NSCLCs. Corinna Altenberger, Gerwin Heller,
Bianca Schmid, Barbara Ziegler, Leonhard Müllauer, György
Lang, Adelheid End-Pfützenreuter, Balazs Döme, BrittMadeleine Arns, Kwun M. Fong, Casey M. Wright, Ian A.
Yang, Walter Klepetko, Christoph C. Zielinski, Sabine
Zöchbauer-Müller.
398
Epigenetic changes in testis specific Y-like 5
gene in human prostate carcinoma: Gene expression
analysis and its potential as a biomarker. Senthil R.
Kumar, Jeffrey Bryan, Magda Esebua.
399
Establishment of hypomethylating agent-resistant
cell lines using a cell line from a patient with acute
myeloid leukemia evolved from myelodysplastic
syndrome (MOLM-13). Dae Ro Choi, Eun-Hye Hur, Ju Hyun
Moon, Bon-Kwan Goo, Yunsuk Choi, Do Young Lee,
Seonggu Ro, Joong Myung Cho, Je-Hwan Lee.
400
5-azacytidine nucleosides and their derivatives:
Molecular hallmarks of drug resistance. Khushboo
Agrawal, Petr Dzubak, Ivo Frydrych, Dusan Holub, Petr Vojta,
Marcela Krecmerova, Miroslav Otmar, Marian Hajduch.
401
Array analysis of cigarette smoke condensate
(CSC) on gene promoter methylation in human lung
cells. Lascelles E. Lyn-Cook, Beverly Word, George
Hammons.
402
Tumor necrosis factor-alpha and apoptosis
induction in melanoma cells through histones
modification by 3-deazaneplanocin A. Ryo Tanaka,
Nicholas Donovan, Qiang Yu, Reiko Irie, Dave S. Hoon.
POSTER SESSION
Epigenetics 2
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
403
Expression of genes spanning a breast cancer
susceptibility locus on 6q25.1 is modulated by
epigenetic modification. Jackie White, Sofie van Huffel,
Jisha Antony, Julia A. Horsfield, Anita K. Dunbier.
404
Function of Brg1 chromatin remodeling factor in
sonic hedgehog-dependent medulloblastoma
development. Xuanming Shi, Zilai Zhang, Qiu Wang, Jiang
Wu.
405
Mbd3 localizes at promoters, gene bodies and
enhancers of active genes. Takashi Shimbo, Ying Du, Sara
A. Grimm, Archana Dhasarathy, Deepak Mav, Ruchir R.
Shah, Huidong Shi, Paul A. Wade.
406
A potential new mechanism for PTEN to maintain
genome stability. Lili Gong, Shiaw-Yih Lin.
407
Targeted Hi-C and integrative analyses reveal
functionality of colorectal cancer risk loci. Roland Jäger,
Gabriele Migliorini, Marc Henrion, Nicola Whiffin, Laura
Broome, Nicola Dryden, Takashi Nagano, Stefan
Schoenfelder, Peter Fraser, Olivia Fletcher, Richard
Houlston.
408
The relationship between LINE-1 hypomethylation
and fibrosis status in noncancerous liver tissues of
hepatocellular carcinoma patients. Yoshifumi Baba,
Kazuto Harada, Keisuke Kosumi, Hiromitsu Hayashi,
Hidetoshi Nitta, Daisuke Hashimoto, Akira Chikamoto, Toru
Beppu, Hideo Baba.
409
Regulation of chromatin remodeling in leukemia
by Ikzf1 and Casein Kinase II. Jonathon L. Payne, Carlos
M. Casiano, Kimberly J. Payne, Justin Sloane, Elanora
Dovat, Chunhua Song, Sinisa Dovat.
410
Epigallocatechin gallate inhibits colon cancer
cell proliferation by modulating epigenetic enzymes
(DNMTs, HDACs, and HATs). April B. Cabang, Yuan Fang,
Jay Morris, Michael J. Wargovich.
411
Targeted PF1, JARID1B inhibition induces
epigenetic reprogramming in triple negative breast
cancer. Rossitza Christova, Kevin Petrie, Nidhi Bansal, Boris
Leibovitch, Louise Howell, Veronica Gil, Ming-Ming Zhou,
Edgardo Ariztia, Eduardo Farias, Arthur Zelent, Samuel
Waxman.
412
DNA methylation in ductal carcinoma in situ and
its relation with disease progression. Kevin C. Johnson,
Panpan Chen, Devin Koestler, Julia E. Weiss, Erik G.
Jenson, Jonathan D. Marotti, Tracy Onega, Brock C.
Christensen.
413
Validation of methylation biomarkers that
distinguish normal colon mucosa from cancer patients
from normal colon mucosa of patients without cancer.
Matteo Cesaroni.
414
Aberrant DNA methylation and expression of
mRNA in EGFR-mutant lung cancer cell line with longterm exposure to gefitinib. Hideki Terai, Kenzo Soejima,
Katsuhiko Naoki, Hiroyuki Yasuda, Takashi Sato, Daisuke
Arai, Keiko Ohgino, Kota Ishioka, Aoi Kuroda, Tetsuo Tani,
Ayano Ohashi, Makoto Nishino, Masayoshi Miyawaki, Junko
Hamamoto, Tomoko Betsuyaku.
415
Aberrant methylation of REPRIMO, a TP53
dependent G2 arrest mediator candidate, in breast
cancer. Kurt Buchegger, Carmen Ili, Pablo Letelier, Ismael
Riquelme, Pamela Leal, Alejandro Corvalán, Tim Huang,
Priscilla Brebi, Juan Carlos Roa.
416
New technology to detect DNA methylation in
plasma sample from lung cancer patients. Keiko Shinjo,
Eisaku Kondo, Yutaka Kondo.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
417
DNA methylation changes in Lynch syndrome
and FAP-associated colorectal tumorigenesis. Satu Valo,
Sippy Kaur, Ari Ristimäki, Laura Renkonen-Sinisalo, Heikki
Järvinen, Jukka-Pekka Mecklin, Minna Nyström, Päivi
Peltomäki.
418
Epigenetic regulation of glypican-3 in
hepatocellular carcinoma. Thu Le Trinh, William Puszyk,
Chen Liu.
419
The role of histone methyltransferase G9a in
chemotherapeutic drugs-induced DNA damage. Chia-Wen
Liu.
420
Tet family proteins and 5-hydroxymethylcytosine
in esophageal squamous cell carcinoma. Asuka Murata,
Yoshifumi Baba, Ryuichi Karashima, Satoshi Ida, Yu
Imamura, Takatsugu Ishimoto, Shiro Iwagami, Yasuo
Sakamoto, Yuji Miyamoto, Naoya Yoshida, Hideo Baba.
421
Differences of DNA methylation patterns
according to histologic subtypes of early gastric
carcinomas. Khalilullah Mia-Jan, Hoon Ryu, Mi-Ra Lee,
Sun-Young Ji, Mee-Yon Cho.
422
DNA hypermethylation or upregulated miRNA21
expression potentially leads to decreased mRNA
expression of COL1A2, SFRP2, SOCS3, BCL2, MAL and
PTGS2 in left-sided colorectal adenoma and cancer. Bela
Molnar, Balint Peterfia, Alexandra Kalmar, Peter Hollosi,
Zsofia Brigitta Nagy, Barnabas Wichmann, Ilona Kovalszky,
Zsolt Tulassay.
423
Epigenetic reprogramming of epithelialmesenchymal transition in triple-negative breast cancer
cells with DNA methyltransferase and histone
deacetylase inhibitors. Yanrong Su, Nathan R. Hopfinger,
Thomas J. Pogash, Theresa D. Nguyen, Julia SantucciPereira, Jose Russo.
424
The transcriptomic and methylomic changes
caused by subtoxic doses of 5-azacytidine and 5-aza2’-deoxycytidine. Evelyn Smit, Nithya Krishnan, Jeffrey
Conroy, Jianmin Wang, Song Lui, Anna Woloszynska-Read.
425
Methylation, copy number, and LOH analysis of
Chr1q21.3 for discovery of ovarian and breast cancer
biomarkers. Matthew L. Poulin, Ann Meyer, Jessica
Alexander, Jessica Xu, Liying Yan.
426
Transcriptional regulation of dnmt1 by E2F1 in
melanoma progression. CAMILA T. DA SILVA, Fernanda
Molognoni, Fabiana H. de Melo, Miriam G. Jasiulionis.
427
Upregulation of KLF4 and inhibition of HDAC
activity by methylseleninic acid in human esophageal
squamous cells. Chenfei Hu, Wei Zhang, Qing Xu,
Lechuang Chen, Kai Ma, Mei Liu, Hongxia Zhu, Ningzhi Xu.
428
HIC-1:a gene silenced in cancer stem cells of
glioma. mohita bhagat, subrata sinha, Parthaprasad
Chattopadhyay.
429
HERP2 as a novel molecular marker and
therapeutic target in glioblastoma. Kiran Kumar Velpula,
Swapna Asuthkar, William Lee, Andrew J. Tsung.
430
Identification of novel methylation-silenced
genes in oral squamous cell carcinomas. Masanobu Abe,
Satoshi Yamashita, Yoshiyuki Mori, Takahiro Abe, Hideto
Saijo, Toshikazu Ushijima, Tsuyoshi Takato.
431
CYP26C1 gene is highly methylated and
correlated with chemoradiation therapy in esophagus
squamous cell carcinoma. Yoshiyuki Watanabe, Ritsuko
Oikawa, Yoshihito Yoshida, Hiroyuki Yamamoto, Fumio Itoh.
18
18
237
POSTER SESSION
Poster
Section
19
19
Functional Studies of Cancer Genes
Poster Abstract
Board Number
1.
432
BIN3 is a novel 8p21 tumor suppressor gene that
regulates the attachment checkpoint in epithelial cells.
Netonia Marshall, Felix Sanchez, David Llobet, Ruth
Rodriguez Barrueco, Veronica Castro, Dylan Kotlia, Maira
Pires, Patricia Villagrasa, Preeti Putcha, Ramon Parsons,
Dana Pe’er, Jose Silva.
2.
433
Triplication of HMGN1 promotes B cell acute
lymphoblastic leukemia (B-ALL) through suppression of
H3K27me3. Andrew A. Lane, Bjoern Chapuy, Charles Y. Lin,
Trevor Tivey, Hubo Li, Elizabeth Townsend, Diederik van
Bodegom, Tovah A. Day, Shuo-Chieh Wu, Huiyun Liu,
Akinori Yoda, Gabriela Alexe, Anna Schinzel, Timothy J.
Sullivan, Sebastien Malinge, Jordan Taylor, Kimberly
Stegmaier, Jacob Jaffe, Michael Bustin, Geertruy te Kronnie,
Shai Izraeli, Marian Harris, Kristen Stevenson, Donna
Neuberg, Lewis B. Silverman, Steven E. Sallan, James E.
Bradner, William C. Hahn, John D. Crispino, David Pellman,
David M. Weinstock.
13.
444
BRM/SMARCA2 is a critical synthetic lethal
target in BRG1-deficient cancers. Mariela Jaskelioff,
Gregory Hoffman, Rami Rahal, Kay Xiang, Kristy Haas,
Veronica Saenz-Vash, Huili Zhai, Nicholas Keen, Frank
Stegmeier, Zainab Jagani.
14.
445
Coordinate loss of CHD1 and MAP3K7 promotes
aggressive prostate cancer. Lindsey Ulkus, Leah Rider,
Cera Nieto, Lina Romero, Haitao Chen, Massimo Loda,
Wennuan Liu, Jianfeng Xu, Scott Cramer.
15.
446
BAP1 mutation in mesothelioma and “BAP1
Cancer Syndrome”. Masaki Nasu, Andrea Napolitano,
Sandra Pastorino, Mika Tanji, Erin Flores, Francine
Baumann, Amy Powers, Giovanni Gaudino, Harvey I. Pass,
Haining Yang, Michele Carbone.
16.
447
The IDH1 mutation in human glioblastoma and
its effects on epigenetic modification and cell fate
selection. Matthew C. Garrett, Jack Mottahedeh, Jantzen
Sperry, Ascia Eskin, Giovanni Coppola, Ya-shin Shih, Albert
Lai, Arthur Chou, Linda Liau, Rob Prins, Timothy Cloughesy,
Hong Wu, Stanley Nelson, Harley Kornblum.
17.
448
Molecular analysis of BRAF gene and PTEN gene
expression in metastatic colorectal cancer patients:
Feasibility study. Christian D. Rolfo, Marta Castiglia,
Daniela Cabibi, Valentina Calo’, Florinda Di Piazza, Viviana
Bazan, Fabio Brocco, Stefano Caruso, Loredana Bruno,
Konstantinos Papadimitriou, Francesco Passiglia, Marc
Peeters, Patrick Pauwels, Antonio Russo.
18.
449
Exome sequencing reveals Bcl6 co-repressor
(Bcor) as a frequently mutated tumor suppressor gene
in E␮-Myc lymphoma. Marcus P. Lefebure, Richard Tothill,
Jason Li, Geoff Matthews, Jake Shortt, Edwin Hawkins,
Elizabeth Kruse, Maria Doyle, Gretchen Poortinga, Ross
Hannan, Vivian Bardwell, Micah Gearhart, Ricky W.
Johnstone.
19.
450
Head and neck cancer and HPV infection: A
potential role for peritumoral neurogenesis in HPVassociated malignancy. Christian A. Graves, Swati Tomar,
Diego Altomare, James R. Wells, Kim E. Creek, Lucia Pirisi.
20.
440
The TRiC chaperonin in breast cancer cell
growth, survival and response to taxane therapy.
Stephen Guest, Jon Irish, Zachary Kratche, Elizabeth
Garrett-Mayer, Robert Wilson, Stephen Ethier.
451
A novel algorithm for prioritizing candidate
genes driving malignant transformation of MCF10F cells
and basal-like breast cancer. Sangjun Lee, Behrouz
Madahian, Carrie Sutter, Charles Dickens, Irma Russo, Jose
Russo, Ramin Homayouni, Thomas Sutter.
21.
10.
441
Functional characterization of recurrent
CD74᎑NRG1 fusions in lung adenocarcinoma. Dennis
Plenker, Lynnette Fernandez-Cuesta, Hirotaka Osada, Ruping
Sun, Marc Bos, Juliane Daßler, Gavin Wright, Elisabeth
Brambilla, Reinhard Büttner, Sascha Ansen, Stefan Haas,
Yasushi Yatabe, Roman K. Thomas.
452
Comprehensive gene expression analysis
identifies molecular markers involved with the
progression of ductal carcinoma in situ of the breast.
Elisa N. Ferreira, Eliana V. Elias, Nadia Castro, Paulo Pineda,
Cynthia Osório, Mabel P. Fernandez, Sabrina D. Silva, Maria
do Socorro Maciel, Fernando A. Soares, Dirce M. Carraro.
23.
11.
442
RASA1 alteration promotes melanoma
tumorigenesis. Hyeran Sung, Li Ding, Krishna L. Kanchi,
Jane L. Messina, Vernon K. Sondak, Mulé J. James, Richard
K. Wilson, Jeffrey S. Weber, Minjung Kim.
454
TET2 alterations facilitate progression of
metastatic prostate cancer. Michael L. Nickerson, Sudipto
Das, Hong Lou, Hongchuan Li, Sevilay Turan, Kate Im,
Stephen Anderson, Thorkell Andresson, Michael Dean.
24.
12.
443
Synergistic inhibition of HER2 positive breast
cancer by triptolide and lapatinib. Paweena Chalugun,
Joong Sup Shim, Preethi C. Korangath, Saraswati Sukumar,
Jun O. Liu.
455
Increased copy number of Septin 9 (SEPT9) in
women with high grade endometrial
adenocarcinoma(EMCA): Is there a potential link to
paclitaxel resistance. Jenna R. Zechmeister, Gary L.
Goldberg, Cristina Montagna.
3.
434
Circulating visfatin promotes malignant cancer
behavior through activation of STAT3 signaling in breast
cancer. Shyng-Shiou F. Yuan, Amos C. Hung, Ming-Feng
Hou.
4.
435
Is PYGM dysregulation involved in breast cancer
cell metabolism. Veronika SMUTNA, Maria Vittoria DIECI,
Céline LEFEBVRE, Véronique SCOTT, Fabrice ANDRE, Olivia
FROMIGUE.
5.
436
⌬Np63 is critical for progression of high grade
non-muscle invasive bladder cancer to muscle-invasive
disease. Mireia Castillo-Martin, Nataliya Gladoun, Josep
Maria Gaya-Sopena, Dennis M. Bonal, Joan Palou Redorta,
Carlos Cordon-Cardo.
6.
437
Novel function of the BAP1 nuclear
deubiquitinase in the non-homologous end joining
(NHEJ) pathway of double strand DNA repair. Tatsuo Ito,
Shigehisa Kitano, Hediye Erdjument-Bromage, Marc Ladanyi.
7.
438
Long non-coding RNA AK023948 enhances breast
cancer progression by activating AKT. Pratirodh Koirala.
8.
439
Mitochondrial uncoupling protein 2 promotes
skin carcinogenesis. Wenjuan Li, Chunjing Zhang, Runhua
Shi, Xin Gu, Yunfeng Zhao.
9.
238
Poster Abstract
Board Number
POSTER SESSION
Gene Expression and Transcriptional Control 1
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
456
ERG regulation of intracrine androgen production
and castration-resistant prostate cancer progression.
Katelyn A. Powell, Louie Semaan, Krishna R. Maddipati,
Katie (Mary) Conley-Lacomb, Yanfeng Li, Michael Cher,
Sreenivasa R. Chinni.
457
Expression, purification, and characterization of
recombinant TAT-SALL4B protein. Mengru Yuan, Yongping
Jiang, Wei Dai.
458
Regulation of HIF1a by Set9 lysine
methyltransferase. Qiong Liu, Hao Geng, Changhui Xue,
Tomasz M. Beer, David Z. Qian.
459
The function of FOXO1 in the late phases of the
cell cycle is suppressed by PLK1-mediated
phosphorylation. Chengfu Yuan, Lei Wang, Liang Zhou,
Zheng Fu.
460
Base resolution epigenomic analysis reveals a
role for Tet2 in modulating enhancer activity. Gary Hon,
Chun-Xiao Song, Fulai Jin, Siddarth Selvaraj, Ah Young Lee,
Chia-an Yen, Zhen Ye, Shi-Qing Mao, Bang-An Wang,
Samantha Kuan, Lee Edsall, Boxuan Simen Zhao, Guo-Liang
Xu, Chuan He, Bing Ren.
461
Modulation of estrogen receptor (ER) and
androgen receptor (AR) by a modified CRISPR-Cas9
system. Nanjiang Zhou, Yin-Yuan Mo.
462
Chromatin signatures of DLBCL subtypes. Ron
McCord, Megan Field, Philip Jordan, Ewan Hunter,
Alexandre Akoulitchev, Kirsten E. Mundt.
463
Evaluation of relative expression of SLC34A2/
NaPi-IIb in lung cancer cell lines treated with estrogen
and PKC and PKA pathway modulators. Murilo F. Cerri,
Lucas C. Rezende, Marcela F. Paes, Klesia P. Madeira,
Renata D. Daltoe, Nayara G. Tessarollo, Ian V. Silva, Leticia
B. Rangel.
464
Methylase meets phosphatase: roles of PRMT
and EYA1 in neuroblastoma. Xingguo Li, Simeng Wang,
Nina F. Schor.
465
EVI1 transcriptionally represses SLUG to regulate
epithelial-mesenchymal transition (EMT) in human colon
cancer. Kasturi B. Nayak, Soumen Chakraborty.
466
LMO1 is a novel oncogene in neuroendocrine
lung cancer. Zhenze Zhao, Xiuye Ma, Xiaojie Yu, Tzu-Hung
Hsiao, Yidong Chen, Milind Suraokar, Ignacio Wistuba, John
D. Minna, Alexander Pertsemlidis, Liqin Du.
467
New molecular model identifying the critical role
of the GLI2 oncogene in human colonic epithelial cell
(HCEC) transformation. Tapati Mazumdar, Akwasi
Agyeman, Jerry W. Shay, Janet A. Houghton.
468
Cancer cells with G/G mdm2 SNP309 have
compromised transcriptional elongation of p53 target
genes. Melissa Rosso, Alla Polotskaia, Jill Bargonetti.
469
Regulated IRE1-dependent mRNA decay occurs
under extreme proteotoxic stress in myeloma, but not
under conditions that would affect therapeutic targeting
of IRE1␣. Michael D. Bright, Christopher P. Wardell, Daniel
N. Itzhak, Tina Bagratuni, Gareth J. Morgan, Faith E. Davies.
470
Artemisinin derivatives synergize with paclitaxel
by targeting FOXM1 through Raf/MEK/MAPK signaling
pathway in ovarian cancer. Yi Chen, Brian W. Chin,
Marcia M. Bieber, Xianjie Tan, Nelson N. Teng.
471
Transcriptional coactivator CBP regulates hTERT
expression through the cooperation with Sp1/AP-2␤ and
predicts poor prognosis in human lung cancers. Wei
Guo.
Poster Abstract
Board Number
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
472
Interactions of the fusion protein Nup98-Hoxa9
with Pbx3, p300 and HDAC1: widening the targeted
therapy window in acute myeloid leukemia (AML). Ana
Rio-Machin, Alba Maiques-Diaz, Sandra Rodriguez-Perales,
Sara Alvarez, Rocio N. Salgado, Álvaro Eguileor, Raul Torres,
Juan C. Ramirez, Juan C. Cigudosa.
473
TRIM59, a novel prognostic marker for gastric
cancer, promotes tumorigenesis via ubiquitination and
degradation of the p53 tumor suppressor. Zhicheng Zhou,
You Wang, Jian Li, Hui Cao, Helen H. Zhu, Wei-Qiang Gao.
474
Changes in global chromatin landscape identify
bladder cancer progression. Sohyoung Kim, Lyuba
Varticovski, Lars Grontved, Songjoon Baek, Bethrice
Thompson, Michael Dean, Daniel Theodoresco, Michael L.
Nickerson, Gordon L. Hager.
475
GATA3 mutations in breast cancer. Motoki
Takaku, Aleksandra Adomas, Sara A. Grimm, Shimbo
Takashi, Paul A. Wade.
476
Overexpression and function of CDCA5 in oral
squamous cell carcinoma. Norihiko Tokuzen, Koh-ichi
Nakashiro, Hiroshi Tanaka, Yohei Fujita, Kazuki Iwamoto,
Hiroyuki Hamakawa.
477
The dynamic changes of KLF4 in the oral
squamous cell carcinogenesis. Man Liu, Ying Su, Xinyan
Zhang.
478
Predicting interactome networks perturbations in
human cancer: application to gene fusions in acute
lymphoblastic leukemia. Leon Hajingabo, Sarah Daakour,
Maud Martin, Reinhard Grausenburger, Renate PanzerGrümayer, Franck Dequiedt, Jacques Van Helden, JeanClaude Twizere, Nicolas Simonis.
479
A novel dynamic delivery system enabling high
efficiency transfection of cells. James Ludtke, Anthony
Lauer, Austin Storck, Nicholas Rossi, Karen Neder, Anatoly
Pinchuk, Laura Juckem.
480
CDK9 (a novel BRCA1/BARD1 interaction partner)
downregulates BRCA1-mediated transcription. Thales C.
Nepomuceno, Vanessa C. Fernandes, Giuliana De Gregoris,
Renato S. Carvalho, Álvaro N. Monteiro, Marcelo A.
Carvalho.
481
Dualistic regulation of NF-kB signaling by CD99
and EWS-FLI1 in Ewing sarcoma: impact on cell
differentiation. Selena Ventura, Chiara Manzalini, Dave
Aryee, Piero Picci, Heinrich Kovar, Katia Scotlandi.
482
FKBP51 sustains the constitutive NF-␬B
activation in melanoma. Simona Romano, Shao-Cong Sun,
Anna D’Angelillo, Paolo D’Arrigo, Rita Bisogni, Maria
Fiammetta Romano.
483
Docosahexaenoic acid inhibits heat shock
protein 90 complex and client proteins by reducing
intracellular ATP levels in breast and lung cancer.
Michael Mouradian, Irvin V. Ma, Erika D. Vicente, Keith D.
Kikawa, Amy M. Chattin, Ronald S. Pardini.
484
Identification of FOXM1 as therapeutic target in
Philadelphia chromosome-positive acute lymphoblastic
leukemia. Maike V. Buchner, Eugene Park, Lars Klemm,
Huimin Geng, Dragana Kopanja, Pradip Raychaudhuri,
Markus Müschen.
485
Chronic exposure to a low dose of interferon-␤
increases levels of DNA damage resistance signature
genes through unphosphorylated ISGF3. HyeonJoo Cheon,
Elise G. Holvey-Bates, George R. Stark.
Poster
Section
20
20
239
POSTER SESSION
Poster
Section
21
21
Hypoxia, Stress Responses, and Unfolded Protein Response
Poster Abstract
Board Number
1.
2.
240
486
Uncovering novel PERK signaling pathways
through chemical-genetic screening. Nancy L. Maas,
Rebecca Levin, Nickpreet Singh, Kevan Shokat, J. Alan
Diehl.
487
The Integrated Stress Response kinase GCN2
regulates cell proliferation and survival through
combined transcriptional and translational control of
p21 (Cip1/Waf1). Stacey L. Lehman, Jiangbin Ye,
Constantinos Koumenis.
3.
488
Inhibition of JNK signaling sensitizes hypoxic
colon cancer cells to DNA-damaging agents. Irina A.
Vasilevskaya, Muthu Selvakumaran, Lucia Cabal-Hierro,
Peter J. O’Dwyer.
4.
489
Hypoxia-mediated ROS enhances HGF-induced
cancer cell invasion and suppresses cell cycle
progression. Young H. Lee, Donald P. Bottaro.
5.
490
Investigation of telomere shortening caused by
dyskeratosis congenita-associated heterozygous TIN2
mutations. Duy C. Tran, Amanda K. Frank, Lifeng Xu.
6.
491
Selective killing of oncogenically transformed
cells by arsenic trioxide and trolox. Genevieve G.
Redstone, Jessica N. Nichol, Brandon Faubert, Russell G.
Jones, Koren K. Mann, Wilson H. Miller.
7.
492
Hepatic oxidative stress activates the Gadd45b
gene via degradation of the transcriptional repressor
STAT3. Jung-Hwan Kim, Aijuan Qu, Janardan K. Reddy, Bin
Gao, Frank J. Gonzalez.
8.
493
NRF2 modulates sensitivity to thymidylate
synthase inhibitors in colon cancer cells. Sarah A.
Clinton, Karen W. Barbour, Ufuk Ozer, Franklin G. Berger.
9.
494
Tumor ascorbate content is associated with
extended disease-free survival and decreased hypoxiainducible factor-1 activation in patients with colorectal
cancer. Caroline Kuiper, Gabi Dachs, Margaret Currie, John
Pearson, Delwyn Munn, Margreet Vissers.
10.
495
Inactive status of cancer cells with suppression
of AKT activity contributes to survival in chronic
hypoxia. Masahiro Inoue, Hiroaki Okuyama, Hiroko Endo,
Masayuki Ohue.
Poster Abstract
Board Number
16.
501
CXCR4 induced ROS accumulation through PI3K/
AKT. Latoya K. Bryant, Kia J. Jones, Cimona V. Hinton.
17.
502
Sp1 and HIFs mediate synergistic activation of
ICAM1 gene under serum starved hypoxia and promotes
growth of ovarian cancer. Shiro Koizume, Shin Ito,
Yoshiyasu Nakamura, Mitsuyo Yoshihara, Yasuo Takano,
Yohei Miyagi.
18.
503
Antioxidants markedly accelerate tumor growth
and reduce survival in mice with KRAS- and BRAFinduced lung cancer by disrupting the ROS-p53 axis.
Volkan I. Sayin, Mohamed X. Ibrahim, Erik Larsson, Jonas A.
Nilsson, Per Lindahl, Martin O. Bergö.
19.
504
Identification of RSK2 as a novel regulator of the
ER stress-activated autophagy in cancer cells. Yan
Cheng, Xingcong Ren, Li Zhang, Jin-ming Yang.
20.
505
Visualization of anatomic site-dependent hypoxia
in micrometastases by immunofluorescent microscopy.
Xiao-Feng Li.
21.
506
H2O2 upregulates xCT in human breast cancer
cells via NRF-2. Eric Habib, Katja Linher-Melville, Gurmit
Singh.
22.
507
ER␤1 decreases breast cancer cell survival by
regulating the unfolded protein response. Christoforos
Thomas, Gayani Rajapaksa, Fotis Nikolos, Igor Bado, JanAke Gustafsson.
23.
508
Hypoxia influences the response to vemurafenib
in V600E mutant melanoma cells. Daniela Pucciarelli,
Martina Takáová, Lucia Csaderova, Filippo Juliano, Nina
Lengger, Heimo Breiteneder, Silvia Pastorekova, Christine
Hafner.
24.
509
Hypoxia and HIF silencing mediated
dysregulation of total choline, CD44 expression, and
metastatic burden in MDA-MB-231 human breast
cancers. Balaji Krishnamachary, Santosh K. Bharti, MarieFrance Penet, Samata M. Kakkad, Flonne Wildes, Keve
Zoltani, Yelena Mironchik, Zaver M. Bhujwalla.
25.
510
Inhibition of IRE1␣-driven pro-survival pathways
is a promising therapeutic application in acute myeloid
leukemia. Haibo Sun, Behzad K. Masouleh, Sigal Gery, Qi
Cao, Serhan Alkan, Takayuki Ikezoe, Chie Akiba, Ronald
Paquette, Wenwen Chien, Carsten Müller-Tidow, Yang Jing,
Kharabi Masouleh, Markus Müschen, H. Phillip Koeffler.
11.
496
Adaptive response to chronic oxidative stress
involves epithelial-mesenchymal transition in MCF-7
breast cancer cells. Prathap Kumar S. Mahalingaiah,
Logeswari Ponnusamy, Kamaleshwar P. Singh.
12.
497
Hypoxic stress enhances tumorigenic potential of
PPAR␦ in colon cancer cells. Joo Young Lee, Eunshil
Jeong, Jung Eun Koo, Sang Hyun Yeon.
26.
511
EGFR-initated NADPH oxidase activity regulates
Fyn expression in glioblastoma multiforme. Blake
Johnson, Joya Chandra.
13.
498
Blunting the radical scavenging property of
mitochondria-targeted, triphenylphosphonium-linked
antioxidants failed to mitigate their anti-proliferative
and antitumor effects. Gang Cheng, Jacek Zielonka, Joy
Joseph, Balaraman Kalyanaraman.
27.
512
Cell-based analysis of oxidative stress, lipid
peroxidation and lipid peroxidation-derived protein
modifications using fluorescence microscopy. Bhaskar S.
Mandavilli, Robert Aggeler.
28.
14.
499
RUNX2 protects human neuroblastoma cells
against apoptosis. Manu Gnanamony, Indra Mohanam,
Sanjeeva Mohanam.
15.
500
Heat shock protein gp96 regulates LRP6-WntSurvivin pathway and myeloma progression. Yunpeng
Hua, Shai White-Gilbertson, Joshua Kellner, Saleh Rachidi,
Zihai Li, Bei Liu.
513
Investigating stress-response pathways in
pancreatic cancer cells using novel PERK inhibitors.
Jihyun Park, Qiantao Wang, Tamer S. Kaoud, Clint D.
Tavares, Ramakrishna Edupuganti, Pengyu Ren, Kevin N.
Dalby.
29.
514
Heat shock transcription factor-1 and heat shock
protein 60 are important for lung carcinoma anoikis
resistance. Jack D. Carter, Suzanne K. Murphy.
POSTER SESSION
MicroRNAs and Solid Tumors 1
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
515
G12 overexpression in hepatocellular carcinoma
promotes epithelial-mesenchymal transition through
microRNAs deregulation. Sang Geon Kim, Yoon Mee Yang,
Tae Hyun Kim, Chan Gyu Lee, Jihyun An, Sung Hoon Kim,
Chang Ho Lee, Sejin Hwang, Seung Jin Lee, Kang Mo Kim.
516
Detection of human satellite RNA in the serum of
high-risk patients of pancreatic cancer. Takahiro
Kishikawa, Motoyuki Otsuka, Takeshi Yoshikawa, Motoko
Ohno, Kazuhiko Koike.
517
MiR-29b is a novel potential prognostic marker
and inhibits cell proliferation in colorectal cancer. Akira
Inoue, Hirofumi Yamamoto, Mamoru Uemura, Junichi
Nishimura, Taishi Hata, Ichiro Takemasa, Tsunekazu
Mizushima, Yuichiro Doki, Masaki Mori.
518
Identification of differentially expressed
microRNAs in human hepatocellular adenoma
associated with type I glycogen storage disease: a
potential utility as biomarkers. Ling-Hui Li, Li-Ya Chiu,
Priya S. Kishnani, Tzu-Po Chuang, Cheng-Yang Tang,
Cheng-Yuan Liu, Deeksha Bali, Dwight Koeberl, Stephanie
Austin, Keri Boyette, David A. Weinstein, Elaine Murphy,
Adam Yao, Yuan-Tsong Chen.
519
MicroRNA-31 is upregulated by EGF through C/
EBP␤ signaling cascade in HNSCC. Wen Cheng Lu, Shu
Chun Lin, Kuo Wei Chang, Hsi Feng Tu.
520
Functional genomic screens identify microRNA
regulators of the oncogenic fusion transcription factor
EWS-FLI1. Suntae Kim, Patrick J. Grohar, Carleen Klumpp,
Ashish Lal, Scott E. Martin, Lee J. Helman, Natasha J.
Caplen.
521
Glioma-associated IDH mutation induces miR34a repression and stem cell-like physiology through
enhanced PDGF signaling. Joachim Silber, Girish Harinath,
Prasanna Tamarapu Parthasarathy, Armida W. Fabius, Sevin
Turcan, Timothy A. Chan, Jason T. Huse.
522
Revealing the complexity of cancer associated
small non-coding RNAs by next generation sequencing
(NGS) and low-density array. Francesca Montani, Matteo
Marzi, Rose Mary Carletti, Pier Paolo Di Fiore, Francesco
Nicassio.
523
Detection of PIWI-piRNAS in the mitochondria of
human normal and cancer cells. ChangHyuk Kwon,
Hyosun Tak, Mina Rho, Hae Ryung Chang, Yon Hui Km,
Kyung Tae Kim, Eun Kyung Lee, Curt Balch, Seungyoon
Nam.
524
Analysis of long non-coding RNA expression and
function in a mouse model of glioblastoma. Chad
Myskiw, Sabah Kadri, Eugene Ke, Alex Shishkin, Dinorah
Friedmann-Morvinski, Yasushi Soda, Mitchell Guttman, Inder
Verma.
525
Automated microRNA detection in formalin-fixed,
paraffin-embedded tissue samples. Zeyu (David) Jiang,
Anne Pedata, Taylor Shingler, Lauren Behman, David Chafin,
William Day.
526
Overexpression of chromosome 3q26 –29 miRNAs
in squamous cell carcinoma of the lung. Jun Qian,
Xiangming Ji, Yong Zou, Megan Hoeksema, Heidi Chen,
Pierre P. Massion.
527
Analysis of the interaction between microRNAs
and Notch pathway members in HNSCC (head and neck
squamous cell carcinoma). Myriam Loyo, Luciane T.
Kagohara, Wenyue Sun, Marietta Tan, Elana Fertig, Michael
Ochs, Evgeny Izumchenko, Mariana Brait, Joseph Califano,
David Sidransky.
528
The modulatory role of miRNA 126 in thyroid
cancer angiogenesis. Ali Salajegheh, Haleh Vosgha, Md.
Atiqur Rahman, Vinod Gopalan, Robert A. Smith, Alfred K.
Lam.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
529
nc886, a noncoding RNA of anti-proliferative
role, is suppressed by CpG DNA methylation in human
gastric cancer. Jong-Lyul Park, Yong Sung Kim, SeonYoung Kim, Kwang Soo Lee, Sung Ho Jeon, Kwanbok Lee,
Yong Sun Lee.
530
MicroRNA expression profiling in MMTV-neu
breast cancer mouse model. Claudia Piovan, Gianpiero Di
Leva, Douglas Cheung, Matteo Fassan, Arpan Kumar, Dario
Palmieri, Marilena V. Iorio, Carlo M. Croce.
531
MiR-199a-5p is a biomarker for and regulator of
epithelial-mesenchymal transition in triple-negative
breast cancer patients. Vivian Y. Shin, Man T. Siu, John C.
Ho, Ava Kwong.
532
Evaluation of the role of miRNA-4728 –3p, a
miRNA located in an intron of HER2 gene, in breast
cancer stem cells. Juliana Laino do Val Carneiro, Diana
Noronha Nunes, Emmanuel Dias-Neto.
533
MicroRNA486 –5p is a KRas target involved in
promoting cell proliferation in lung cancer. Mateus N.
Aoki, Amanda C. Salviatto, Tatiana C. Lobo, Ana Cláudia O.
Carreira, Mari C. Sogayar, Daniela S. Basseres.
534
MicroRNA-143 is a putative predictive biomarker
for 5-FU-based chemotherapy in patients with
metastatic colorectal cancer. Femke Simmer, Jeroen
Dijkstra, Sabine Venderbosch, Claudius Faber, Leonie
Mekenkamp, Miriam Koopman, Ton de Haan, Cornelis Punt,
Iris Nagtegaal.
535
Expression of miR-21 in cancer associated
fibroblasts in lung adenocarcinoma. Akiko Kunita, Shigeki
Morita, Masashi Fukayama.
536
Elucidating the role of miRNA-31 in
retinoblastoma. Vanessa Montoya, Paul J. Bryar, Marilyn
Mets, Joanna Weinstein, Nikia Laurie.
537
Toll-like receptor (TLR3) signaling in human
hepatocellular carcinoma (HCC) depends on the tumorassociated long-noncoding RNA H19. Patrick Paulus, Anja
Urbschat, Christin Reissig, Kai Zacharowski, Stefan Dröse,
Bertram Scheller, Elisabeth Tybl.
538
microRNAs as modifiers of stem cell properties
in breast cancer: a whole genome approach. Paola
Bonetti, Matteo J. Marzi, francesco nicassio.
539
Downregulation of hnRNP A1 by miRNAs as a
new mechanism of survival in ovarian cancer. Cristian
Rodriguez-Aguayo, Paloma Monroig, Maria I. Almeida,
Cristina Ivan, Vianey Gonzalez-Villasana, Maitri Y. Shah, Anil
K. Sood, George Calin, Gabriel Lopez-Berestein.
540
Characterization of miR-9 expression and
activation in canine osteosarcoma. Joelle M. Fenger,
Jason I. Couto, Misty D. Bear, Stefano Volinia, Jaime F.
Modiano, Matthew Breen, Cheryl A. London, William C.
Kisseberth.
541
The role of long noncoding RNA SChLAP1 in
prostate cancer. Anirban Sahu, Matthew K. Iyer, John R.
Prensner, Arul M. Chinnaiyan.
542
Regulation of the telomere healing process by
the lncRNA TERRA. Diego A. Oliva-Rico, Rodrigo GonzalezBarrios, Eunice Fabian-Morales, Luis A. Herrera.
543
Identification of lincRNAs in the HOX domain in
adult medulloblastoma by microarray analysis. Julia B.
Veiga, Ricardo Bonfim Silva, Kuruvilla J. Abraham, Daniela
B. Pretti da Cunha Tirapelli, Fernando Silva Ramalho, Gerson
Chadi, Jéssica Ruivo Maximino, Dimas B. Tadeu Covas,
Angelo A. Cardoso, Carlos Gilberto B. Carlotti, Aparecida M.
Fontes.
544
Recurrent DICER1 hotspot mutations in
endometrial cancer and their impact on microRNA
biogenesis. Jiamin Chen, Yemin Wang, Melissa McConechy,
Michael Anglesio, Janine Senz, Winnie Yang, Jamie Rosner,
Andy Chu, Grace Cheng, Gregg Morin, David Huntsman.
22
22
241
POSTER SESSION
Poster
Section
23
23
Molecular Marker Studies
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
242
545 Frameshift mutations of chromosome cohesion-related
genes SGOL1 and PDS5B in gastric and colorectal cancers with
high microsatellite instability. Min Sung Kim, Youn Jin Choi, Min
Gwak, Hyerim Oh, Mi Ryoung Choi, Sun Yong Hwang, Nam Jin Yoo,
Sug H. Lee.
546 CD44 variant expression is a poor prognostic marker in
early gastric cancer and well-differentiated gastric cancer. Won
Sup Lee, Se-Il Go, Jeong-Hee Lee, Sang-Ho Jeong, Young-Joon Lee,
Soon Chan Hong, Woo Song Ha, Gyung Hyuck Ko.
547 Ethnic differences in CYP19A1 intronic SNPs and
haplotype distributions among African American and Caucasian
populations. Athena Starlard-Davenport, Rosalind B. Penney, Ishwori
Dhakal, Susan Kadlubar.
548 CEP 3/CEP 17 in the genetic diagnosis and its
prognostic relevance of Kazakh esophageal cancer patients.
Edris Awut.
549 Gene expression changes of GAEC1 in a large cohort of
human cancer tissues. Vinod Gopalan, Robert A. Smith, Suja Pillai,
Ali Salajegheh, Johnny C. Tang, Alfred K. Lam.
550 Genomic instability and telomere characteristics as
predictive biomarkers of therapeutic response in triple-negative
breast cancer. Mathilde Gay-bellile, Nina Radosevic-Robin, Eleonore
Eymard-Pierre, Fabrice Kwiatkowski, Marie-Mélanie Dauplat, Maud
Privat, Catherine Abrial, Patricia Combes, Gwendoline Soler, YvesJean Bignon, Jean-Marc Nabholtz, Philippe Vago, Frédérique
Penault-Llorca, Andreï Tchirkov.
551 Clinical significance of adiponectin receptor 1 (AdipoR1)
expression in invasive breast cancer. Lee-Su Kim, Younok Lee,
Hae Sung Kim.
552 Genetic polymorphisms of the drug transporter ABCB5
associated with advanced liver cancer. Idy C.Y. Leung, Wallace
C.W. Yip, Phyllis. F.Y. Cheung, Tan To Cheung, Ronnie T.P. Poon,
Sheung Tat Fan, Siu Tim Cheung.
553 Can MACC1 plasma transcripts in colon adenoma
patients be used as an early indicator of metastasis potential.
Hassan Brim, Pia Hermann, Mehdi Nouraie, Babak Shokrani, Ed Lee,
Tahmineh Haidary, Hassan Ashktorab, Ulrik Stein.
554 GPNMB methylation: a new marker of potentially
colonic adenoma in African Americans. Hamed Rahi, Tahmineh
Haidary, Hassan Brim, Edward L. Lee, Babak Shokrani, H Zhifeng,
Peter M. Siegel, Hassan Ashktorab.
555 DNA methylation patterns are associated with
subpopulations of diffuse large B-cell lymphoma. Jenny Wu, Ron
McCord, Thomas Sandmann, Kim Walter, Richard Bourgon, Robert
Soriano, Zora Modrusan, Walter Darbonne, Kirsten E. Mundt.
556 Interleukin 32 is an independent prognostic biomarker
of human gastric cancer correlated with tumor progression and
metastasis. Chia-Siu Wang, Chung-Ying Tsai, Kuan-Huei Lin.
557 Noninvasive analysis of acquired resistance to EGFRTKI. Hideharu Kimura, Makoto Nishio, Tsutomu Daito, Kazuto Nishio.
558 Mutational heterogeneity related to neoadjuvant therapy
response in muscle invasive urothelial cell carcinoma revealed
by whole-exome sequencing. Masamichi Hayashi, Enrico Munari,
Christina Michailidi, Mariana Brait, Mark Schoenberg, Trinity
Bivalacqua, George Netto, Wayne Koch, David Sidransky, Mohammad
O. Hoque.
559 Patterns of Telomerase reverse transcriptase (TERT)
promoter mutations in melanoma and bladder cancer. Rajiv
Kumar, Barbara Heidenreich, Ismail Hosen, Sivaramakrishna
Rachakonda, Kari Hemminki.
560 Distinct protein expression patterns of solid
pseudopapillary neoplasm of pancreas. Minhee Park, Minhee Cho,
SeongJu Yoon, Hoguen Kim.
561 A natural copy number variant in the GAEC1 oncogene
is associated with breast cancer susceptibility. Vinod Gopalan,
Robert A. Smith, Suja Pillai, Lyn R. Griffiths, Alfred K. Lam.
562 Impact of ER␣ expression status and ESR1 genetic
variation on progression in tamoxifen-treated breast cancer
patients. Nataliya Babyshkina, Sergey Vtorushin, Stanislav Patalyak,
Tatyana .Dronova, Elena Slonimskaya, Nadejda Cherdyntseva.
Poster Abstract
Board Number
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
563 A prospective biomarker study to demonstrate high MET
expression and gene amplification in a subset of patients with
advanced gastric cancer. Yang Han-Kwang, Hiroya Takeuchi,
Seong-Ho Kong, Hyuk-Joon Lee, Elias Shamiyeh, Nikki Daskalakis,
Hélène Goulaouic, Christelle Castell, Marie-Laure Ozoux, Ju OK Lim,
Kaida Wu.
564 Favorable prognostic features at diagnosis along with
young age, early remission, high relapse rate and poor survival
of TCF3-PBX1 positive adult ALL necessitates the need for
differential genetic diagnosis and treatment using pediatric ALL
protocols. Zafar Iqbal*, Tanveer Akhtar, Noreen Sabir, Tashfeen K.
Awan, Salman Basit, Aamer Aleem, Ahmad M. Khalid, Mudassar
Iqbal, Mahmood Rasool.
565 Telomerase reverse transcriptase promoter alterations
in human bladder cancer. Sevilay Turan.
566 The clinicopathological features and prognostic impact
of ALK-positivity in resected gastric or gastro-esophageal
cancer patients. Hongjae Jeon, HyeRyun Kim, Sung Hoon Noh,
Hyun Cheol Chung, Sun Y. Rha.
567 Multiparametric analysis of an ultra-large prostate
cancer tissue microarray with attached histo-pathological,
clinical, and molecular data: A tool for rapid evaluation of
clinically relevant gene sets. Martina Kluth, Maria Christina
Tsourlakis, Claudia Hube-Magg, Christoph Burdelski, Katharina
Grupp, Hartwig Huland, Hans Heinzer, Markus Graefen, Stefan
Steurer, Ronald Simon, Thorsten Schlomm, Guido Sauter, Sarah
Minner.
568 Few Carney’s Triad patients have mutations in two
subunits of the succinate dehydrogenase enzyme (SDHB, SDHC).
Sosipatros A. Boikos*, Paraskevi Xekouki*, Fabio R. Faucz, Karel
Pacak, Margarita Raygada, Karen Adams, Evan Szarek, Evan Ball, Su
Young Kim, Elena Fumagalli, Lee J. Helman, J A. Carney,
Constantine A. Stratakis, *sharing first authorship.
569 AKT1 (E17K) mutation: coexistence with oncogenic
alterations, prevalence, and correlation to clinical parameter in
a large series of breast cancer patients. Marion Rudolph, Tobias
Anzeneder, Matthias Ocker, Eleni Lagkadinou, Oliver Politz, Martin
Michels, Anke Schulz, Georg Beckmann, Michael Teufel, Henrik
Seidel, Richie Soong, Heinz Bodenmüller, Ulla Ohlms, Khusru
Asadullah, Joachim Reischl.
570 Tp53 mutation screening in adult acute myeloid
leukemia (AML) patients shows a strong association with
complex karyotype and poor outcome. Anna Ferrari, Ilaria
Iacobucci, Cristina Papayannidis, Carmen Baldazzi, Chiara Sartor,
Emanuela Ottaviani, Nicoletta Testoni, Valentina Robustelli,
Margherita Perricone, Claudia Venturi, Maria Chiara Abbenante,
Viviana Guadagnuolo, Antonella Padella, Federica Cattina, Giorgia
Simonetti, Domenico Russo, Giovanni Martinelli.
571 Comparative immunohistochemical study of basaloid
and usual squamous cell carcinoma of the esophagus. Yukie
Sato-Kuwabara, Juliano Jampietro, José I. Neves, Felipe J. Coimbra,
Carolina Parucce, Wilson L. Costa Junior, Fernando A. Soares.
572 Reduced AZGP1 expression is an independent predictor
of early PSA recurrence and associated with ERG fusion
positive, PTEN deleted prostate cancers. Maria Christina
Tsourlakis, Martina Kluth, Sandra Kleinhaus, Sawinee Masser,
Christoph Burdelski, Hartwig Huland, Hans Heinzer, Markus Graefen,
Burkhard Beyer, Stefan Steurer, Ronald Simon, Christina Koop,
Thorsten Schlomm, Guido Sauter, Sarah Minner.
573 BRG1-inactivating mutations as potential predictive
markers for Aurora kinase A-targeted therapies in non-small
cell lung cancers (NSCLCs). Vural Tagal, Shuguang Wei, Wei
Zhang, Bruce A. Posner, John D. Minna, Adi F. Gazdar, Michael G.
Roth.
574 Exosomal miR-1290 and miR-375 as prognostic markers
in metastatic castrate resistant prostate cancer. Xiaoyi Huang,
Tiezheng Yuan, Meihua Liang, Meijun Du, Shu Xia, Rachel L.
Dittmar, Zhifu Sun, Yan Lu, Stephen N. Thibodeau, Lisa Boardman,
Manish Kohli, Liang Wang.
POSTER SESSION
Tumor Suppressors 1
Poster
Section
Poster Abstract
Board Number
Poster Abstract
Board Number
1.
575
NKX6.1 functions as a tumor suppressor in
hepatocellular carcinoma. Hsin-Jung Li, Yu-Lueng Shih,
Ming-De Yan, Pei-Ning Yu, Ya-Wen Lin.
16.
590
RARRES1 is a modulator of angiogenesis and
autophagy. Arpita Roy, Okjin J. Kim, Malathi Ramalinga,
Solomon Lynch, Stephen Byers, Deepak Kumar.
2.
576
The role of retinal determination gene network in
renal cell carcinoma. Na Han, Qian Chu, Yu Chen, Hua
Wu, Xin Nie, Yuan Chen, Kongming Wu.
17.
591
LKB1 regulates COX-2 transcription via CRTCs
dependent pathway. Chunxia Cao, Ruli Gao, Min Zhang,
Zirong Chen, Lizi Wu, Maria Zajac Kaye, Frederic Kaye.
3.
577
Genetic and epigenetic alterations of the WWOX
gene in head and neck cancer. NUR BUYRU, Seda
Ekizoglu, Hikmet Koseoglu, Emin Karaman.
18.
4.
578
RARRES1 is a tumor suppressor in triplenegative breast cancer cell lines. Krysta M. Coyle, Ahmad
Vaghar-Kashani, Florence Wong, Cheryl Dean, Carman
Giacomantonio, Paola Marcato.
592
HOXD10 suppresses mammary tumor growth and
metastasis coincident with decreased CD11bⴙGr1ⴙ
leukocyte infiltration and angiogenesis. Suraj Kachgal,
Amy Chen, Mazen Sidani, Shahrzad Afghani, Nancy J.
Boudreau.
19.
579
HPP1’s tumor suppressive effects are mediated
by ectodomain shedding but not by juxtacrine signaling.
Abul Elahi, Abidemi Ajidahun, Whalen Clark, Jonathan
Hernandez, Leigh Ann Humphries, David Shibata.
593
Rb association with Bax is regulated by
phosphorylation. Lisa Antonucci, Jacklynn V. Egger, Nancy
A. Krucher.
20.
580
Epigenetic silencing of ARRDC3 expression in
basal-like breast cancer cells. Young Hwa Song, Jun
Chung.
594
DNAJB6a as tumor suppressor in esophageal
squamous cell carcinoma. Valentine Zhuoyou YU, Victor
Chun Lam WONG, Kwok Wah CHAN, Maria Li LUNG.
21.
595
Tumor suppressor SCUBE2 inhibits breast-cancer
cell migration and invasion through the reversal of
epithelial-mesenchymal transition. Yuh-Charn Lin, YiChing Lee, Ling-Hui Li, Chien-Jui Cheng, Ruey-Bing Yang.
22.
582
Human papillomavirus and the inactivation of
expression of multiple large common fragile site genes
in oropharyngeal squamous cell carcinoma. David I.
Smith, Ge Gao, Nicole Tombers, Jan Kasperbauer, Vivian
Wang.
596
DKK3 expression and its function in head and
neck squamous cell carcinoma. Naoki Katase, Mehmet
Gunduz, Hidetsugu Tsujigiwa, Satoshi Ito, Masae Fujii,
Hitoshi Nagatsuka, Akira Sasaki, Tsutomu Nohno.
23.
583
Differential expression of codon 72 of TP53 in
colorectal tumors. Ligia P. Oliveira, Bianca G. Lisboa,
Ignácio Lopez, Erika M. Santos, Dirce M. Carraro, Fernando
A. Soares, Benedito M. Rossi, Renata A. Coudry.
597
Negative regulation of TNF␣-induced NF␬B
activation by XAF1 via inhibition of the TRADD/TRAF2/
RIP1 signal complex. Boren Lin, Da Xu, Douglas W.
Leaman.
24.
584
NVP-BEZ235 decreases mutant p53 and
downregulates miR-23a-24 –27a to inhibit metastasis in
breast cancer cells. Dongsheng Wang, Qin Du, Binfeng He,
Yibin Deng, Xiaolan Guo.
598
Forkhead transcription factor FOXF1 is a novel
p53 target gene and regulates cancer cell migration and
invasion. Takashi Tokino, Miyuki Tamura, Masashi Idogawa,
Yasushi Sasaki.
25.
599
Id4 acts as a tumor suppressor by inducing
apoptosis and senescence in p53-dependent manner.
Derrick J. Morton.
26.
586
Prognostic significance of Tip60 expression in
human glioma. Rongpang Bai, Yu Weng, Zhongsheng Zhao,
Jin Bai, Guangdi Chen.
600
Maternally expressed gene 3 (MEG3) as a tumor
suppressor in nasopharyngeal carcinoma. Wing Po Chak,
Joanna Hung-Man Tong, Raymond Wai-Ming Lung, Yat Yee
Chan, Kwok Wai Lo, Ka Fai To.
27.
587
Loss of colonic claudin-3 expression
characterize colon cancer patients and predicts poor
patient survival. Rizwan Ahmad, Zhimin Chen, Jian Wang,
xi chen, Robert D. Beauchamp, Mary K. Washington, Punita
Dhawan, Amar B. Singh.
601
Essential role of LRF in mesenchymal stem cell
differentiation and tumorigenesis through Dlk1 and Sox9
repression. Jlenia Guarnerio, Andrea Lunardi, Pier Paolo
Pandolfi.
29.
603
TNFR1 is indispensable in the development of
spontaneous lung squamous cell carcinomas. Zuoxiang
Xiao, Jami Willette-Brown, Yinling Hu, Sichuan Xi.
14.
588
Lrig1 suppresses breast cancer stem cell
expansion and promotes mesenchymal to epithelial
transition. Nucharee Yokdang, Colleen Sweeney.
30.
15.
589
DNA demethylating agent and histone
deacetylation inhibitor synergistically induce paired box
5 gene expression in non-small cell lung cancer cell
lines. Yuanxin Liang, Roman Perez-Soler, Yiyu Zou.
604
Olfactomedin 4 inhibits prostate stem/progenitor
cells growth through regulating the hedgehog signaling
pathway. Hongzhen Li, Wenli Liu, Weiping Chen, Jianqiong
Zhu, Chu-Xia Deng, Griffin P. Rodgers.
5.
6.
7.
8.
9.
10.
11.
12.
13.
581
Identification of PCDHB3 as a potential tumor
suppressor in colorectal cancer by exome sequencing.
Wen Ye, Ranyi Liu, Jiangxue Wu, Yingchang Li, Wenlin
Huang.
585
WIF1 re-expression in glioblastoma impairs
migration through downregulation of the lncRNA
MALAT1. Irene Vassallo, Marie-France Hamou, Monika E.
Hegi.
24
24
243
POSTER SESSION
Endocrinology 1
Poster
Section
26
26
Preclinical Analyses in Hormone-responsive Cancers
Poster Abstract
Board Number
1.
605
ErbB receptors and cisplatin resistance: the case
for bladder cancer. Benjamin A. Mooso, Duanna
Challenger, Paramita Ghosh.
11.
615
TRPM8 channel as a novel molecular target in
androgen-regulated prostate cancer cells. Swapna
Asuthkar, Kiran Velpula, Eleonora Zakharian.
2.
606
Therapeutic efficacy of ER␤ agonists on ovarian
cancer. Gangadhara Reddy Sareddy, Javier E. Chavez,
Humberto Salazar, Monica Mann, Jocelyn Hernandez,
Samaya Rajeshwari Krishnan, Edward Kost, Rajeshwar Rao
Tekmal, Ratna K. Vadlamudi.
12.
616
Transcription-regulating kinases CDK8 and
CDK19 as novel therapeutic targets for advanced
prostate cancer. Mengqian Chen, Vimala Kaza, Jiaxin
Liang, Martina McDermott, Igor Roninson.
3.
607
Targeting PIM1 kinase enhances 1,25dihydroxyvitamin D3-mediated anti-tumor activity in
bladder cancer cells. Wei Luo, Carmen M. Baldino, Justin
Caserta, Yingyu Ma, Candace Johnson, Donald L. Trump.
13.
617
Repression of cell proliferation and androgen
receptor activity by 2’-hydroxyflavanone in prostate
cancer cells. Atsushi Mizokami, Mitsuo Ofude, Misako
Kumaki, Kouji Izumi, Hiroyuki Konaka, Yoshifumi Kadono,
Minkyoung Shin, Jian Zhang, Evan T. Keller, Mikio Namiki.
4.
608
Targeting the estrogen pathway in a male mouse
model of lung tumor prevention. Laura P. Stabile, Mary E.
Rothstein, Brenda F. Kurland, Diana Cunningham, Matthew
Orlowski, Jill M. Siegfried.
14.
618
Implications of inhibition of steroid receptor coactivator-1 in human prostate cancer. Birgit Luef, Florian
Handle, Frédéric R. Santer, Zoran Culig.
5.
609
Targeting IGF-I receptor for hepatocellular
carcinoma. Yasushi Adachi, Yasutaka Matsunaga, Hiroyuki
Yamamoto, Katsuhiko Nosho, Hiromu Suzuki, Yoshiaki
Arimura, Takao Endo, Yasuo Kato, David P. Carbone,
Yasuhisa Shinomura.
15.
619
Selective estrogen mimics for the treatment of
tamoxifen-resistant breast cancer. Mary Ellen Molloy,
Bethany Perez White, Huiping Zhao, Bradley T. Michalsen,
Hitisha K. Patel, Jiong Zhao, Rui Xiong, Marton I. Siklos,
Gregory R. Thatcher, Debra A. Tonetti.
6.
610
Preclinical evaluation of novel androgen receptor
N-terminal domain inhibitor EPI-002 for the treatment of
castration-resistant prostate cancer. Yu Chi (Kevin) Yang,
Nasrin (Rina) Mawji, Jean Wang, Marianne Sadar.
16.
7.
611
Co-targeting the PI3K and androgen receptor
signal pathways in castration resistant prostate cancer.
Marco A. De Velasco, Yurie Kura, Naomi Ando, Emiko
Fukushima, Yuji Hatanaka, Yutaka Yamamoto, Nobutaka
Shimizu, Kazuhiro Yoshimura, Masahiro Nozawa, Kazuhiro
Yoshikawa, Kazuto Nishio, Hirotsugu Uemura.
620
Evidence for combination tamoxifen and betulinic
acid to treat hormone responsive- and unresponsive
breast cancer by attenuation of Pygopus expression.
Youlian Tzenov, Philip Andrews, Cathy Popadiuk, Kenneth R.
Kao.
17.
621
Effect of diet-induced obesity on MCF-7Ca
xenografts grown in ovariectomized athymic nude mice.
Gauri J. Sabnis, Olga Goloubeva, Preeti Shah, Saranya
Chumsri, Angela Brodie.
8.
612
Endostatin is a novel inhibitor of androgen
receptor function in prostate cancer. Joo Hyoung Lee,
Tatyana Isayeva, Matthew Larson, Diptiman Chanda, Igor
Chesnokov, Selvarangan Ponnazhagan.
18.
622
S-equol, an estrogen receptor ␤ agonist, inhibits
tumor growth and progression of breast cancer. Cathy
Samayoa, Naveen K. Krishnegowda, Samaya R. Krishnan,
Ratna K. Vadlamudi, Rajeshwar R. Tekmal.
9.
613
Combining PI3K and 5alpha-reductase inhibitors
improves the treatment response in a mouse model of
PTEN-deficient prostate cancer. Yurie Kura, Marco A. De
Velasco, Naomi Ando, Emiko Fukushima, Yutaka Yamamoto,
Yuji Hatanaka, Nobutaka Shimizu, Masahiro Nozawa,
Kazuhiro Yoshimura, Kazuhiro Yoshikawa, Kazuto Nishio,
Hirotsugu Uemura.
19.
623
BIG3-PHB2 interaction is a key therapeutic target
in luminal-type of breast cancer. Toyomasa Katagiri,
Tesuro Yoshimaru, Masato Komatsu, Taisuke Matsuo.
20.
624
Preliminary study of the follicle-stimulating
hormone ␣/␤ and the pathogenesis of postmenopausal
breast cancer. Yi-Ding Chen.
614
Proxalutamide (GT0918), a potent androgen
receptor pathway inhibitor. Youzhi Tong, Chunyun Chen,
Juan Wu, Jiangtao Yang, Huihui Zhang, Xiaojun Wu, Yanmei
Duan, Wei Gao, Weidong Qian, Xiaoxia Niu, Lili Mi,
Chuangxing Guo.
21.
625
Proliferative effects of the phytoestrogens 8Prenylnaringenin, 6-(1.1-dimethylallyl)naringenin and
Naringenin in MCF-7 cells and the rat mammary gland.
Janina Helle, Oliver Zierau, Kristin Kräker, Annekathrin
Keiler, Günter Vollmer, JoEllen Welsh, Georg Kretzschmar.
10.
244
Poster Abstract
Board Number
POSTER SESSION
Immunology 1
Immune Mechanisms Invoked by Radiation, Chemotherapy, or Targeted
Therapy
Poster Abstract
Board Number
1.
626
Cisplatin-based concurrent chemoradiotherapy
antagonizes anti-tumor immunity in patients with HPVpositive oropharyngeal cancer. Andrew Sikora, Marshall
Posner, Falguni Parikh, Seunghee Kim-Schulze, Vishal
Gupta, Krzysztof Misiukiewicz, Alexis Patsias, Amelia Clark,
Sangkon Oh, Dorothee Duluc.
2.
627
Immunogenic cell death as novel immune
response mechanism to EGFR-targeted therapy in CRC.
Giuseppe Penna, Chiara Pozzi, Elena Magni, Giuseppe
Curigliano, Maria Giulia Zampino, Maria Rescigno.
3.
628
Pan-Bcl-2 inhibitor, GX15– 070 (Obatoclax),
decreases human T regulatory lymphocytes while
preserving effector T Lymphocytes: A rationale for its
use in combination immunotherapy. Peter S. Kim,
Caroline Jochems, Italia Grenga, Renee N. Donahue, Kwong
Y. Tsang, James L. Gulley, Jeffrey Schlom, Benedetto
Farsaci.
4.
629
Combination hypoxia-specific chemotherapy and
immunotherapy of prostate cancer. Midan Ai, Todd
Bartkowiak, Ashvin R. Jaiswal, Krishna Shah, Casey Ager,
Beatrisa Lerman, Michael A. Curran.
5.
630
Induction of anti-melanoma immunity after
intralesional ablative therapy. Hao Liu, Krithika Kodumudi,
Amy Weber, Amod A. Sarnaik, Shari Pilon-Thomas.
6.
631
Gastrointestinal toxicities of 5-FU increase the
proportion of regulatory T cells in murine intestinal
tract: Advantages of alternate-day S-1 administration.
Taiki Kajiwara, Koh Miura, Shinobu Ohnuma, Tetsuhiko
Shirasaka, Toshihiro Komura, Masahide Toshima, Atsushi
Kohyama, Katsuyoshi Kudoh, Sho Haneda, Hiroaki Musha,
Fuyuhiko Motoi, Yu Katayose, Takeshi Naitoh, Michiaki
Unno.
7.
632
Radiation-induced immunogenic modulation of
tumor enhances antigen processing and calreticulin
exposure, resulting in enhanced T-cell killing. Sofia R.
Gameiro, Momodou L. Jammeh, Max M. Wattenberg, Kwong
Y. Tsang, Soldano Ferrone, James W. Hodge.
8.
633
Inhibition of TGF␤ as a strategy to convert the
irradiated tumor into in situ individualized vaccine.
Claire I. Vanpouille-Box, Julie M. Diamond, Jiri Zavadil,
James Babb, Dörthe Schaue, Mary Helen Barcellos-Hoff,
William H. McBride, Silvia C. Formenti, Sandra Demaria.
9.
634
Combination chemotherapy significantly reduces
indoleamine 2,3-dioxygenase activity in NSCLC patients.
Cara C. Schafer, Yong Wang, Anandi Sawant, Tong Huan
Jin, Selvarangan Ponnazhagan, Stefan C. Grant, Jessy S.
Deshane.
Poster Abstract
Board Number
10.
635
Antigen-specific immune responses in melanoma
using stereotactic radiotherapy combined with anti-PD1
checkpoint blockade. Andrew Sharabi, Christopher Nirschl,
Tina Ceccato, Brian Francica, Angela Alme, Thomas Nirschl,
Esteban Velarde, Theodore DeWeese, Charles Drake.
11.
636
Sub-lethal irradiation of diverse human
carcinoma cells imparts enhanced and sustained
expression of important modulators of effector CTL
activity. Anita Kumari, Orpha R. Mott, Ercan Cacan,
Susanna F. Greer, Charlie T. Garnett.
12.
637
Chemotherapy enhances recombinant
lipoimmunogen-based antitumor immunity against
cervical cancer. Shih-Jen Liu, Li-Sheng Chang, Yi-Chen
Yeh, Chih-Hsiang Leng.
13.
638
Lenalidomide treatment enhances the anti-tumor
activities of XBP1 specific cytotoxic T lymphocytes by
increasing the frequency and tumor-specific response
of central memory CD3ⴙCD8ⴙ T cells. Jooeun Bae, Rao
Prabhala, Ruben Carrasco, Paul Richardson, Glen Dranoff,
Kenneth C. Anderson, Nikhil C. Munshi.
14.
639
Antibody-mediated blockade of
phosphatidylserine combined with radiation improves
survival and tumor eradication in a rat model of nonsmall cell lung cancer. Olivier Belzile, Zhang Zhang,
Xianming Huang, Debabrata Saha, Rolf A. Brekken.
16.
641
Targeted inhibition of BRAF signaling in
melanoma enhances the activity of a multivalent
immunotherapeutic vaccine. Robert Suriano, Neha Tuli,
Jan Geliebter, Raj K. Tiwari, Marc K. Wallack.
17.
642
Transcend, a protein vector for brain delivery,
allows trastuzumab to reach the brain at effective
concentration after incorporation to form BT2111.
Reinhard Gabathuler, Timothy Z. Vitalis, Mohamed I.
Nounou, Chris E. Adkins, Paul R. Lockman, Wilfred A.
Jefferies.
18.
643
The histone deacetylase inhibitor Quisinostat
augments the anti-tumor reponses of T-cells:
Implications in adoptive cell therapy. David M. Woods,
Andressa L. Sodre, Jason B. Brayer, Eduardo M. Sotomayor.
19.
643A
Characterization of the ␥␦ T-cell response in
high-grade glioma. Hyung Kim, Rebecca O’Brien, George
Y. Gillespie, Gretchen A. Cloud, Cathy Langford, Lualhati
Harkins, Lawrence S. Lamb.
Poster
Section
27
27
245
POSTER SESSION
Immunology 2
Poster
Section
28
28
Therapeutic Antibodies
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
246
644 Novel anti-B cell maturation antigen-monomethyl
auristatin F antibody-drug conjugate (GSK2857916) induces
potent and selective anti-multiple myeloma activity via
enhanced effector function and direct tumor cell killing . Yu-Tzu
Tai, Chirag Acharya, Mike Y. Zhong, Michele Cea, Antonia Cagnetta,
Patrick A. Mayes, Jenny Craigen, Louise Gliddon, James Smothers,
Amanda L. Christie, Andrew L. Kung, Paul Richardson, Nikhil C.
Munshi, Kenneth C. Anderson.
645 IGM-55.5, a novel monoclonal human recombinant IgM
antibody with potent activity against B cell leukemia and
lymphoma. Omar Duramad, Beatrice Wang, Fen Zheng, Lena Keyt,
Claire Repellin, Lucia Beviglia, Neelima Bhat, Marcia Bieber, Nelson
Teng, Bruce Keyt.
646 Bi-specific T-cell engaging antibody activates T-cells to
target the tumor associated antigen PR1. Amanda Herrmann, Jin
Im, Sijie Lu, Jeffrey Molldrem.
647 CD20-specific Engineered Toxin Body demonstrates
direct cell kill of multiple B-cell Non-Hodgkin’s lymphoma types.
Sangeetha Rajagopalan, Rachel Wirth, Jennifer Erdman, Kari Grant,
Brigitte Brieschke, Rodney Flores, William Null, Jen-Sing Liu, Erin K.
Willert, Jack P. Higgins.
648 Semi-synthetic peptibodies are a novel personalized
therapeutic with activity against lymphoma in vitro and in vivo.
James Torchia, Patrick Ng, Homer Chen, Kipp Weiskopf, Ronald
Levy.
649 Development and preclinical characterization of an Fcoptimized CD133 antibody for improved induction of NK cell
reactivity against myeloid leukemia. Samuel Koerner, Julia
Leibold, Ludger Grosse-Hovest, Hans-Jörg Bühring, Helmut R. Salih,
Gundram Jung.
650 KIR/HLA interactions negatively affect rituximab, but not
GA101 (obinutuzumab)-induced ADCC. Grzegorz Terszowski,
Christian Klein, Martin Stern.
651 Ex vivo and in vivo characterization of IPH4102, a
humanized anti-KIR3DL2 antibody for the treatment of
cutaneous T-cell lymphomas . Anne Marie-Cardine, Nicolas Viaud,
Arnaud Dujardin, Rachel Joly, Laurent Gauthier, Cecile Bonnafous,
Mathieu Blery, Carine Paturel, Armand Bensussan, Martine Bagot,
Helene Sicard.
652 Development and characterization of anti-FGFR4
monoclonal antibodies as therapeutic agents for human
rhabdomyosarcoma. Sivasubramanian Baskar, Zhongyu Zhu, Ramon
Lorenzo Labitigan, Michelle Ovanesian, Rimas J. Orentas, Samuel Q.
Li, Yohe E. Marielle, John Shern, Dimiter S. Dimitrov, John Maris,
Crystal Mackall, Khan Javed.
653 NKTT320, a novel monoclonal antibody activates the
immuno-stimulatory functions of human invariant natural killer
T cells. Rupali Das, Felix Scheuplein, Nishant P. Patel, Peng Guan,
Robert G. Schaub, Kim E. Nichols.
654 Targeting K-ras mutant cancer cells with a lupus antiguanosine antibody. Melissa R. Young, Philip W. Noble, Richard H.
Weisbart, James E. Hansen.
655 Effect of antibody mixtures on HER-family
heterodimerization. Sofie Ellebæk, Thomas Bouquin, Michael V.
Grandal, Michael Kragh, Thomas T. Poulsen.
656 A bispecific HER2/CD3 targeting FynomAb with excellent
tumor killing and favorable pharmacokinetic properties. Ulrich
Wuellner, Fabian Buller, Kristina Klupsch, Simon Brack, Irene
Zbinden, Roger Santimaria, Isabella Attinger-Toller, Susann KönigFriedrich, Julian Bertschinger, Dragan Grabulovski.
657 Simultaneous inhibition of HER-family receptors by PanHER antibody mixture prevents compensatory HER-family
receptor upregulation and induces cell death in a broad range
of tumor models. Anna Dahlman, Helle J. Jacobsen, Thomas T.
Poulsen, Paolo Conrotto, Mikkel W. Pedersen, Ivan D. Horak, Michael
Kragh, Johan Lantto.
658 A bispecific HER2 targeting FynomAb with superior antitumor activity and novel mode of action. Babette Schade, Simon
Brack, Isabella Attinger-Toller, Kristina Klupsch, Richard Woods,
Helen Hachemi, Ulrike von der Bey, Susann Ko¨nig-Friedrich, Julian
Bertschinger, Dragan Grabulovski.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
659 Integrated therapeutic antibody development at the
National Research Council of Canada. Maria L. Jaramillo, Anne
Marcil, Yves Durocher, Renald Gilbert, Alaka Mullick, John Kelly,
Maureen O’Connor-McCourt, Bernard Massie.
660 Engineering strategies to control stoichiometry, site of
conjugation, serum stability and effector functions of antibodydrug conjugates. Nazzareno Dimasi, Ryan Fleming,.
661 Proteomics and selecting the right combination of
target and toxin for antibody-drug-conjugate (ADC)
development. Jonathan A. Terrett, Rachel Dusek, Dee Aud, Rahel
Awdew, Sudha Swaminathan, San Lin Lou, Michael Trang, Arnima
Bisht, Mary Do, Jim Ackroyd, Robert Boyd, Lindsey Hudson, Phuoc
Pham, Nickolas Attanasio, Ami Antani, Carmel Lynch, Christian
Rohlff.
662 Generation and characterization of antibodies specific
for IL1RAP antigen to target quiescent and proliferating AML
leukemic stem cells. Ping Jiang, Sharmili Roy, Jen Huang, Trang
Dao-Pick, Jennifer Lu, Madhavi Mishra, Jeffrey Lin, Eric D. Hsi,
Robert J. Tressler, Holger Karsunky.
663 Development of a cancer-specific monoclonal antibody
LpMab-2 specific for cancer-type podoplanin. Yukinari Kato, Mika
K. Kaneko.
664 Amanitin-based antibody-drug conjugates targeting the
prostate-specific membrane antigen. Torsten Hechler, Michael
Kulke, Christoph Mueller, Andreas Pahl, Jan Anderl.
665 Therapeutic targeting of breast cancer stem cells using
PG-101 improves breast cancer survival. Madhuri Wadehra,
Meagan Kiyohara.
666 AB-3A4: A novel KAAG1-targeting antibody-drug
conjugate is active in models of ovarian carcinoma, triplenegative breast cancer and castration-resistant prostate cancer.
Gilles B. Tremblay, Anna Moraitis, Dominique Bédard, Adriana
Orimoto, Martine Pagé, Anne-Marie Mes-Masson, Mario Filion.
667 IMGN853, a folate receptor (FR) ␣-targeting antibodydrug conjugate (ADC), is highly effective against xenograft
models with clinically relevant levels of receptor expression.
Olga Ab, Laura M. Bartle, Xiuxia Sun, Rui Wu, Holly A. Johnson,
Kathleen R. Whiteman, Alyssa LaBelle, Victor S. Goldmacher.
668 Folate conjugated site-specifically to anti-human-CD3Fab is efficacious in mouse models of ovarian cancer. Sandra L.
Biroc, Marco Gymnopoulos, Shailaja Srinagesh, Brad Hayes, Nick
Knudsen, Anthony Manibusan, Jason Pinkstaff, Tim Buss, Kari Cox,
Robin Marsden, Lillian Skidmore, Jinming Xia, Ying Sun, Ning Zou,
Tsotne Javahishvili.
669 Development of MGD007, a gpA33 x CD3 bi-specific
DART for T-cell immunotherapy of metastatic colorectal cancer.
Paul A. Moore, Ralph Alderson, Kalpana Shah, Yinhua Yang, Steve
Burke, Hua Li, Valentine Ciccarone, Ezio Bonvini, Syd Johnson.
670 ImmTACs: Bi-specific TCR-anti-CD3 fusions for potent
re-directed killing of cancer cells. Giovanna Bossi, Debbie Baker,
Katherine Adams, Jane Harper, Joseph Dukes, Nathaniel Liddy,
Samantha Paston, Yvonne McGrath, Tara Mahon, Pater Molloy,
Malkit Sami, Emma Baston, Brian Cameron, Andrew Johnson,
Annelise Vuidepot, Namir Hassan, Bent Jakobsen.
671 CD38-specific engineered toxin body: Therapeutic
potential for multiple myeloma. Sangeetha Rajagopalan, Brigitte
Brieschke, Garrett L. Robinson, Jennifer Erdman, William Null, Jack
P. Higgins, Erin K. Willert.
672 Pharmacokinetic and pharmacodynamic (PK/PD)
modeling of preclinical data of a novel anti-fibroblast growth
factor receptor 2(FGFR2) antibody (BAY 1179470) to guide
dosing in Phase 1. Sabine Wittemer-Rump, Charlotte Kopitz, Hung
Huynh, Lars Lindbom, Bernhard Beckermann, Motonobu Osada, Dirk
Laurent, Jörg Lippert.
673 A Monoclonal Antibody, MORAb-075, Targeting Claudin3 & Claudin-4 Inhibits human ovarian, pancreatic and prostate
cancer progression in mice. Jian-Min Lin, allis soto, Christopher
maddage, earl Albone, yuhong zhou, luigi grasso.
POSTER SESSION
Experimental and Molecular Therapeutics 1
Drug Resistance 1: Hormonal Agents and Novel Mechanisms
Poster Abstract
Board Number
1.
674
ODM-201 - New generation androgen receptor
inhibitor targeting resistance mechanisms to androgen
signalling-directed prostate cancer therapies. Anu-Maarit
Moilanen, Reetta Riikonen, Pekka J. Kallio.
2.
675
Dual inhibition of the androgen receptor and PI3K/mTor pathways has significant antitumor activity in
castrate-resistant prostate cancer. Daruka Mahadevan,
Carla Morales, Laurence S. Cooke, Bradley Somer, Wenqing
Qi.
3.
676
Inhibition of FOXM1 targets both high and low
PSA expressing prostate cancer cells resistant to
Enzalutamide. Kirsi Ketola, Jennifer Bishop, Ka Mun Nip,
Soojin Kim, Fazli Ladan, Martin Gleave, Amina Zoubeidi.
4.
677
Co-targeting of AR and N-cadherin with
Enzalutamide and 2A9 monoclonal antibody to treat
castration resistant prostate cancer. Evelyn A. Kono,
Sean H. Lee, Tatsuya Shimomura, Shu Lin, Joyce
Yamashiro, Robert E. Reiter.
5.
678
The Ets factor ETV5 regulates E2F target genes
and mediates drug resistance. Barbie Taylor-Harding,
Hasmik Agadjanian, Paul-Joseph Aspuria, Dong-Joo Cheon,
Takako Mizuno, Danielle Greenberg, Jenieke R. Allen,
Sandra Orsulic, Christine Walsh, Beth Y. Karlan, W. Ruprecht
Wiedemeyer.
6.
679
Glutamine metabolism in MYC-driven
antiestrogen resistant breast cancer cells confers
metabolic flexibility through the unfolded protein
response. Ayesha N. Shajahan-Haq, Katherine L. Cook,
Jessica L. Schwartz-Roberts, Ahreej E. Eltayeb, Diane M.
Demas, Anni M. Warri, Leena A. Hilakivi-Clarke, Robert
Clarke.
Poster Abstract
Board Number
14.
687
The mechanisms of anti-VEGF therapy resistance
in renal cell carcinoma. Lijun Zhou, Xiande Liu, Mianen
Sun, Nizar M. Tannir, Douglas Laird, Eric Jonasch.
15.
688
Characterization and circumvention of drug
resistance mechanisms in SGN-35-resistant HL and
ALCL clonal cell lines. Timothy S. Lewis, Kristine Gordon,
Fu Li, Allana Weimann, Rebecca Bruders, Jamie Miyamoto,
Dana Chace, Che-Leung Law.
16.
689
Nuclear factor erythroid-2 related factor-2
regulates ATM and ATR transcription that contributes in
drug resistance in ovarian cancer cell lines. Hilal S.
Khalil, Yusuf Deeni, Aftab Amin, Alexey Goltsov, Simon
Langdon, David Harrison, James Bown.
17.
690
In vivo modeling identifies RB1 suppression and
inactivation as being responsible for acquired
PD0332991 resistance in glioblastoma. Yu-Jen Lu, ManTzu Wang, Todd Waldman, Tomoko Ozawa, David James.
18.
691
Down-regulation of Wnt10b following targeted
theranostic nanoparticles in a patient derived xenograft
model of triple negative breast cancer. Jasmine MillerKleinhenz, Weiping Qian, Ruth O’Regan, Toncred Styblo,
Amelia Zelnak, Andrew Wang, Lily Yang.
19.
692
A novel resistance mechanism to PLX4032 in the
human melanoma cell line MEL-XY3 involves acquisition
of stem cell-like characteristics. Florencia Madorsky,
Antonela Barón, José Mordoh.
20.
693
AXL tyrosine kinase inhibition selectively
sensitizes mesenchymal cancer cells to antimitotic
agents. Catherine Wilson, Thinh Pham, Xiaofen Ye, Eva Lin,
Sara Chan, Erin McNamara, Richard M. Neve, Lisa Belmont,
Hartmut Koeppen, Robert L. Yauch, Avi Ashkenazi, Jeff
Settleman.
21.
694
Different pancreatic cancer cells have their own
core signaling pathway. Eunkyung Kim, Sujin Kang, So Y.
Kim, Dongxu Kang, Seungha Lee, Hye J. Choi, Joo-Hang
Kim, Jae J. Song.
7.
680
HMGB1 regulates autophagy and apoptosis to
promote chemotherapy resistance in multiple myeloma.
Xingding Zhang, Lin Qi, Lin Yang.
8.
681
Heat shock-mediated suppression of ODC protein
expression in colorectal cancer cells. Christina T. Wales,
Aaron T. Jacobs.
9.
682
Identification of HSP90 inhibitor sensitizers
through pooled RNA interference screen. Yaoyu Chen,
Jinyun Chen, Alice Loo, Margaret Mclaughlin, Raymond
Pagliarini, Wenlai Zhou.
22.
695
p70S6 kinase is a critical node that integrates
HER-family and PI3 kinase signaling. Mark J. Axelrod,
Rolando E. Mendez, Daniel G. Gioeli, Mark J. Jameson,
Michael J. Weber.
10.
683
Sensitizing tumors to pro-oxidant therapy by
inhibiting gamma-glutamyl transpeptidase. Marie H.
Hanigan, Nancy Wakeham, Stephanie Wickham, Simon S.
Terzyan.
23.
696
ASS1, ANXA4 and MVP underlie acquired
multicellular resistance of mesothelioma 3D cell
cultures. Dario Barbone, Loes van Dam, Shu-Dong Zhang,
Jithesh Puthen, Dean Fennell, V. Courtney Broaddus.
11.
684
Structural basis for resistance to NAMPT
inhibitors. Weiru Wang, Kristi Elkins, Yen-Ching Ho, Angela
Oh, Jiansheng Wu, Hong Li, Yang Xiao, Eric Cheng, Lisa
Crocker, Peter Dragovich, Deepak Sampath, Thomas
O’Brien, Xiaozhang Zheng, Kenneth Bair, Lisa D. Belmont.
24.
697
Development of spheroid based high-throughput
screening of cell-cell adhesion inhibitors to reverse
acquired multicellular resistance. Kazuya Arai, Manabu
Itho, Atsushi Mizuno, Hiromi Miura.
25.
12.
685
Antagonism of sorafenib and regorafenibmediated HCC growth inhibition by platelet factors. Brian
I. Carr, Rosalba D’Alessandro, Maria Grazie Refolo, Catia
Lippolis, Caterina Messa, Aldo Cavallini.
698
Variability in xenograft growth rates can be
explained by intra-tumor evolutionary dynamics.
Christopher J. Zopf, Andrew Chen, Mayank Patel, Santhosh
Palani, Syamala Bandi, Derek Blair, Wen Chyi Shyu, Arijit
Chakravarty.
13.
686
Regulation of intracellular sequestration of
sunitinib by cystine transporter xCT in renal cancer.
Sreenivasulu Chintala, Hillary Nguyen, Swathi Ramakrishnan,
Sheng-Yu Ku, Eric Ciamporcero, Kiersten M. Miles, Roberto
Pili.
26.
698A
Bitter melon juice targets molecular
mechanisms underlying gemcitabine resistance in
pancreatic cancer cells. Ranganatha Somasagara, Gagan
Deep, Sangeeta Shrotriya, Manisha Patel, Chapla Agarwal,
Rajesh Agarwal.
Poster
Section
29
29
247
POSTER SESSION
Poster
Section
30
30
Experimental Gene Transfer, Vector Systems, and Antisense
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
248
699
Mesenchymal stem cells (MSC) as cell-based
vectors for PSA-activated proaerolysin to sites of
prostate cancer. W. Nathaniel Brennen, Oren Levy, Sudhir
Ranganath, Michael Schweizer, Marc Rosen, Sandrine Billet,
Neil Bhowmick, Samuel Denmeade, Jeffrey Karp, John
Isaacs.
700
Systemic administration of DNA nanoparticles
containing the diphtheria toxin gene reduces pancreatic
tumor load in mice. Janet A. Sawicki, Weidan Peng, Kelly
Rhodes, Robert Getts.
701
In vivo anti-metastatic effects of uPAR
retargeted oncolytic measles virus. Yuqi Jing, Julia Zaias,
Jaime Merchan.
702
DCVex(TM): A novel integration-deficient
lentivector technology that incorporates genetic and
post-translational elements to target dendritic cells.
Semih U. Tareen, Brenna Kelley-Clarke, Christopher J.
Nicolai, Megan M. Slough, Chintan D. Vin, Neal Van Hoeven,
Scott H. Robbins, Jan H. ter Meulen, Peter Berglund.
703
Highly selective HSV virotherapy for
glioblastoma. Aofei Li, Marco Marzulli, Lucia Mazzacurati,
Hiroaki Uchida, Justus Cohen, Joseph Glorioso, Paola
Grandi.
704
Comparison of Salmonella typhimurium A1-R and
VNP20009 on the Lewis Lung carcinoma. Yong Zhang,
Nan Zhang, Robert M. Hoffman, Ming Zhao.
705
In vivo audition of tumor homing peptides using
high-throughput sequencing and q-PCR. Kadri Toome,
Tarmo Mölder, Kuldar Kõiv, Pille Säälik, Kazuki N. Sugahara,
Erkki Ruoslahti, Tambet Teesalu.
706
A novel photodynamic therapy with virusmediated delivery of photosensitive cytotoxic
fluorescent protein KillerRed for human cancers. Kiyoto
Takehara, Hiroshi Tazawa, Yuuri Hashimoto, Hiroyuki
Kishimoto, Toshiyoshi Fujiwara, Nobuhiro Narii, Hiroyuki
Mizuguchi.
707
Tumor-targeted delivery of siRNA using
stabilized calcium phosphate nanoparticles based on
bio-inspired hyaluronic acid conjugate. Min Sang Lee,
Jung Eun Lee, Eunkyoung Byun, Nak Won Kim, Haeshin
Lee, Ji Hoon Jeong.
708
Toca 511 gene therapy in combination with 5fluorocytosine for intratumoral production of 5fluorouracil in a colon cancer metastasis model. Maria
E. Rodriguez-Aguirre, Fernando Lopez Espinoza, Bryan
Martin, Kader Yadiz, Tiffany T. Huang, Carlos E. Ibanez,
Derek G. Ostertag, Noriyuki Kasahara, Harry E. Gruber,
Douglas J. Jolly, Joan M. Robbins.
709
Efficacy of Salmonella typhimurium A1-R on
experimental breast cancer brain metastasis. Yong
Zhang, Shinji Miwa, Nan Zhang, Robert M. Hoffman, Ming
Zhao.
710
The efficacy of tumor-targeting Salmonella
typhimurium A1-R on bone metastasis. Shinji Miwa, Ming
Zhao, Shuya Yano, Yong Zhang, Fuminari Uehara, Yasunori
Matsumoto, Yukihiko Hiroshima, Mako Yamamoto, Hiroaki
Kimura, Katsuhiro Hayashi, Hiroyuki Tsuchiya, Robert M.
Hoffman.
711
Salmonella typhimurium A1-R induces quiescent
FUCCI-expressing cancer cells to cycle and become
chemosensitive. Shuya Yano, Yong Zhang, Ming Zhao,
Yukihiko Hiroshima, Shinji Miwa, Fuminari Uehara, Hiroyuki
Kishimoto, Hiroshi Tazawa, Toshiyoshi Fujiwara, Robert M.
Hoffman.
712
Salmonella typhimurium A1-R inhibits surgically
induced breast cancer metastasis. Yong Zhang, Nan
Zhang, Robert M. Hoffman, Ming Zhao.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
713
Utilizing a potent and selective nonreplicating
adenoviral mutant (Ad5-TV-CU), with gene expression
controlled by androgen receptor-dependent activation
domains in the TMPRSS2 gene, as a novel prodrugconverting enzyme therapy for prostate cancer. Emma J.
Mercer, Ahmet Imrali, Kevin Sharpe, Gunnel Hallden, YongJie Lu.
714
Bioengineering of the adeno-associated virus
(AAV) vectors for dendritic cell (DC)-based
immunotherapy. Pandya Jheel, Kellee Britt, George
Aslanidi.
715
Vivo-Morpholino antisense oligomers decrease
tumor growth in mice by altering mVEGF mRNA splicing
to knock down mVEGF expression. Shan Jiang.
716
ASPH_0047: a potent and selective antisense
oligonucleotide-targeting transforming growth factor
beta 2 (TGF-␤2). Katja Wosikowski, Frank Jaschinski,
Hanna Kohonen, Stephan Braun, Eugen Leo, Michel Janicot.
717
Novel potent antisense oligonucleotides targeting
transforming growth factor beta1 (TGF-␤1). Frank
Jaschinski, Hanna Korhonen, Stephan Braun, Katja
Wosikowski, Michel Janicot.
718
Systemic delivery of therapeutic siRNA by
multifunctional mesoporous silica-based nanocarrier
inhibits lung cancer growth and metastasis. Yijie Chen,
Hongchen Gu, Weiliang Xia.
719
Development of systemically-deliverable
telomerase-specific oncolytic adenovirus. Katsuyuki
Aoyama, Shinji Kuroda, Hiroshi Tazawa, Shunsuke Kagawa,
Toshiyoshi Fujiwara.
720
Dual MMP-7-proximity-activated and folatetargeted nanoparticles for siRNA delivery. Todd D.
Giorgio, Hongmei Li, Martina Miteva, Kellye C. Kirkbride,
Ming Cheng, Chris E. Nelson, Craig L. Duvall.
721
Suppression of orthotopic liver cancers by a
combinatorial therapy of radiation and adenoviral
vectors expressing interleukin 12. Mi-Hua Tao, Wen-Shan
Tsao, Ping-Yi Wu.
722
Gene therapy for peritoneal dissemination model
of gastric cancer using SOCS-1 by Adenoviral Vector.
Rie Nakatsuka, Tsuyoshi Takahashi, Satoshi Serada, Minoru
Fujimoto, Yoshihito Souma, Yasuhiro Miyazaki, Yukinori
Kurokawa, Makoto Yamasaki, Hiroshi Miyata, Kiyokazu
Nakajima, Shuji Takiguchi, Masaki Mori, Yuichiro Doki,
Yuichiro Doki, Tetsuji Naka.
723
Liver-detargeted Ad5/48 chimaeric hexon based
oncolytic adenovirus targeting TGF␤ signaling: A safe
and effective approach for the treatment of prostate
cancer bone metastases. Weidong Xu, Zhenwei Zhang,
Theresa Guise, Charles B. Brendler, Prem Seth.
724
Systemic injection of fiber-redesigned oncolytic
adenovirus eliminates tumors in vivo. Yoshiaki Miura,
Mizuho Sato, Julia Davydova, Masato Yamamoto.
725
Combination therapy of telomerase-specific
oncolytic adenovirus and zoledronic acid in human
osteosarcoma cells. Yasuaki Yamakawa, Joe Hasei, Hiroshi
Tazawa, Toshinori Omori, Shuhei Osaki, Tsuyoshi Sasaki,
Aki Yoshida, Toshiyuki Kunisada, Yasuo Urata, Toshifumi
Ozaki, Toshiyoshi Fujiwara.
726
Oncolytic adenoviruses modulate autophagy in
cancer cells via sumoylation of LC3. Sujan Piya, Hong
Jiang, Sarah Klein, W.K.Alfred Yung, Raymond Sawaya,
Candelaria Gomez-Manzano, Juan Fueyo.
727
Does gene transfer of gulono-lactone oxidase
into human hepatocellular carcinoma cells restore
ascorbate biosynthesis. Teresa Flett, Elizabeth Campbell,
Elisabeth Phillips, Margreet C. Vissers, Gabi U. Dachs.
POSTER SESSION
Kinase Inhibitors 1
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
728 AMG 337, a novel, potent and selective MET kinase
inhibitor, has robust growth inhibitory activity in MET-dependent
cancer models. Paul E. Hughes, Yajing Yang, Karen Rex, Yihong
Zhang, Paula J. Kaplan-Lefko, Sean Caenepeel, Jodi Moriguchi,
Martin Broome, Deborah Choquette, Robert Radinsky, Richard
Kendall, Angela Coxon, Isabelle Dussault.
729 Norleual a hepatocyte growth factor/c-Met inhibitor
blocks malignant phenotypes in cancerous cells. Leen H. Kawas,
Kevin J. Church, Malte Lange, Michelle Mcmicheal, Brent Yamamoto,
Joseph W. Harding.
730 Efficacy of a novel small molecule MER receptor
tyrosine kinase inhibitor in B-RAF wild-type and B-RAF mutant
melanoma cell lines. Lenka S. Teodorovic, Jacqueline Carrico,
Deborah DeRyckere, Weihe Zhang, Xiaodong Wang, Stephen Frye, S.
Gail Eckhardt, H. Shelton Earp, Douglas K. Graham.
731 SRI-28731, a highly potent and selective MAP4K4 (HGK)
inhibitor for cancer therapy. Chih-Tsung Chang, Jaehyeon Park,
Wei Zhou, Xiaohe Liu, Barbara Sato, Dominic Dinh, Anna Furimsky,
Lucia Beviglia, Lidia Sambucetti, Ling Jong.
733 Effects of cabozantinib on breast cancer bone
metastases, overall survival, and bone mass in a mouse model.
Khalid S. Mohammad, Ahmed Harhash, Sutha K. John, Xianghong
Peng, Maria Niewolna, Sreemala Murthy, A. Douglas Laird, Dana T.
Aftab, Theresa A. Guise.
734 Effects of Cabozantinib in the 5TGM1 murine multiple
myeloma model. Mari I. Suominen, Douglas O. Clary, Rami
Käkönen, Katja M. Fagerlund, Esa Alhoniemi, Jukka P. Rissanen,
Jussi M. Halleen, Dana T. Aftab.
735 Evaluation of cabozantinib in combination with
abiraterone, enzalutamide or docetaxel in a castration-resistant
prostate cancer xenograft in vivo. Holly M. Nguyen, Lisha G.
Brown, Jessica L. Olson, Dana T. Aftab, Robert L. Vessella, Eva
Corey.
736 DJ4, a novel ROCK and MRCK inhibitor, potently inhibits
migration and invasion of cancer cells. Vijaykumar P. Kale,
Dhimant Desai, Taryn Dick, Katherine Choe, Ashley Colledge, Shantu
Amin, Jeremy Hengst, Jong Yun.
737 Assessment of cabozantinib activity in diverse prostate
cancer xenograft models. Lisha G. Brown, Holly M. Nguyen, Ilsa M.
Coleman, Peter S. Nelson, Robert L. Vessella, Dana T. Aftab, Eva
Corey.
738 Increased Ret signalling and impact of vandetanib in
acquired tamoxifen resistant breast cancer. Julia M. Gee, Lindy
Goddard, Huw J. Mottram, Rajpal S. Burmi, Sara L. Pumford, Carol
M. Dutkowski, Denise Barrow, Iain R. Hutcheson, Robert I. Nicholson,
Ian O. Ellis, Paul Elvin.
739 The MEK-inhibitor pimasertib in B-cell lymphomas:
Evaluation of the pre-clinical activity as single agent or in
combination and identification of biomarkers of response.
Eugenio Gaudio, Ivo Kwee, Chiara Tarantelli, Elena Bernasconi,
Andrea Rinaldi, Luciano Cascione, Maurilio Ponzoni, Anastasios
Stathis, Emanuele Zucca, Samantha Goodstal, Francesco Bertoni.
740 Phenotypic profiling and selectivity optimization of ERK
inhibitors using a high-throughput imaged-based cell cycle
assay. Grace Ka-Yan Chan, Tracy Kleinheinz, Matthew Martinson,
Hok-Sum Cheung, John G. Moffat.
741 Combined inhibition of MDM2 and MEK for KRAS mutant
non-small cell lung cancer. Aaron N. Hata, Hannah L. Archibald,
Maria D. Gomez-Caraballo, Laurent R. DeBussche, Sukhvinder Sidhu,
James Watters, Jeffrey A. Engelman.
742 Antitumor activity of Trametinib, a MEK1/2 inhibitor, in
malignant pleural mesothelioma cells in vitro. Hiroyuki Cho, Seiji
Matsumoto, Yoshiko Fujita, Ayumi Kuroda, Masaki Hashimoto,
Teruhisa Takuwa, Toshi Menju, Makoto Sonobe, Nobuyuki Kondo,
Hiroshi Date, Seiki Hasegawa.
743 Potent anti-tumor activity of the MEK1/2 inhibitor
MEK162 in human non-small cell lung cancer (NSCLC) and
squamous cell carcinoma of the head and neck (SCCHN) cell
lines. Deborah J. Wong, Edward B. Garon, Danielle D. Silveira,
Naeimeh Kamranpour, Sharon Pitts, Meenal Chalukya, Habib Hamidi,
Steven Dubinett, Ronald Linnartz, Richard S. Finn, Dennis J. Slamon.
Poster Abstract
Board Number
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
744 Effective use of MDK/Midkine and MEK inhibitor to treat
KRas mutated pulmonary adenocarcinoma cells. Takuya
Fukazawa, Yutaka Maeda, Naomasa Ishida, Tomoki Yamatsuji,
Munenori Takaoka, Minoru Haisa, Nagio Takigawa, Jeffery Whitsett,
Yoshio Naomoto.
745 A non-redox reactive allosteric inhibitor of MAPK
phosphatases with selective toxicity to human cancer cells.
Laura Vollmer, Lawrence Vernetti, Ahmet Bakan, Vasiliy Korotchenko,
Ivet Bahar, Billy Day, Michael Tsang, Andreas Vogt.
746 PKC412 (Midostaurin) is safe and highly effective in
systemic mastocytosis patients: Follow up of a single-center
Italian compassionate use. Cristina Papayannidis, Simona Soverini,
Caterina De Benedittis, Maria Chiara Abbenante, Chiara Sartor, Ilaria
Iacobucci, Carmen Baldazzi, Emanuela Ottaviani, Anna Ferrari,
Viviana Guadagnuolo, Alberto Conficoni, Strefania Paolini, Sarah
Parisi, Federica Frabetti, Silvia Piccari, Sandro Grilli, Elisa Lani,
Giovanni Martinelli.
747 Evaluation of Src as a therapeutic target and
development of biomarkers of Src inhibitor in cancer. Ah-Rong
Nam, Hyun-Jin Nam, Kyo Hwa Kang, Ji Eun Park, Tae Yong Kim,
Sae-Won Han, Sang-Hyun Song, Seock-Ah Im, Tae-You Kim, DoYoun Oh, Yung-Jue Bang.
748 Novel selective orally bioavailable small molecule PAK4
allosteric modulators display antitumor activity and induce
apoptosis in vitro and in vivo. William Senapedis, Erkan Baloglu,
Natalie Pursell, Marsha Crochiere, Dilara McCauley, Joel Ellis,
Trinayan Kashyap, Boris Klebanov, Robert Carlson, Ori Kalid, Michael
Kauffman, Sharon Shacham, Yosef Landesman.
749 Highly potent and orally available SIK2 inhibitors block
growth of human ovarian cancer cells in culture and xenografts.
Albandri Alfredi, Shu Zhang, Weiqu Mao, Yan Wang, Hiroshi
Takemori, Zhen Lu, Robert C. Bast, Hariprasad Vankayalapati.
750 JNK-IN-8: a novel covalent inhibitor targeting JNK
signaling in triple-negative breast cancer. Xuemei Xie, Tamer S.
Kaoud, Ramakrishna Edupunganti, Tinghu Zhang, Takahiro Kogawa,
Gaurav B. Chauhan, Nathanael S. Gray, Chandra Bartholomeusz,
Kevin N. Dalby, Naoto T. Ueno.
751 Preclinical efficacy of the novel PIM inhibitor, JP_11646,
in pancreatic cancer. Yi Ding, Vun-Sin Lim, Carmen M. Baldino,
Justin Caserta, Yvonne Flanders, Stephane Dumas, Gerald Fetterly,
Alex A. Adjei.
752 Genetic and pharmacological FAK inhibition disrupt a
␤5 integrin signaling axis controlling anchorage-independent
ovarian carcinoma growth. Isabelle Tancioni, Sean Uryu, Florian
Sulzmaier, Nina Shah, Christine Lawson, Nichol L. Miller, Christine
Jean, Xiao Lei Chen, Kristy K. Ward, David D. Schlaepfer.
753 Enhanced anti-tumor activity of erlotinib in combination
with FAK tyrosine kinase inhibitors in non-small cell lung
cancer. Grant A. Howe, Bin Xiao, Huijun Zhao, Glenwood Goss,
Christina L. Addison.
754 Selective ALK inhibitor alectinib
(CH5424802/RO5424802) with potent antitumor activity in
models of crizotinib resistance, including intracranial
metastases. Tatsushi Kodama, Toshiyuki Tsukaguchi, Masami
Hasegawa, Miyuki Yoshida, Kenji Takanashi, Osamu Kondoh, Hiroshi
Sakamoto.
755 Repression of tumor survival pathways by novel and
selective inhibitors of MNK1 and MNK2 kinases in glioblastoma
and colorectal cancer. Tomasz Rzymski, Malgorzata SzajewskaSkuta, Adrian Zarebski, Kamil Sitarz, Lukasz Sapala, Malgorzata
Zurawska, Magdalena Salwinska, Renata Windak, Ewa Trebacz,
Joanna Daniel-Wojcik, Radoslaw Obuchowicz, Bozena Winnik,
Ewelina Wincza, Urszula Kulesza, Katarzyna Kucwaj-Borysz, Mariusz
Milik, Agnieszka Dreas, Krzysztof Brzozka.
756 First MNK degrading agents block phosphorylation of
eIF4E, induce apoptosis, and inhibit cell growth, migration and
invasion in triple-negative and HER2-overexpressing breast
cancer cell lines. Senthilmurugan Ramalingam, Lalji Gediya, Puranik
Purushottamachar, Andrew Kwegyir-Afful, Vidya priyadarsini
Ramamurthy, Hannah Mbatia, Vincent Njar.
757 ET-D5, first-in-class synthetic selective Protein
Phosphatase 1 (PP1) inhibitor with anti-proliferative and antivascular activity. Aurelie Juhem, Delphine Lecercle, Julie
Deverchère, Arnaud Gazel, Jean-Claude Florent, Andrei Popov.
31
31
249
POSTER SESSION
Poster
Section
32
32
Multiple Drug Resistance / Antimetabolites
Poster Abstract
Board Number
1.
758
CD44 induces P-gp expression through
hyaluronic acid binding and transcriptional activation.
Swayamjot Kaur, Kyle Murphy, Karl Miletti, Abhilash
Ravindranath, Lorna Rodriguez-Rodriguez.
2.
759
ATP-binding cassette (ABC) genes genotype and
expression: A potential association with pancreatic
cancer development and chemoresistance. Li Pang,
Beverly Word, Joshua Xu, George Hammons, Shiew-Mei
Huang, Beverly Lyn-Cook.
760
Suppression of ABCG2 mediated MDR in vitro
and in vivo by a novel inhibitor of ABCG2 transport.
Atish S. Patel.
3.
4.
5.
6.
7.
8.
250
Poster Abstract
Board Number
15.
772
CCL2 regulates EMT-mediated chemo-resistance
in prostate cancer. Wenchu Wang, Yi Lu, Xiaolin Zhou,
Atsushi Mizokami, Evan Keller, Jian Zhang.
16.
773
Restoration of LKB1 defect in EKVX cells leads to
resistance to microtubule targeting agents. Kaisheng
Mao, Fakeng Liu, Xiuju Liu, Yulong He, Fadlo Khuri, Adam
Marcus, Mingsong Li, Wei Zhou.
17.
774
EGFR-regulated RGS expression contributes to
paclitaxel resistance in human lung cancer cells. ShinHyung Park, Myung-A Sung, Ho-Young Lee.
18.
775
Targeting the stress survival oncoprotein LEDGF/
p75 to overcome prostate cancer resistance to taxane
therapy. Leslimar Rios Colon, Catherine Elix, Anamika Basu,
Tino W. Sanchez, Nouri Neamati, Carlos A. Casiano.
19.
776
Study on the induced resistance reversal by
JAK2 gene RNAi and inhibitor AG490 in ovarian cancer
paclitaxel-resistant cells. Hongxia Li.
20.
777
Efficacy of nab-paclitaxel on 5-fluorouracil (5FU) resistant human gastric cancer cell lines. Mamoru
Nukatsuka, Takashi Kobunai, Kazuaki Matsuoka, Teiji
Takechi.
21.
764
A role for GLI1 in the development of multidrug
resistance in rhabdomyosarcoma (RMS) cells. Joon Won
Yoon, Marilyn Lamm, King-Fu Leong, Stephen Iannaccone,
Philip Iannaccone, David Walterhouse.
778
Antioxidants decrease the apoptotic effect of
5-Fu in colon cancer by regulating Src-dependent
caspase-7 phosphorylation. Yang Fu, Ge Yang, Feng Zhu,
Cong Peng, Wei Li, Haitao Li, Hong-Gyum Kim, Ann M.
Bode, Ziming Dong, Zigang Dong.
22.
765
Short- and long-term TNF-alpha mediated NF-␬B
signaling exerts diverging effects on ABCB1/PgP
expression. Wolfgang Walther, Lisa Bauer, Jutta Aumann,
Dennis Kobelt, Ulrike S. Stein.
779
Osteopontin gene expression is associated with
5-fluorouracil drug resistance in colon cancer. Go
Nakajima, Hidekazu Kuramochi, Masakazu Yamamoto,
Kazuhiko Hayashi.
23.
780
Metformin induces apoptotic cell death and
inhibits CD133ⴙ cancer stem cells in 5-Fu-resistant
colorectal cancer cells. Sunghee Kim, Ja-Lok Ku.
24.
781
Efficacy of trifluridine for 5-fluorouracil-resistant
human gastric cancer cell lines and their mechanisms.
Kazuaki Matsuoka, Takashi Kobunai, Teiji Takechi.
25.
782
Transmembrane 2–3 loop domain of the proton
coupled folate transporter (PCFT) forms a novel
“reentrant loop” structure and is functionally important.
Michael R. Wilson, Zhanjun Hou, Larry H. Matherly.
26.
783
Identification of structural determinants of
human proton-coupled folate transporter
oligomerization. Zhanjun Hou, M. R. Wilson, Lucas Wilson,
Sita Kugel Desmoulin, Jenny Huang, Larry H. Matherly.
761
Acid ceramidase promotes drug resistance in
acute myeloid leukemia through P-gp upregulation
mediated by NF- kB activation. Su-Fern Tan, Xin Liu,
Kenichiro Doi, Hong-Gang Wang, Myles Cabot, David Feith,
Thomas P. Loughran.
762
Prevention and reversion of multidrug resistance
(MDR) in cancer by NSC23925. Xiaoqian Yang, Francis
Hornicek, Zhenfeng Duan.
763
Resistance to cabazitaxel is associated with
ABCB1/P-glycoprotein activation, alterations in ␤tubulin content and dynamics, reduced BRCA1, and a
mesenchymal phenotype in MCF-7 human breast cancer
variants. George E. Duran, Yan C. Wang, E B. Francisco,
Francisco J. Martinez, Branimir I. Sikic.
9.
766
Human ABCB1 and ABCG2 confer acquired
resistance to Polo-like kinase 1 inhibitors, BI 2536,
volasertib and GSK641364. Chung-Pu Wu, Hong-May Sim,
Suresh V. Ambudkar.
10.
767
Cyclosporin-modulated intensified-dosage
chemotherapy for saving eyes with Group D intraocular
retinoblastoma. Helen S. Chan, Elise Héon, A L. Murphree,
Paulita P. Astudillo, Helen Dimaras, Furqan Shaikh, Brenda
L. Gallie.
11.
768
CB-PIC sensitizes chemoresistant cancer cells to
drugs via suppression of MDR1 and its upstream signal
molecules, AKT and p38-MAPK. Duckgue Lee, Miyong
Yun.
27.
12.
769
Regulation of drug metabolizing enzyme and
transporter gene expression by dietary and
chemopreventive phytochemicals in breast cancer.
Sudha Kondraganti, Lihua Wang, Weiwu Jiang, Bhagavatula
Moorthy.
784
Significance of osteopontin in the sensitivity of
malignant pleural mesothelioma to pemetrexed. Susumu
Takeuchi, Masahiro Seike, Rintaro Noro, Chie Soeno, Teppei
Sugano, Fenfei Zou, Masaru Matsumoto, Akihiko Miyanaga,
Yuji Minegishi, Kaoru Kubota, Akihiko Gemma.
28.
13.
770
Gender differences in the expression of drug
metabolizing enzymes in human liver tissues. Stancy J.
Joseph, Tamara Nicolson, Honggang Wang, Beverly R.
Word, George Hammons, Beverly Lyn-Cook.
785
ETS-mediated expression of miR-24 regulates
Top1 levels and resistance of prostate cancer cell lines
to camptothecin. Samer Kayali, Emmanuel Roche, Danièle
Montaudon, Philippe Pourquier, Nadine Houédé.
29.
14.
771
TLR4 activation by paclitaxel promotes breast
cancer recurrence and metastasis. Sandeep Rajput, Lisa
Volk-Draper, Kelly Hall, Sophia Ran.
786
Alternative RNA processing leads to decreased
DNA topoisomerase II␣ in etoposide (VP-16) resistant
human leukemia K562 cells. Lucas D. Serdar, Ragu
Kanagasabai, Jack C. Yalowich.
POSTER SESSION
Novel Combinations / Retrospective Analyses
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
787
DNA repair and metabolism inhibitors are tumorselective when combined with NQO1 bioactivatable
drugs for therapy against pancreatic and nonsmall cell
lung cancers. Xiumei Huang, Zachary Moore, Xiuquan Luo,
Gaurab Chakrabarti, Mariya Ilcheva, Rolf Brekken, Sandeep
Burma, Jinming Gao, Ralph Deberardinis, William Bornmann,
Paul Hergenrother, David A. Boothman.
788
Lichen-derived metabolites show synergistic
effects in combination with lapatinib and doxorubicin
against breast cancer cells. Margret Bessadottir, Edda A.
Skuladottir, Sindri Baldursson, Sesselja Omarsdottir, Helga
M. Ögmundsdottir.
789
Parthenolide sensitizes colorectal cancer cells to
TRAIL-induced apoptosis by regulating mitochonrial
pathway. Se Lim Kim, Sang-Wook Kim, Soo-Teik Lee,
Seong Hun Kim, In Hee Kim, Seung Ok Lee, Dae Ghon Kim.
790
A high-throughput chemical screen identifies
synergistic activity between neurotransmitter receptor
inhibitors and crizotinib in ALK-mutated neuroblastoma.
Nathan Moore, Srunphut Pukma, Nathanael Gray, Rani
George.
791
Rational dose optimization for multi-drug
cocktails. Christopher J. Zopf, Andrew Chen, Santhosh
Palani, Rachael Brake, Mark Manfredi, Jeffrey Ecsedy, Wen
Chyi Shyu, Arijit Chakravarty.
792
Usefulness of alternate-day administration of S-1
and leucovorin in a xenograft mouse model of
colorectal cancer: A shorter drug-free interval leads to
more efficient antitumor effects. Toshihiro Komura,
Shinobu Ohnuma, Koh Miura, Tetsuhiko Shirasaka, Taiki
Kajiwara, Katsuyoshi Kudoh, Sho Haneda, Masahide
Toshima, Atsushi Kohyama, Hiroaki Musha, Takeshi Naitoh,
Yu Katayose, Michiaki Unno.
793
NOSH-aspirin and 5-fluorouracil demonstrate
synergistic efficacy in a xenograft model of colon
cancer. Clarissa J. Martinez, Mitali Chattopadhyay, Khosrow
Kashfi.
794
The ATR inhibitor VE-821 in combination with
the novel topoisomerase I inhibitor LMP-400 selectively
kills cancer cells by disabling DNA replication initiation
and fork elongation. Rozenn Jossé, Scott E. Martin,
Rajarshi Guha, Pinar Ormanoglu, Thomas Pfister, Joel
Morris, James H. Doroshow, Yves Pommier.
795
Metronomic chemotherapy with
cyclophosphamide and metformin inhibits tumor and
metastasis growth M-406 murine mammary
adenocarcinoma. Antonela S. Asad, Jesús Basualdo, Lucía
Micheletti, María C. Capello Gardenal, Herman A. Perroud,
María J. Rico, Viviana R. Rozados, O. G. Scharovsky.
796
Histone deacetylase inhibitors restore toxic BH3
domain protein expression in anoikis-resistant
mammary and brain cancer stem cells, thereby
enhancing the response to anti-ERBB1/ERBB2 therapy.
Nichola A. Cruickshanks, Hossein A. Hamed, Larry A. Booth,
Seyedmehrad Tavallai, G B. Sajithlal, Steven Grant, Andrew
Poklepovic, Paul Dent.
797
Interaction of multitargeted tyrosine kinase
inhibitors with human nucleoside transporters. Vijaya L.
Damaraju, Michelle Kuzma, Delores Mowles, Carol E. Cass,
Michael B. Sawyer.
798
Androgen receptor, PI3K/mTOR and PSMA:
Exploring and exploiting the interplay between
therapeutic targets in prostate cancer. Jose D. Murga,
Wells W. Magargal, Sameer M. Moorji, Vincent A. DiPippo,
William C. Olson.
799
Diminishing Mcl-1 protein leads to apoptosis of
acute myeloid leukemia cells responding to all trans
retinoic acid differentiation. Rui Wang, Lijuan Xia, Janice
Gabrilove, Samuel Waxman, Yongkui Jing.
800
Synergistic effects of CBL0137 and gemcitabine
against non-small cell lung and pancreatic cancer
xenografts. Catherine Burkhart, Rachael Kohrn, Brittany
Walker, David Meyer, Katerina Gurova, Andrei Gudkov.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
801
Sensitivity of cell lines to Fatty Acid Synthase
inhibitors depends on the lipid content in the cellular
environment. Karine A. Smans, Sabine De Breucker,
Norbert Esser, Erwin Fraiponts, Ron Gilissen, Ralph Graeser,
Boudewijn Janssen, Lieven Meerpoel, Danielle Peeters,
Geert Van Hecke, Luc Van Nuffel, Yolanda Chong, Peter
Vermeulen, Gilles Bignan, James Bischoff, Peter Connolly,
Bruce Grasberger, Tianbao Lu, Donald Ludovici, Carsten
Schubert, Michael Parker, Christophe Meyer, Suzana Vidic.
802
Synergistic effect of curcumin on FL118 efficacy
in colon cancer. Xiang Ling, Nishant Gandhi, Boyang Jiao,
Dhyan Chandra, Fengzhi Li.
803
A vertical combination strategy hitting multiple
steps along the MAPK cascade: Molecular mechanisms
of action and putative genetic determinants of
synergism. Anais Del Curatolo, Ursula Cesta Incani,
Ludovica Ciuffreda, Italia Falcone, Senji Shirasawa, Massimo
Broggini, Isabella Sperduti, Adriana Eramo, Ruggero De
Maria, Francesco Cognetti, Michele Milella.
804
Combination simvastatin and metformin induces
cell death by autophagy and secondary necrosis in
osseous metastatic castration-resistant prostate cancer
cells. Melissa A. Babcook, R. Michael Sramkoski, Christine
Z. Oak, Sanjay Gupta.
805
Disruption of the MDM2-p53 interaction
synergizes with MEK inhibition to induce cell death and
promote tumor regression in p53 wild-type, Ras or Rafmutant tumor models. Isabelle Meaux, Jean-Paul Nicolas,
Steve Rowley, Sukhvinder Sidhu, Francoise Herve, Laurent
Dassencourt, Fanny Windenberger, Dimitri Gorge-Bernat,
Pascal Pannier, Donald Bergstrom, Laurent Debussche,
James Watters.
806
Selective killing of cancer cells with
mitochondrial respiratory dysfunction induced by
activation of oncogenic Ras. Weiqin Lu, Yaying Yang,
Craig Logsdon, Peng Huang.
807
Selamectin and ivermectin are small molecule
inhibitors that interfere with Sin3A-PAH2 function and
exert anti-tumor activity in triple-negative breast
cancer. Yeon-Jin Kwon, Boris A. Leibovitch, Lei Zeng,
Mihaly Mezei, Rossitza Christova, Shuai Yang, Rajal Sharma,
Edgardo Aritzia, nidhi bansal, Ming-Ming Zhou, Authur
Zelent, Eduardo Farias, Samuel Waxman.
808
Combination therapy with a MEK inhibitor plus
T-type calcium channel inhibitor is highly effective in
patient-derived pancreatic ductal adenocarcinomas.
Timothy E. Newhook, James M. Lindberg, Sara J. Adair,
Edik Blais, Jason Papin, Lloyd Gray, J. Thomas Parsons,
Todd W. Bauer.
809
BRAF wild-type melanoma survival hinges upon
AKT activity and adaptive autophagic reprogramming in
response to chemotherapy. Vito W. Rebecca, Renato
Massaro, Inna Fedorenko, Geoffrey T. Gibney, Vernon K.
Sondak, Ravi K. Amaravadi, Shengkan Jin, Silvya S. MariaEngler, Ragini Kudchadkar, Keiran S. Smalley.
810
O6 methylguanine DNA methyltransferase
inhibition sensitizes pancreatic cancer cells to
temozolomide. George C. Bobustuc, Jonathan Ticku, Anand
Patel, Kalkunte S. Srivenugopal, Santhi D. Konduri.
811
Schweinfurthin activity enhanced by verapamil.
Ryan M. Sheehy, Zoe C. Bachman, Raymond J. Hohl.
812
Assessing combinations of FDA approved
chemotherapy in childhood sarcoma cell lines. Diana Yu,
Christopher Cubitt, Daniel Sullivan, Damon Reed.
813
A combination of cisplatin, irinotecan, and
paclitaxel (CIP) as frontline treatment of patients with
metastatic esophageal cancer (mEC). Thomas A. Giever,
Paul S. Ritch, James P. Thomas, Lauren A. Wiebe, George
B. Haasler, Mario G. Gasparri, David Johnstone, Candice A.
Johnstone, Elizabeth M. Gore, Ben George.
33
33
251
POSTER SESSION
Poster
Section
34
34
Novel Cytotoxic Strategies
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
252
814
Novel aspirin based selenium compounds as
therapy against pancreatic cancer. Deepkamal N. Karelia,
Manoj K. Pandey, Daniel Plano, Shantu Amin, Arun K.
Sharma.
815
CBL0137 demonstrates significant antitumor
activity against hepatocellular carcinoma alone and in
combination with sorafenib. Catherine Burkhart, Rachael
Kohrn, Brittany Walker, Katerina Gurova, Andrei Purmal,
Andrei Gudkov.
816
Antitumor efficacy of a novel anthracycline
derivative aldoxorubicin in an orthotopic mouse model
of glioblastoma. Om Prakash, Albero E. Musto, Dorota
Wyczechowska, Luis Marrero, Adriana Zapata, Chelsey P.
Walker, Christopher Parsons, Scott Wieland, Daniel Levitt,
Krzysztof Reiss.
817
Sepantronium is a DNA damaging agent that
potentiates PLK1 inhibitor volasertib. Mei Hong,
Mingqiang Ren, Jeane Silva, Zhonglin Hao.
818
Repurposing Artemisinins for treatment of acute
leukemias. Jennifer M. Fox, James R. Moynihan, Gary H.
Posner, Patrick Brown, Curt I. Civin, Xiaochun Chen.
819
A novel small molecule cytidine analog, RX-3117,
shows potent efficacy in xenograft models, even in
tumors that are resistant to treatment with gemcitabine.
Mi Young Yang, Young Bok Lee, Deog Joong Kim, Chang-Ho
Ahn, Joel Kaye, Tania Fine, Rina Kashi, Osnat Ohne.
820
Inhibition of Rad6 sensitizes triple negative
breast cancer cells to platinum-based therapy. Brittany
Haynes, Matthew Sanders, Malathy Shekhar.
821
Fusogenic liposomes: A novel therapeutic
strategy to efficiently target and destroy prostate
cancer. Jihane Mriouah, Rae-Lynn Nesbitt, Desmond Pink,
Roy Duncan, Andries Zijlstra, John D. Lewis.
822
Thienoindoles, a novel class of DNA minor
groove alkylating agents highly suited for the
generation of novel antibody drug conjugates (ADCs).
Barbara Valsasina, Fabio Gasparri, Italo Beria, Nicoletta
Colombo, Paolo Orsini, Rita Perego, Simona Rizzi, Ulisse
Cucchi, Clara Albanese, Aurelio Marsiglio, Ivan Fraietta,
Marina Ciomei, Sabrina Cribioli, Carlo Visco, Eduard R.
Felder, Antonella Isacchi, Enrico A. Pesenti, Arturo Galvani,
Daniele Donati, Michele Caruso.
823
Water-soluble ureidomustine (BO-1055) potently
suppresses orthotopic 22Rv/HL2 prostate tumor
xenografts: early preclinical studies. Tsann-Long Su, YiRen Chen, Jae-Hung Shieh, Tung-Hu Tsai, Malcolm A.
Moore, Te-Chang Lee.
824
In vivo efficacy of VAL-083 in the treatment of
non-small cell lung cancer. Anne Steino, Jeffrey Bacha,
William J. Garner, Sarath Kanekal, Dawn Waterhouse, Nancy
Dos Santos, Dennis M. Brown.
825
The development of a novel PARP inhibitor with
potent antitumor activity in various tumor xenograft
models. Ji-Seon Park, Jang-Hyun Kim, Kwang-Woo Cheon,
Bo-Young Cho, Kang-Jeon Kim, Han-Chang Lee, YoungCheol Kim, Hyung-Chan Oh, Hyun-Ho Lee, Jeong-Min Kim.
826
Myeloperoxidase (MPO) dependency for DNA
damage, genotoxicity and cytotoxicity induced by
etoposide (VP-16): Implications for therapy-induced
second malignancies. Ragu Kanagasabai, Jason
Goodspeed, Soumendra Krishna Karmahapatra, Alex
Klausing, Anna Skwarska, Michael Darby, Yuan Zhao, Jiang
Wang, Mitchell A. Phelps, Jack C. Yalowich.
827
Camptothecins: Tissue penetration and
implications for therapy. Alastair H. Kyle, Maria Jose
Gandolfo, Jennifer H. Baker, Andrew I. Minchinton.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
828
A novel non-microsomal activation pathway for
the camptothecin prodrug CZ48. Lauren R. Brown, Lauren
E. Battershell, Dana M. Vardeman, Beppino C. Giovanella,
Constantine S. Markides.
829
The novel camptothecin derivative and IAP
inhibitor FL118 is an effective treatment for irinotecanrefractory colorectal cancer. David Westover, Xiang Ling,
Xiaojun Liu, Hong Lam, Celine Gongora, Maguy Del Rio,
Fengzhi Li.
830
Disulfiram is a potent inhibitor of topoisomerase
II. Xing Wu, Jack C. Yalowich, Daywin Patel, Brian B.
Hasinoff.
831
BAL101553 (prodrug of BAL27862): A unique
microtubule destabilizer active against drug refractory
breast cancers alone and in combination with
trastuzumab. Felix Bachmann, Karin Burger, George E.
Duran, Branimir I. Sikic, Heidi A. Lane.
832
Pre-clinical development of EC1456: A potent
Folate targeted Tubulysin SMDC. Joseph A. Reddy, Alicia
Bloomfield, Melissa Nelson, Ryan Dorton, Marilynn Vetzel,
Christopher P. Leamon.
833
Photolabeling of ␤-tubulin isotypes by
radiolabeled 2-(m-azidobenzoyl)taxol. Chia-Ping H. Yang,
Hui Xiao, Susan B. Horwitz.
834
The microtubule-disrupting drug BNC105 is a
potent inducer of acute apoptosis in CLL. Darcy J. Bates,
Edmundo J. Feris, Alexey V. Danilov, Alan Eastman.
835
Fisetin enhances the efficacy of cabazitaxel
chemotherapy in prostate metastatic and multidrugresistant cancer cells. Eiman Mukhtar, Vaqar M. Adhami,
Hasan Mukhtar.
836
Potent antitubulin and antitumor activities
influenced by the 3-D conformational shape of bicyclic
fused pyrimidines. Aleem Gangjee, Weiguo Xiang, Susan L.
Mooberry, Ernest Hamel.
837
The unique profile of microtubule stability
initiated by the taccalonolides leads to potent antitumor
activities. April L. Risinger, Jing Li, Jiangnan Peng, Melissa
J. Bennett, Cristina C. Rohena, David C. Schriemer, Susan
L. Mooberry.
838
Establishment, identification and treatment data
of TCGA glioblatoma xenograft subtypes. Stephen T. Keir,
B A. Rasheed, Katherine A. Hoadley, Martin A. Roskoski,
Danuta Gasinski, Patrick J. Killela, Hai Yan, Madan M.
Kwatra, Henry S. Friedman, Darell D. Bigner.
839
N-acetylcysteine chemoprotection without
decreased cisplatin antitumor efficacy in pediatric
tumor models. Leslie L. Muldoon, Y. Jeffrey Wu, Michael A.
Pagel, Kathleen A. Beeson, Edward A. Neuwelt.
840
Enhancement of antitumor effect of platinum
complexes by PXR antagonist. Shuichi Kishimoto, Erika
Bou, Kaho Higashi, Ryosuke Suzuki, Shoji Fukushima.
841
Therapeutic targeting of cancer cells in the
hypoxic microenvironment using an orally bioavailable
small molecule inhibitor of carbonic anhydrase IX. Paul
C. McDonald, Jasbinder Sanghera, Madhu Singh, Yuanmei
Lou, Marylou Vallejo, Claudiu T. Supuran, Shoukat Dedhar.
842
DNA opilymerase ␤ participates in the repair of
DNA damage from topoisomerase II. Yilun Sun, Sule
Bertram, John L. Nitiss.
843
Methylthioadenosine phosphorylase (MTAP)deficient T-cell ALL xenografts are sensitive to
pralatrexate and 6-thioguanine alone and in
combination. Philip M. Tedeschi, Yamini K. Kathari, Iqra
Farooqi, Joseph R. Bertino.
POSTER SESSION
Radiation Oncology: Modifiers and Signal Transduction, Sensitivity,
Resistance, and Therapy
Poster Abstract
Board Number
1.
844
Contribution of dual oxidase 2 (DUOX2) to hyper
radiosensitivity in human gastric cancer cells. Duc
Nguyen, Elizabeth Chang, Navesh Sharma, France Carrier.
2.
845
Silibinin radiosensitizes prostate cancer cells by
enhancing radiation-induced cell death and inhibiting
nuclear EGFR-mediated DNA repair. Dhanya K. Nambiar,
Paulraj Rajamani, Rana P. Singh.
Poster Abstract
Board Number
13.
856
Combination of crizotinib and radiation in the
treatment of ALK-positive and cetuximab-resistant lung
cancer. Chunrong Li, Shyhmin Huang, Noah Walters, Eric A.
Armstrong, Paul M. Harari.
14.
857
Preclinical evaluation: efficacy of DI17E6, a
therapeutic antibody against alpha v integrins,
compared to cilengitide in sensitizing human cancers to
radiation therapy. Amit A. Deorukhkar, David P.
Molkentine, David R. Valdecanas, Kathryn A. Mason, Uma
Raju.
15.
858
Treatment resistance of colon cancer with low
proteasome activity. Koji Munakata, Mamoru Uemura,
Junichi Nishimura, Taishi Hata, Ichiro Takemasa, Tsunekazu
Mizushima, Hirofumi Yamamoto, Yuichiro Doki, Masaki Mori.
16.
859
Regulation of cell cycle and NAD biosynthesis II
pathways are associated with differential response to
preoperative radiotherapy in locally advanced breast
carcinoma. Miljana Tanic, Ana Krivokuca, Jasmina
Mladenovic, Snezana Susnjar, Sinisa Radulovic, Radmila
Jankovic.
17.
860
Carbon ion radiotherapy for recurrent basal cell
carcinoma: preliminary report of six cases and review
of the literature. Yingtai Chen, Feng Dong, Yantao Tian,
Chengfeng Wang, Liang Cui, Xuezhong Chen.
18.
861
Survivin-mediated adaptive response: a risk
factor for IGRT. David J. Grdina, Jeffrey S. Murley, Richard
C. Miller, Gayle E. Woloschak, Jian Jian Li, Ralph R.
Weichselbaum.
3.
846
Inhibition of lysophosphatidic acid receptor 1
radiosensitizes lung cancer cells. David Y. Dadey, Rowan
M. Karvas, Rama Kotipatruni, Jerry Jaboin, Dennis Hallahan,
Dinesh Thotala.
4.
847
Suppression of p53R2 but not R2 radiosensitizes
mutant p53 tumor cells. Sheryl A. Flanagan, Jeffrey J.
Ackroyd, Sudha Mannava, Mikhail A. Nikiforov, Donna S.
Shewach.
5.
848
Galectin-1 mediates radiation-related
lymphopenia in non-small cell lung cancer and
attenuates tumor radiation response. Peiwen Kuo, Scott
Bratman, David Shultz, Rie von Eyben, Cato Chan, Ziwei
Wang, Carmen Say, Aparna Gupta, Bill W. Loo, Amato
Giaccia, Albert Koong, Maximilian Diehn, Quynh-Thu Le.
6.
849
Profiling signaling networks using reverse phase
protein arrays: validating FOXM1 as a potential target to
radiosensitize glioblastoma (GBM) stem cells. Uday
Bhanu Maachani, Anita T. Tandle, Uma Shankavaram,
Tamalee Meushaw, Philip J. Tofilon, Kevin A. Camphausen.
7.
850
Vascular based strategies for enhancing tumour
response to radiation administered in a stereotactic
schedule. Michael R. Horsman, Thomas Wittenborn.
8.
851
Gold nanoparticle-mediated infrared
hyperthermia reduces the radiotherapy dose required
for tumor therapy. James F. Hainfeld, Michael J. O’Connor,
Lynn Lin, Daniel N. Slatkin, F. Avraham Dilmanian, Henry M.
Smilowitz.
19.
862
Sensitization of pancreatic cancer to
chemoradiation by the Wee1 inhibitor AZD1775. Tasneem
Kausar, Leslie A. Parsels, Joshua D. Parsels, David Karnak,
Mary A. Davis, Jonathan Maybaum, Theodore S. Lawrence,
Meredith A. Morgan.
9.
852
Enhanced expression of secretory
clusterin/apolipoprotein J (sCLU) in pulmonary alveolar
stem cells after ionizing radiation exposure. Eunjoo
Chung, Jason Horton, Ayla White, Bradly Scroggins, Kathryn
Hudak, Deborah Citrin.
20.
863
Clinical significance of mucinous production in
rectal cancer after preoperative chemoradiotherapy.
Kensuke Kaneko.
21.
864
Increased rates of radiation pneumonitis in
patients receiving stereotactic ablative radiotherapy for
central versus peripheral lung tumors. Aadel A.
Chaudhuri, Chad Tang, Nicholas Trakul, Jacob Wynne, Billy
Loo, Maximilian Diehn.
22.
865
Evolving biological and clinical concepts of
radiation delivery in NSCLC: response to ablative versus
fractionated radiotherapy. Ayman J. Oweida, Zeinab
Sherifi, Yaoxian Xu, Siham Sabri, Bassam Abdulkarim.
11.
854
Inhibition of PRMT5 results in radiosensitization
in lung cancer cell lines. Smitha Sharma, X Wu, P Smith,
N Denko, C Li, H Lai, F Yan, K Shilo, A Chakravarti, S Sif, R
Baiocchi, G Otterson, Meng Xu-Welliver.
12.
855
Targeting STAT3 in vitro and in vivo reveals a
novel therapeutic strategy to sensitize colorectal cancer
cells to chemoradiotherapy. Melanie Spitzner, Birte
Roesler, Christian Bielfeld, Carolin Herzberg, Georg Emons,
Jochen Gaedcke, Margret Rave-Fränk, Tim Beißbarth,
Thomas Ried, B. Michael Ghadimi, Marian Grade.
Poster
Section
35
35
253
POSTER SESSION
Clinical Research 1
Poster
Section
36
36
Circulating Biomarkers for Early Detection
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
254
866
Identification of novel early detection candidate
protein biomarkers for ERⴙ/PRⴙ invasive ductal breast
carcinoma using pre-clinical plasma from the Women’s
Health Initiative Observational Study. Matthew F. Buas,
Yuzheng Zhang, Junghyun Rho, Margaret Pepe, Paul Lampe,
Christopher Li.
867
Serum microRNAs as diagnostic biomarkers for
early colorectal neoplasms. Atsushi Yamada, Takahiro
Horimatsu, Yoshinaga Okugawa, Naoshi Nishida, Tadayuki
Kou, Toshihiro Kusaka, Hajime Honjo, Yusuke Amanuma,
Osamu Kikuchi, Manabu Muto, Ajay Goel, C. R. Boland.
868
Characterization of LASEP3 as a serological and
prognostic biomarker and a therapeutic target for lung
cancer. Atsushi Takano, Yusuke Nakamura, Yataro Daigo.
869
Evaluate breast cancer diagnostic antibody
specificity by using high density protein microarray
technology. Donghui Ma, Jian Chen, Wei Fu, Julie
McDowell, Kehu Yuan.
870
16S rRNA saliva analysis unveils microbiome
biomonitors linked to human papilloma virus and
oropharyngeal squamous cell carcinoma. Rafael E.
Guerrero-Preston, Christina Michailidi, Anne Jedlicka,
Rajagowthamee Thangavel, Tal Hadar, Maartje G. Nordhuis,
William Westra, Wayne Koch, Joseph Califano, David
Sidransky.
871
Clinical utility of a plasma microRNA biomarker
within lung cancer screening. Mattia Boeri, Carla Verri,
Gabriella Sozzi, Luca Roz, Davide Conte, Paola Suatoni,
Alfonso Marchiano, Carlo La Vecchia, Marta Rossi,
Francesca Bravi, Eva Negri, Nicola Sverzellati, Ugo
Pastorino.
872
APE1/Ref-1 as a serological biomarker for the
detection of bladder cancer. Sunga Choi, Ju Hyun Shin,
Yu Ran Lee, Myoung Soo Park, Chang Nam Yim, Young Gil
Na, Jae Sung Lim, Byeong Hwa Jeon.
873
Correlation of plasma biomarker levels with
early-stage tumor viability in an orthotopic ovarian
cancer mouse model. Sharon S. Hori, Amelie M. Lutz,
Ramasamy Paulmurugan, Sanjiv S. Gambhir.
874
Autoantibody biomarker discovery in basal-like
breast cancer using nucleic acid programmable protein
array. Jie Wang, Jonine D. Figueroa, Garrick Wallstrom,
Joshua Sampson, Eliseo Mendoza Garcia, Jason Steel, Jin
Park, Karen S. Anderson, Louise Brinton, Montserrat GarciaClosas, Jolanta Lissowska, Mark E. Sherman, Ji Qiu, Joshua
LaBaer.
875
PAX8 protein detection in serum of patients with
serous ovarian cancer. Zahra Bahrani-Mostafavi, Pourya
Naderi Yeganeh, Megan E. Parrott, Christine Richardson,
David L. Tait, M. Taghi Mostafavi.
876
Comprehensive analysis of the complexity of
HBV DNA integration sites in the circulation of patients
with HBV-related liver disease. Selena Lin, Surbhi Jain,
Batbold Boldbaatar, Timothy Block, Wei Song, Ying-Hsiu Su.
877
Detection of colorectal cancer-associated genetic
alterations in urine of patients with CRC. Adam W.
Clemens, Selena Lin, Surbhi Jain, Sitong Chen, Ying-Hsiu
Su, Wei Song.
878
Identification and characterization of tumorassociated antigens as biomarkers in human prostate
cancer. Jitian Li, Liping Dai, Carlos A. Casiano, Jianying
Zhang.
879
New serum biomarkers for prostate cancer
diagnosis. Kailash C. Chadha, Austin Miller, Bindukumar B.
Nair, Stanley A. Schwartz, Donald L. Trump, Willie
Underwood.
880
Des-g-carboxyprothrombin (DCP) and NX-DCP
expressions and their relationship with
clinicopathological features in hepatocellular carcinoma.
Akiko Sumi, Jun Akiba, Sachiko Ogasawara, Masamichi
Nakayama, Yoriko Nomura, Sakiko Sanada, Osamu
Nakashima, Takuji Torimura, Toshi Abe, Hirohisa Yano.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
30.
881
Identification of autoantibody biomarkers to
wild-type and mutant p53 in pancreatic and ovarian
cancer. Benjamin A. Katchman, Rizwan Alam, Garrick
Wallstrom, Joshua LaBaer, Michael A. Hollingsworth, Daniel
W. Cramer, Karen S. Anderson.
882
Non-invasive diagnostic testing for lung cancer
in a prospective cohort. Martin Tobi, Joe Sayre, MaryAnn
Rambus, Fadi Antaki, Ann Schwartz, Michael J. Lawson.
883
Angiopoietin-like protein 2, a driver of cancer
cell metastasis, is a novel serum biomarker for the
diagnosis and prognosis in patients with gastric cancer.
Yuji Toiyama, Takahito Kitajima, Tadanobu Shimura, Hiroki
Imaoka, Satoru Kondo, Shozo Ide, Masato Okigami, Hiromi
Yasuda, Susumu Saigusa, Masaki Ohi, Koji Tanaka, Yasuhiro
Inoue, Yasuhiko Mhori, Ajay Goel, Masato Kusunoki.
884
Circulating microRNAs as non-invasive
biomarkers for early detection of lung cancer.
Magdalena B. Wozniak, Ghislaine Scelo, David Muller, Anush
Moukeria, David Zaridze, Paul Brennan.
885
Using immunomic approach to enhance tumorassociated autoantibody detection in diagnosis of
hepatocellular carcinoma. Liping Dai, Mei Liu, Qing Zhu,
Xinxin Liu, Yurong Chai, Pengfei Ren, Kaijuan Wang,
Chunhua Song, Peng Wang, Mingan Wang, Eng M. Tan,
Jianying Zhang.
886
Serum Mac-2 binding protein levels as a novel
diagnostic biomarker for prediction of disease severity
and nonalcoholic steatohepatitis. Yoshihiro Kamada, Kayo
Mizutani, Hironobu Fujii, Maaya Akita, Yuka Ohara, Shinji
Takamatsu, Eiji Miyoshi.
887
Proteome scale identification of autoantibody
biomarkers in colorectal cancer. Gokhan Demirkan, Leah
Soderberg, Garrick Wallstrom, Emily Szeto, Kristi Barker, Jie
Wang, Joshua LaBaer, Noralane M. Lindor, Ji Qiu.
888
Development of a urine DNA based marker panel
for early detection of liver cancer. Sitong Chen, Surbhi
Jain, Selena Lin, Ying-Hsiu Su, Wei Song.
889
MicroRNA-21–5p upregulation in urine samples
serves as novel biomarkers for early stage renal cell
carcinoma patients diagnosis. Wei Meng, Hansjuerg Alder,
Kirsteen Maclean, Simon Kirste, Petra Stegmaier, Anca
Grosu, Arnab Chakravarti, Tim Lautenschlaeger.
890
Serum inflammatory biomarkers predict
esophageal and lung cancer risk two years prior to
diagnosis in a prospective cohort. Brieze R. Keeley,
Farhad Islami, Akram Pourshams, Hossein Poustchi, Jamie
S. Pak, Paul Brennan, Hooman Khademi, Shu-hsia Chen,
Eric M. Genden, Christian C. Abnet, Sanford M. Dawsey,
Paolo Boffetta, Reza Malekzadeh, Andrew G. Sikora.
891
Urinary ADAM12 levels detect the presence of
pancreatic cancer. Roopali Roy, David Zurakowski,
Matthew Kulke, Marsha A. Moses.
892
Potential of urinary MMP-9/NGAL complex as a
novel biomarker for the early detection of gastric
cancer. Takaya Shimjura, Adelle Dagher, Masahide Ebi,
Tamaki Yamada, Tomonori Yamada, Takashi Joh, Marsha A.
Moses.
893
Mining the circulating immune cell transcriptome
for ovarian cancer-specific biomarkers: A proof of
concept study. Shitanshu Uppal, Arvinder Kapur, Mildred
Felder, Erin Medlin, Hadi Shojaei, Jesus Gonzalez-Bosquet,
Manish S. Patankar.
895
Discriminant, identifiable plasma metabolites in
pancreatic cancer-associated diabetes - candidate
early-detection biomarkers. Shiro Urayama, Vladimir
Tolstikov.
POSTER SESSION
Clinical Research 2
Predictive Biomarkers 1
Poster
Section
Poster Abstract
Board Number
Poster Abstract
Board Number
1.
896 Serum-vascular endothelial growth factors (sVEGF) A and C
have a potential as predictive tests for neoadjuvant bevacizumab in
primary breast cancer. Barbro K. Linderholm, Günter von Minckwitz,
Stefano Caramuta, Fabrice André, Christos Sotiriou, Maria A. Cerone,
Matthias Schwenkglenks, Patricia Blank, Carsten Denkert, Stephan Gade,
Sibylle Loibl, on behalf of the GBG neoadjuvant board and the
RESPONSIFY consortium.
16.
911 Prostate-specific membrane antigen (PSMA) expression as a
potential patient selection marker in patients with refractory solid
tumors administered BIND-014, a PSMA-targeted nanoparticle
containing docetaxel. Susan Low, Daniel Von Hoff, Monica Mita, Howard
Burris, Peter Eisenberg, Lowell Hart, Patricia LoRusso, Glen Weiss, Jasgit
Sachdev, Alain Mita, Ramesh Ramanathan, Jeff Hrkach, Jason Summa,
Gregory Berk.
2.
897 Elucidating the molecular basis of intrinsic taxane
resistance in gastric cancer. Giuseppe Galletti, Kyle Cleveland, Chao
Zhang, Ada Gjyrezi, Alexandre Matov, Doron Betel, Manish A. Shah,
Paraskevi Giannakakou.
17.
912 P21-activated kinase 4 (PAK4) as a predictive marker for
gemcitabine in pancreatic cancer cell line. Sung Ung Moon, Jin Won
Kim, Ji Hea Sung, Mi Hyun Kang, Hyun Chang, Jeong Ok Lee, Yu Jung
Kim, Keun Wook Lee, Jee Hyun Kim, Soo Mee Bang, Jong Seok Lee.
3.
898 Expression of immunoglobulin and its receptor are major
determinants of multiple myeloma patient sensitivity to proteasome
inhibitors. Brian B. Tuch, Andrea Loehr, Jeremiah D. Degenhardt, Kevin
A. Kwei, Eric Lowe, Kristi Stephenson, Jonathan J. Keats, Christopher J.
Kirk.
18.
913 Differences in basal isoform phosphorylation of signaling
proteins between normal and tumor tissue in different cancer types
detected by the NanoPro™1000 technology. Florian T. Unger, Jana
Krueger, Janina Schaller, Rebecca Giese, Cordula Dede, Alexandra
Samsen, Hartmut Juhl, Kerstin A. David.
4.
899 Combination of PI3K and MEK inhibitor chemosensitivity in
human tumor explants and cell lines using the Mosaic Blue assay
and relationship to biomarkers by immunohistochemistry. Lisa M.
Dauffenbach, Gela C. Sia, Patricia A. Cash, Sherif K. Girees, Ryan S. Lim,
Jianping Zheng, Eric P. Olsen, Christopher A. Kerfoot.
19.
914 Development of a prognostic and predictive E2F signature in
formalin-fixed, paraffin-embedded early-stage non-small cell lung
cancer samples. Courtney A. Kurtyka, Lu Chen, Matthew B. Schabath,
Dung-Tsa Chen, William Brazelle, Eric A. Welsh, Anders E. Berglund,
Steven A. Eschrich, Jhanelle E. Gray, Eric B. Haura, W. Douglas Cress.
5.
900 Computing tumor growth rate across pre- and posttreatment periods uncovers anti-tumor activity in patients treated by
a pan-CDK inhibitor (BAY1000394). Antoine Hollebecque, Charles Ferte,
Gerard Nitenberg, Mathieu Felices, Alexandre Durand-Salmon, Matthias
Ocker, Jean-Charles Soria.
20.
915 Expanded biomarker results from a phase I dose escalation
study of GDC-0032, a beta isoform-sparing PI3K inhibitor. Timothy R.
Wilson, Heidi Savage, Carol O’Brien, Sandra Sanabria, Ray S. Lin, MarieClaire Wagle, Yibing Yan, Mark R. Lackner, Hema Parmar, Jerry Y. Hsu,
Dejan Juric, Ian E. Krop, Ramesh K. Ramanathan, Daniel D. Von Hoff,
Jose Baselga.
6.
901 Plasma proteins characterize second-line therapy response
in progressive renal cell carcinoma. Sebastian Hölters, Lothar
Bergmann, Viktor Grünwald, Ulrich Keilholz, Carsten Ohlmann, Michael
Staehler, Diana Schmerler, Kerstin Junker.
21.
916 A multidimensional analysis of predictive biomarkers in
colorectal cancer. Marisa Mariani, Shiquan He, Mark McHugh, Mirko
Andreoli, Deep Pandya, Steven Sieber, Zheyang Wu, Paul Fiedler, Shohreh
Shahabi, Cristiano Ferlini.
7.
902 XRCC1 induction after cisplatin treatment in head and neck
squamous carcinoma cell lines: Evaluation using nanoimmunoassay.
Stephen S. Schoeff, Dane M. Barrett, James Teng, Ashraf Khalil, Matthew
A. Hubbard, Anne K. Maxwell, Amir Allak, Rolando E. Mendez, Mark
Axelrod, Mark J. Jameson.
22.
917 Post-treatment changes in levels of TNF family ligands and
XIAP may predict sensitivity to IAP antagonist CUDC-427. Ruzanna
Atoyan, Maria Elena S. Samson, Brianne Hantzis, Anna W. Ma, Ling Yin,
Mylissa Borek, Steven Dellarocca, Brian Zifcak, Guangxin Xu, Jing Wang.
8.
903 Evaluation of predictive biomarkers and resistance
mechanisms of PI3K pathway inhibition in head and neck squamous
cell carcinoma. Tuhina Mazumdar, Lauren A. Byers, Patrick Ng, Gordon
B. Mills, Shaohua Peng, Lixia Diao, Youhong Fan, Katherine Stemke-Hale,
John V. Heymach, Jeffrey N. Myers, Bonnie S. Glisson, Faye M. Johnson.
23.
918 Clinical validation of a multiplexed ChemoPlex SRM assay in
FFPE human tumor tissue. Eunkyung An, Wei-Li Liao, Sheeno
Thyparambil, Adele Blackler, Jamar Uzzell, Kathleen Bengali, Marlene
Darfler, Jon Burrows, Todd Hembrough.
24.
919 BIM as a predictive biomarker for VEGFR inhibitor in
metastatic renal cell carcinoma. Jee Hung Kim, Hoi Young Lee, Woo
Sun Kwon, Kyu Hyun Park, Ho-yeong Lim, Joong Bae Ahn, Hyun Cheol
Chung, Sun Young Rha.
25.
905 Molecular dissection of platinum resistance through
functional analysis. Amy W. Pan, Sisi Wang, Hongyong Zhang, Ruth
Vinall, Tzu-yin Lin, Michael Malfatti, Maike Zimmermann, Tiffany
Scharadin, Kenneth Turteltaub, Ralph de Vere White, Chong-xian Pan, Paul
Henderson.
920 Secreted frizzled related protein 1 (SFRP1) as potential
regulator of chemotherapy response for patients with triple negative
breast cancer (TNBC). Carolin Huelsewig, Christof Bernemann, Christian
Ruckert, Ludwig Kiesel, Martin Goette, Achim Rody, Lajos Pusztai, Georg
Hempel, Cornelia Liedtke.
26.
906 Molecular imaging of RRx-001-induced oxidative stress in
Nrf2-luciferase expressing SCC VII tumors in mice. Shoucheng Ning,
Thillai V. Sekar, Ramasamy Paulmurugan, Jan Scicinski, Bryan Oronsky,
Donna Peehl, Susan J. Knox.
921 Fibroblast growth factor receptor 1 (FGFR1) protein
expression and gene copy number in small cell lung cancer. Liping
Zhang, Andrzej Badzio, Theresa Boyle, Xian Lu, Rafal Dziadziuszko, Jacek
Jassem, Fred R. Hirsch.
27.
907 Bcl-xL dependence predicts response to alvocidib in chronic
lymphocytic leukemia patients. William E. Pierceall, Steven L. Warner,
Ryan J. Lena, Camille Doykan, Noel Blake, Michael Elashoff, Daniel D. Von
Hoff, David J. Bearss, Michael H. Cardone, Michael Grever, Mark C.
Lanasa, John C. Byrd, Amy J. Johnson.
922 Evaluating markers of cisplatin sensitivity and survival in
small cell lung cancer. Taofeek K. Owonikoko, Guojing Zhang, Gabriel L.
Sica, Zhengjia Chen, Jeffrey M. Switchenko, Sungjin Kim, Anthony A. Gal,
Suresh S. Ramalingam, Xingming Deng, Michael R. Rossi, Jeanne
Kowalski, Fadlo R. Khuri.
28.
923 Analysis of microtubule perturbations and androgen
receptor localization in circulating tumor cells from castration
resistant prostate cancer patients as predictive biomarkers of clinical
response to docetaxel chemotherapy. Shinsuke Tasaki, Matthew Sung,
Alexandre Matov, Giuseppe Galletti, Elan Diamond, Neil Bander, Kathy
Zhou, Scott Tagawa, David Nanus, Paraskevi Giannakakou.
29.
924 Predictive biomarker identification for combined anti-mTOR
and anti-IGF-1R treatment in luminal B breast cancer. Martin A. Rivas,
Yasir H. Ibrahim, Olga Rodríguez, Pilar Antón, Patricia Cozar, Patricia
Gómez-Pardo, Claudia Aura, Brian B. Haines, Sriram Sathyanarayanan,
Theresa Zhang, Violeta Serra, José Baselga.
30.
925 Single nucleotide polypmorphisms in the estrogen receptor
gene as a determining factor in Tamoxifen-treated ovarian cancer.
Wilfrido Mojica, Paul Mojica, Don Sykes.
9.
10.
11.
12.
13.
14.
15.
904 EGFR expression predicts recurrence in patients undergoing
adjuvant chemotherapy for advanced bladder cancer. Ahmed Mansour,
Mona Abdulreheem, Mamdouh Elsherbeeny, Mohammed Sultan, Ahmed
Shokeir, Ahmed Mosbah, Hassan Abol-Enein, Taeeun Park, Hyung Kim,
Jayoung Kim.
908 Development of a cell proliferation assay to be used as a
read-out system for determining the in vivo potency of bevacizumab
in neutralizing the biological activity of VEGF in cancer patients.
Madelon Q. Wentink, Henk J. Broxterman, Tanja D. de Gruijl, Roberto Pili,
Hans J. van der Vliet, Arjan W. Griffioen, Henk M. Verheul.
909 Defining molecular and laboratory predictive biomarkers of
response to cisplatin-based neoadjuvant chemotherapy (NC) in
muscle-invasive bladder cancer (MIBC) - preliminary results and
future plans. Raya Leibowitz-Amit, Jo-An Seah, Raanan Berger, Srikala S.
Sridhar.
910 NOTCH3 expression is predictive of efficacy in pancreas
tumor models treated with OMP-59R5, a monoclonal antibody
targeting the NOTCH2 and NOTCH3 receptors. Belinda Cancilla, WanChing Yen, Chun Zhang, Marcus M. Fischer, May Ji, Tracy Tang, Yu-Wang
Liu, Raymond S. Tam, Min Wang, Austin Gurney, Timothy Hoey, John
Lewicki, Ann M. Kapoun.
37
37
255
LATE-BREAKING POSTER SESSION
Sunday, 1:00 p.m.-5:00 p.m.
Hall A-E, San Diego Convention Center
Abstracts will be available online and in the Proceedings Part 2 beginning Friday, April 4.
Poster Section 39
Late-Breaking Research: Carcinogenesis
Poster Section 40
Late-Breaking Research: Cancer Chemistry
Poster Section 42
Late-Breaking Research: Tumor Biology 1
256
MEET THE RESEARCH ICON
Sunday, 1:15 p.m.-1:45 p.m.
AACRcentral, Exhibit Hall A-E, San Diego Convention Center
Meet the Research Icon:
Walter C. Willett, MD, DrPH
Formerly known as Meet the Research Pioneer, these informal sessions, organized by the
Associate Member Council, provide early-career scientists with the opportunity to hear from an
esteemed senior researcher in a small-group setting to learn about the speaker’s professional and
personal experiences as well as key decisions that shaped their career path. Walter C. Willett, MD,
DrPH, is the Fredrick John Stare Professor of Epidemiology and Nutrition and Chair of the
Department of Nutrition at the Harvard School of Public Health and Professor of Medicine at
Harvard Medical School. Dr. Willett has focused much of his work over the last 35 years on the
development of methods, using both questionnaire and biochemical approaches, to study the
effects of diet on the occurrence of major diseases. This session is open to all graduate students,
medical students, residents, and clinical and postdoctoral fellows and will take place in the
Associate Member Resource and Career Center located in AACRcentral. #AACR14 #AACRicon
257
MICR MEET AND GREET
Sunday, 1:30 p.m.-3:00 p.m.
Minorities in Cancer Research (MICR) Council Meet and Greet
Organized by the Minorities in Cancer Research (MICR) Council
The MICR Meet and Greet is an opportunity for the MICR Council to meet and answer questions
form MICR members, as well as the general Annual Meeting attendance, on issues related to
award opportunities, programs sponsored by the MICR Council, as well as other topics of interest
to attendees. The 2014 recipients of Minority Serving Institution Faculty Scholar in Cancer
Research Awards and Minority Scholar Awards will also be present. All attendees are encouraged
to visit the MICR Networking and Resource Center in AACRcentral.
Chairperson: Christopher I. Li, Fred Hutchinson Cancer Research Center, Seattle WA
Chairperson-Elect: Chanita Hughes-Halbert, Medical University of SC Hollings Cancer Center,
Charleston, SC
Chairperson-Elect Designate: Edith A. Perez, Mayo Clinic, Jacksonville, FL
Past-Chairperson: Marcia R. Cruz-Correa, University of Puerto Rico Comprehensive Cancer
Center San Juan, PR
Council Members
A. William Blackstock, Wake Forest University School of Medicine, Winston-Salem, NC
Wayne D. Bowen, Brown University, Providence, RI
Malcolm V. Brock, Johns Hopkins University School of Medicine, Baltimore, MD
John M. Carethers, VA San Diego Healthcare System, San Diego, CA
Rick. A. Kittles, University of Illinois at Chicago, Chicago IL
Lisa A. Newman, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
John H. Stewart, Wake Forrest University, Winston- Salem, NC
Charles Richard Thomas, OHSU Knight Cancer Institute, Portland, OR
Sanya A. Springfield, National Cancer Institute-CRCHD, Rockville, MD
258
AMC MEET AND GREET
Sunday, 2:00 p.m.-4:00 p.m.
Associate Member Council (AMC) Meet and Greet
Co-Chairpersons: Kerry L. Reed, Northern Ontario School of Medicine, Sudbury, ON, Canada,
Jessica N. Clague Dehart, City of Hope Comprehensive Cancer Center, Duarte, CA, and Michelle
Kinder, Janssen Research and Development, LLC, Wayne, PA
Council Members:
Alexandra Joelle Greenberg, Mayo Clinic College of Medicine, Rochester, MN
Geraldine Gueron, University of Buenos Aires School of Sciences, Buenos Aires, Argentina
Takashi Kobayashi, Kyoto University Graduate School of Medicine, Kyoto, Japan
Shih-Wen (Wenny) Lin, Genentech, Inc., South San Francisco, CA
Angelina I. Londono-Joshi, University of Michigan at Ann Arbor, Ann Arbor, MI
Diana M. Merino, The Hospital for Sick Children, Toronto, ON, Canada
Richard (Rick) L. Price III, The Ohio State University, Columbus, OH
Mark D. Stewart, University of Alabama at Birmingham, Birmingham, AL
Marijn T.M. van Jaarsveld, UMC Utrecht, Utrecht, The Netherlands
Anna Woloszynska-Read, Roswell Park Cancer Institute, Buffalo, NY
The Associate Member Council (AMC) Meet and Greet is open to all graduate students, medical
students, residents, and clinical and postdoctoral fellows and will take place in the Associate
Member Resource and Career Center located in AACRcentral. This is an opportunity to meet the
AMC and learn more about their programs, as well as network with other early-career scientists
attending the Annual Meeting. Light refreshments will be provided. #AACR14 #AACRAMC
259
WICR MEET AND GREET
Sunday, 2:00 p.m.-4:00 p.m.
Women in Cancer Research (WICR) Council Meet and Greet
Organized by the Women in Cancer Research (WICR) Council
The WICR Meet and Greet is an opportunity for the WICR Council to meet and answer questions
from WICR members, as well as the general Annual Meeting attendance, on issues related to
award opportunities, programs sponsored by the WICR Council, as well as other topics of interest
to attendees. The 2014 recipients of WICR Scholar Awards will also be present. All attendees are
encouraged to visit the WICR Networking and Resource Center in AACRcentral.
Chairperson: Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston, TX
Chairperson-Elect: Jessie M. English, Dana-Farber Cancer Institute, Boston, MA
Past Chairperson: Worta McCaskill-Stevens, National Cancer Institute, Rockville, MD
Council Members:
Lucile L. Adams-Campbell, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC
Leslie Bernstein, City of Hope, Duarte, CA
Janet E. Dancey, Ontario Institute for Cancer Research, Toronto, ON, Canada
Mary J. C. Hendrix, Lurie Children’s Research Center, Chicago, IL
Pearl S. Huang, GlaxoSmithKline, King of Prussia, PA
Nancy E. Hynes, Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
S. Percy Ivy, National Cancer Institute-DCTD, Rockville, MD
Patricia M. LoRusso, Barbara Ann Karmanos Cancer Institute, Detroit, MI
Victoria M. Richon, Sanofi Oncology, Wellesley Hills, MA
Judith S. Sebolt-Leopold, University of Michigan, Ann Arbor, MI
Lillian L. Siu, University Health Network Princess Margaret Hospital, Toronto, ON, Canada
Thea D. Tlsty, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
260
Sunday, 2:15 p.m.-3:00 p.m.
Precision Medicine Initiatives at NCI
Chairperson: Barbara Conley, National Cancer Institute-DCTD, Bethesda, MD
NCI is initiating four clinical research initiatives aimed at contributing to a national strategy for
precision cancer medicine.
1. Exceptional Responders Initiative. In this “Phenotype to Genotype” project, we will identify
molecular features that predict response from “failed” therapies. Most drugs that enter phase II
clinical trials do not go on to FDA approval for that indication. However, up to 10% of patients on
these trials nevertheless have “exceptional” responses (complete response or partial response
lasting at least 6 months). We will obtain formalin-fixed tissue from these cases and perform whole
exome mRNA sequencing and copy number assessment. All data will be placed into a controlled
access database. In this way, we hope to decipher the molecular factors that may explain these
exceptional responses and improve our understanding of the biology of disease in these patients,
as well as potentially develop predictive assays that could identify additional responders to the
same agents. We anticipate opening this study in 2014.
2. NCI MATCH (Molecular Analysis for Therapy Choice): This clinical trial for patients with solid
tumors or lymphoma who have progressed after standard treatment will use defined molecular
abnormalities to assign drugs that are selected based upon each tumor’s molecular abnormalities.
We will open this trial across our National Clinical Trials Network (NCTN). Patients will be biopsied,
and tumors will undergo targeted DNA sequencing in a CLIA-certified lab for specific
mutations/amplifications/translocations that correspond to the mechanism of action of the
targeted agents in the clinical trial. Approximately 3,000 patients will be screened for mutations.
We will have 15-30 drugs in the trial. A second biopsy is planned at relapse, and patients may go
on another study drug if they have an appropriate molecular abnormality/change. We anticipate
opening the trial in 2014.
3. ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing
Trial): This trial for patients with lung adenocarcinoma completely removed by surgery will screen
tissue samples from several thousand patients for two relatively rare genetic alterations in EGFR
and ALK genes. Those with these alterations in their tumor will be enrolled on one of two NCI
NCTN trials, each testing an agent specific for one of the alterations with adjuvant therapy. All
patients will also be studied for cancer risk characteristics with their tumor tissue analyzed in a
research genomics initiative conducted by NCI Center for Cancer Genomics.
4. Advanced Lung SCCA Master Protocol: This initiative is a public-private effort with
collaboration from NCI, NCTN Groups, FDA, NIH Foundation, Friends of Cancer Research patient
advocacy group, and the pharmaceutical industry. By pooling resources to screen tumor samples
from about 1,000 patients per year with advanced squamous cell lung cancer for multiple genetic
alterations, this master protocol will enable several randomized, phase II clinical trials with new
agents to be conducted in parallel within a single study framework. Agents will either be further
evaluated in a phase III trial or replaced by other new agents without having to develop individual
trials de novo each time.
Speaker:
P. Mickey Williams, National Cancer Institute-DCTD, Rockville, MD
Panelists:
Alice P. Chen, National Cancer Institute, Rockville, MD
Keith Thomas Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA
261
WRIGHT MEMORIAL LECTURESHIP
Sunday, 3:15 p.m.-4:30 p.m.
Ninth Annual AACR-Minorities in Cancer Research
Jane Cooke Wright Memorial Lectureship
The Cancer Genome in Biology, Therapy, and
Drug Resistance
Levi A. Garraway, MD, PhD
Associate Professor of Medicine
Department of Medical Oncology
Dana-Farber Cancer Institute, Boston, MA
The AACR-Minorities in Cancer Research Jane Cooke
Wright Lectureship was established in 2006 to give
recognition to an outstanding scientist who has made
meritorious contributions to the field of cancer research
and who has, through leadership or by example,
furthered the advancement of minority investigators in
cancer research.
Dr. Levi A. Garraway is an Associate Professor of
Medicine in the Department of Medical Oncology at the
Dana-Farber Cancer Institute and Harvard Medical
School. He is also the inaugural director of the Joint
Center for Cancer Precision Medicine (CCPM) at the
Dana-Farber Cancer Institute, the Brigham and Women’s
Hospital, and the Broad Institute. In addition, he is a
faculty member of Dana-Farber’s Center for Cancer
Genome Discovery, and an Associate Member of the
Broad Institute of Harvard and MIT, where he leads
several large cancer genome analyses and functional
genomics efforts in the Broad Institute Cancer Program.
Dr. Garraway has made seminal research contributions in
cancer genomics, drug resistance, and genomics-driven
(or “precision”) cancer medicine. He published the first
genome sequencing studies of aggressive primary
prostate cancer, and has led major sequencing initiatives
in melanoma and head/neck cancers. This work
identified multiple new cancer genes and uncovered
mechanisms by which complex rearrangements arise. At
the Broad Institute, he also leads the Cancer Cell Line
Encyclopedia, a collaboration with Novartis that involves
a genomic and pharmacological study of ~1000 human
cancer cell lines to characterize sensitivity and
resistance to anticancer agents.
pioneered the use of systematic gain-of-function screens
to characterize resistance to RAF inhibition. This work
has identified novel resistance effector (the COT kinase)
and informed a conceptual framework for interpreting
resistance mechanisms relevant to many tumor types.
Dr. Garraway is perhaps best known for his contributions
to precision cancer medicine. He described the first
high-throughput adaptation of a genomic technology to
profile human tumors for hundreds of “actionable”
cancer gene mutations. This provided a basis for tumor
mutation profiling as a means to stratify cancer patients
for clinical trial enrollment and, in the future, optimal
therapeutic choices. He also demonstrated the promise
of massively parallel sequencing as a clinical tumor
genomic profiling approach. This research has inspired
precision medicine initiatives at many cancer centers
worldwide.
For all his remarkable contributions to the field of cancer
research, Dr. Garraway has been the recipient of several
awards and honors, including the Minority Scholar
Award from the American Association for Cancer
Research, the Partners in Excellence Award, and the
Career Award in the Biomedical Sciences from the
Burroughs-Wellcome Fund. In the fall of 2007, he was
awarded one of the first prestigious New Innovator
Awards from the National Institutes of Health and in 2009
was inducted into the American Society for Clinical
Investigation.
Dr. Garraway was the first to describe a mechanism of
clinical resistance to MEK and RAF inhibitors (MEK1
mutations) in BRAF-mutant melanoma. Subsequently, he
262
Sunday, 3:15 p.m.-4:45 p.m.
Enhancing Scientific Discovery through Data Sharing and Biomedical
Informatics: NCI Resources and Data Repositories
Chairperson: Stephanie Morris, National Cancer Institute, Rockville, MD
The ability to share and reuse data across the biomedical research community is vital to
accelerating scientific discovery and clinical translation. Yet challenges arise as datasets increase
in size and diversity, as can be seen in the analysis of cancer genomes. Other areas of science, in
particular those that involve contributions from several different disciplines like medical
nanotechnology, require integration of different data formats between laboratories, highlighting the
importance of data sharing and management. To address these needs, NCI supports a number of
resources that facilitate data sharing between researchers, and the development of publicly
available data repositories and informatics tools. In this session, several NCI programs will discuss
their efforts to provide data management, sharing, and analytical tools to the biomedical and
cancer research communities. Specifically, speakers from the National Cancer Informatics
Program (NCIP) will give an overview of the developing NCI Cancer Genomics Cloud Pilots project
in which researchers will be able to simultaneously access and analyze data through co-localized
data repositories and advanced computing resources. The overall goals for this project and its
interaction with the Center for Cancer Genomics (CCG) and its current Data Coordinating Centers
(DCCs), as well as the future Genomics Data Commons (GDC) for genomics projects, including
TCGA and TARGET, will be highlighted in the discussion. Additionally, speakers from the NCIP
Nanotechnology Working Group, which supports the informatics needs of cancer and
nanotechnology researchers, will provide an overview of the group’s objectives, projects, and
recent accomplishments. Publicly available nanotechnology data repositories, the cancer
Nanotechnology Laboratory data portal and the Nanomaterial Registry, will also be described in
this session. Speakers will further address the development of standard vocabularies and data
formats that will facilitate broader use of diverse datasets across disciplines, with a focus on
challenges in establishment and utilization.
NCI Genomics Data Commons
Jean Claude Zenklusen, Center for Cancer Genomics, National Cancer Institute,
Bethesda, MD
The NCI Cancer Genomics Cloud Pilots
Tanja Davidsen, Center for Biomedical Informatics and Information Technology,
National Cancer Institute, Bethesda, MD
Informatics approaches for nanotechnology
Martin Fritts, Frederick National Laboratory for Cancer Research/National Institute of
Standards and Technology, Frederick, MD
The NIH Nanomaterial Registry
Anthony Hickey, Research Triangle Institute, Research Triangle Park, NC
263
CLINICAL TRIALS SYMPOSIUM
Sunday, 3:15 p.m.-5:15 p.m.
Ballroom 20A-C, San Diego Convention Center
Novel Immune and Targeted Therapies for Hematologic Malignancies
and Solid Tumors
Chairperson: Joseph Paul Eder, Yale University, New Haven, CT
3:15 p.m.
CT102 Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell
acute lymphoblastic leukemia
Renier J. Brentjens, Memorial Sloan-Kettering Cancer Center, New York, NY
3:35 p.m.
Discussant: Carl H.June, Abramson Cancer Center of the University of
Pennsylvania, Philadelphia, PA
3:45 p.m.
CT103 Clinical safety and activity in a phase 1 trial of AG-221, a first-in-class,
potent inhibitor of the IDH2-mutant protein, in patients with IDH2
mutant positive advanced hematologic malignancies
Eytan M. Stein, Memorial Sloan-Kettering Cancer Center, New York, NY
4:05 p.m.
Discussant to be announced
4:15 p.m.
CT104 Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in
melanoma (MEL): Correlation of tumor PD-L1 expression with outcome
Adil I. Daud, UCSF School of Medicine, San Francisco, CA
4:35 p.m.
CT105 MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung
cancer (NSCLC): Antitumor activity and association with tumor PD-L1
expression
Leena Gandhi, Dana-Farber Cancer Institute, Boston, MA
4:55 p.m.
Discussant: Mario Sznol, Yale Cancer Center, New Haven, CT
264
DRUG DEVELOPMENT TRACK:
SPECIAL SESSION
Sunday, 3:15 p.m.-5:15 p.m.
New Drugs on the Horizon 2
Co-Chairpersons: Nancy K. Pryer, Novartis Institutes for BioMedical Research, Emeryville, CA,
and Stacie S. Canan, Celgene Global Health, San Diego, CA
Advances in the understanding of the molecular basis of cancer have led to the identification of
key pathways involved in tumor initiation and progression, and translating this innovative science
into the next generation of therapeutic agents remains one of the major hurdles to meaningful
improvements in cancer treatment. While clinical successes remain extremely challenging to
achieve, increasing numbers of targeted agents are emerging through clinical trials and making
differences in the lives of patients. This symposium will provide the first disclosure of several new
clinical agents that continue the drive for successful targeted therapies.
3:15 p.m.
In vitro and in vivo characterization of a novel anti-fibroblast growth factor
receptor (FGFR) 2 antibody (BAY 1179470) for the treatment of gastric cancer
Charlotte Kopitz, Bayer Pharma AG, Berlin, Germany
3:40 p.m.
Discussion
3:45 p.m.
Identification of LY3009120 as a pan inhibitor of Raf isoforms and dimers
with minimal paradoxical activation and activities against BRaf or Ras mutant
tumor cell
Sheng-Bin Peng, Eli Lilly and Company, Indianapolis, IN
4:10 p.m.
Discussion
4:15 p.m.
Discovery of GDC-0994: A potent and selective ERK1/2 inhibitor in early
clinical development
John G. Moffat, Genentech, Inc., South San Francisco, CA
4:40 p.m.
Discussion
4:45 p.m.
AMG 595: An antibody drug conjugate directed against the mutant receptor
EGFRvIII for the treatment of glioblastoma
Mark A. Rosenthal, Royal Melbourne Hospital, Melbourne, Australia
5:10 p.m.
Discussion
265
MINISYMPOSIA
Sunday, 3:15 p.m.-5:15 p.m.
Carcinogenesis 1
Clinical Research 3
Carcinogenesis
Profiling and Monitoring Cancer
Genomics for Diagnosis and Therapy
Chairpersons: S. Perwez Hussain and Nune Markosyan
Chairpersons: Paul S. Mischel and Grant A. McArthur
3:15
Introduction
3:20
926
Nitric oxide enhances tumor progression and disease
aggressiveness in pancreatic cancer. Jian Wang, Peijun He,
Matthias M. Gaida, Shouhui Yang, Aaron Schetter, Jochen
Gaedcke, Michael Ghadimi, Thomas Ried, Harris G. Yfantis, Dong
H. Lee, Jonathan M. Weiss, Jim Stauffer, Nader Hanna, H. Richard
Alexander, S. Perwez Hussain.
3:35
927
Targeted capture next generation sequencing of fresh
frozen lobular carcinoma in situ and invasive lobular cancer
identifies a common repertoire of mutations. Rita A. Sakr, Jose
V. Scarpa, Michael Schizas, Dilip Giri, Marina De Brot, Russell
Towers, Charlotte K. Ng, Raymond Lim, Victor P. Andrade, Britta
Weigelt, Jorge S. Reis-Filho, Tari A. King.
3:15
Introduction
3:20
933
Copy number changes are associated with BRAF and
NRAS mutations and response to treatment with carboplatin,
paclitaxel and sorafenib. Melissa A. Wilson, Fengmin Zhao,
Sanika Khare, Richard Letrero, Kurt D’Andrea, David L. Rimm,
John M. Kirkwood, Harriet M. Kluger, Sandra J. Lee, Lynn M.
Schuchter, Keith T. Flaherty, Katherine L. Nathanson.
3:35
934
BRAF inhibitors induce skin and extra-cutaneous
tumors via paradoxical activation of the MAPK pathway:
Molecular study of 66 tumors and visualization of BRAF/CRAF
protein dimers. Lise Boussemart, Isabelle Girault, Christine
Mateus, Marina Thomas, Emilie Routier, Hugo Cazenave, Gorana
Tomasic, Janine Wechlser, Nyam Kamsu-Kom, Séverine Roy,
Michel Favre, Ludovic Lacroix, Alexander Eggermont, Stéphan
Vagner, Caroline Robert.
3:50
935
Exome sequencing reveals BRAF mutations in papillary
craniopharyngiomas. Amaro N. Taylor-Weiner, Priscilla K.
Brastianos, Peter E. Manley, Robert T. Jones, Dora Dias-Sangata,
Aaron Thorner, Fausto Rodriguez, Lindsay Bernardo, Laura
Schubert, Chip Stewart, Mark Keiran, William C. Hahn, Adam
Resnick, David Louis, Sandro Sangata, Gad Getz.
3:50
928
Deletion of mammary epithelial mPGES1 suppresses
tumor development in mice: a possible effect of substrate
re-diversion. Nune Markosyan, Emer M. Smyth.
4:05
929
Identification of ZBTB20 as a novel oncogene
associated with the gender bias occurrence of hepatocellular
carcinoma. Vincent W. Keng, Barbara R. Tschida, Timothy P.
Kuka, Branden S. Moriarity, Jason B. Bell, David A. Largaespada.
4:20
930
Inducible ROCK 2/rasHa cooperation requires wound
promotion to achieve malignancy in transgenic mouse skin
carcinogenesis, whereas inducible ROCK 2/PTEN loss fails to
achieve benign papilloma. Siti F. Masre, Michael S. Samuel,
Michael F. Olson, David A. Greenhalgh.
4:05
931
Role of IKK␣ in K-ras-driven lung carcinogenesis. NaYoung Song, Jami Willette-Brown, Mahesh Dalta, Yinling Hu.
936
Comprehensive and integrative genomic
characterization of diffuse lower grade gliomas. Roel G.
Verhaak, Lee A. Cooper, Sofie S. Salama, Kenneth Aldape, W.K. A.
Yung, Daniel J. Brat.
4:20
932
The impact of e-cigarette exposure on pulmonary
epithelium gene expression and transformation. Stacy J. Park,
Tonya C. Walser, Catalina Perdomo, Teresa Wang, Long-Sheng
Hong, Paul C. Pagano, Elvira L. Liclican, Kostyantyn Krysan, Jill E.
Larsen, Michael C. Fishbein, John D. Minna, Marc E. Lenburg,
Avrum Spira, Steven M. Dubinett.
937
Molecular analysis of KRAS exon 2 wild type colorectal
cancer patients enrolled in the CAPRI clinical trial reveals
high degree of tumor heterogeneity. Anna Maria Rachiglio,
Matilde Lambiase, Francesca Fenizia, Claudia Esposito, Cristin
Roma, Giuseppe Tonini, Saverio Cinieri, Giuseppe Colucci,
Fortunato Ciardiello, Nicola Normanno.
4:35
938
Single-cell whole-genome sequencing verifies the
surrogacy of circulating tumor cells for prostate cancer. YiTsung Lu, Runze Jiang, Hsian-Rong Tseng, Leland W. Chung,
Edwin M. Posadas.
4:50
939
Serial monitoring of EGFR mutations in plasma and
matched tissue from EGFR mutant non-small cell lung cancer
patients on erlotinib. Cloud P. Paweletz, Geoffrey R. Oxnard,
Yanan Kuang, Allison O’Connell, Masahiko Yanagita, Melissa M.
Messineo, Paul Kirschmeier, Jessie M. English, David M. Jackman,
Pasi A. Jänne.
5:05
Discussion
4:35
4:50
5:05
266
Discussion
MINISYMPOSIA
Sunday, 3:15 p.m.-5:15 p.m.
Epidemiology 3
Recent Advances in Molecular and
Genetic Epidemiology
Novel Small Molecule Inhibitors and
Targets
Chairpersons: Jonine D. Figueroa and Zsofia Kote-Jarai
Chairpersons: Monica L. Guzman and Steven Grant
3:15
Introduction
3:15
Introduction
3:20
940
The contribution of common breast cancer
susceptibility loci to the breast density and breast cancer
association and the Breast Cancer Surveillance Consortium
(BCSC) risk model. Celine M. Vachon, V. S. Pankratz, Christopher
G. Scott, Lothar Haeberle, Elad Ziv, Matthew R. Jensen, Kathleen
R. Brandt, Dana H. Whaley, Janet E. Olson, Katharina Heusinger,
Carolin C. Hack, Sebastian M. Jud, Matthias W. Beckmann, Jeffrey
A. Tice, Kristen S. Purrington, Thomas A. Sellers, Karla
Kerlikowske, Peter A. Fasching, Fergus J. Couch.
3:20
947
A small molecule Mer tyrosine kinase inhibitor (UNC
MerTKi) effectively inhibits growth of murine melanoma. H
Shelton Earp, David Darr, Albert Zimmermann, Kelly Clark, Norman
E. Sharpless, Wolfgang Bergmeier, Weihe Zhang, Xiaodong Wang,
Deborah DeRyckere, Stephen Frye, Douglas Graham.
3:35
948
Discovery of dual MNK 1 and 2 and BCR-ABL kinase
inhibitors for the treatment of blast crisis chronic myeloid
leukemia. Joseph Cherian, Kassoum Nacro, Zhi Ying Poh,
Samantha Guo, Melvyn Ho, Haiyan Yang, Sharon Lim, Meng Ling
Choong, Jun Li Ding, Joma Kanikadu Joy, Zekui Perlyn Kwek,
Boping Liu, Hongqian Esther Ong, Vishal Pendharkar, Anders
Poulsen, May Ann Lee, Kanda Sangthongpitag, Charles Chuah,
Tiong S. Ong, Jeffrey Hill, Thomas H. Keller, Alex Matter.
3:50
949
Identification of OXPHOS inhibitors which selectively
kill tumors with specific metabolic vulnerabilities. Joseph R.
Marszalek, Madhavi Bandi, Jennifer Bardenhagen, Christopher
Bristow, Christopher Carroll, Edward Chang, Ninping Feng, Barbara
Czako, Jason Gay, Mary Geck Do, Jennifer Greer, Ryan M.
Johnson, Marina Konopleva, Zhijun Kang, Gang Liu, Timothy
Lofton, Timothy McAfoos, Marina Protopopova, Alessia Petrocchi,
Florian Muller, Jay Theroff, Yuanqing Wu, Lynda Chin, Giulio
Draetta, Philip Jones, Carlo Toniatti, Emilia Di Francesco.
4:05
950
Selective cytotoxicity of A6 peptide against ZAP-70
expressing CLL B-cells. Hsien Lai, Suping Zhang, Christina Wu,
Liguang Chen, Grace Liu, RongRong Wu, Fitzgerlad Lao, Jian Yu,
Laura Rassenti, Michael Choi, Stephen Howell, Malcolm Finlayson,
Thomas Kipps.
4:20
951
CB-5083 is a novel first in class p97 inhibitor that
disrupts cellular protein homeostasis and demonstrates antitumor activity in solid and hematological models. Ronan Le
Moigne, Steve Wong, Ferdie Soriano, Eduardo Valle, Daniel J.
Anderson, Stevan Djakovic, Mary-Kamala Menon, Bing Yao, Julie
Rice, Jinhai Wang, Szerenke Kiss Von Soly, Brajesh Kumar, Marta
Chesi, P. Leif Bergsagel, Han-Jie Zhou, David Wustrow, Mark
Rolfe, F. Michael Yakes.
4:35
952
Preclinical efficacy of maternal embryonic leucinezipper kinase (MELK) inhibition in acute myeloid leukemia.
Houda Alachkar, Martin Mutonga, Suyoun Chung, Yo Matsuo,
Wendy Stock, Yusuke Nakamura.
4:50
953
Novel inhibitors of signal transducer and activator of
transcription 3 (STAT3) show potent activity in cell cultures
and tumor xenografts. Davide Genini, Lara Brambilla, Erik
Laurini, Gianluca Civenni, Sandra Pinton, Manuela Sarti, Ramon
Garcia-Escudero, Laurent Perez, Giuseppina M. Carbone, Sabrina
Pricl, Carlo V. Catapano.
5:05
Discussion
3:35
3:50
4:05
4:20
4:35
941
Exome sequencing identified POT1, a telomere
shelterin gene, as a major susceptibility gene for familial
cutaneous malignant melanoma. Jianxin Shi, Xiaohong R. Yang,
Bari Ballew, Melissa Rotunno, Donato Calista, Maria C. Fargnoli,
Paola Ghiorzo, Brigitte B. Paillerets, Eduardo Nagore, NCI DCEG
Cancer Sequencing Working Group, Xing Hua, Paula Hyland, Jinhu
Yin, Haritha Vallabhaneni, Weihang Chai, Sarangan Ravichandran,
Alexander Eggermont, Mark Lathrop, Ketty Peris, Giovanna
Bianchi-Scarra, Giorgio Landi, Sharon Savage, Joshua Sampson, Ji
He, Meredith Yeager, Lynn Goldin, Florence Demenais, Stephen
Chanock, Margaret Tucker, Alisa Goldstein, Yie Liu, Maria T. Landi.
942
Imputation from The 1000 Genomes Project identifies
rare large effect variants of BRCA2-K3326X and CHEK2-I157T
as risk factors for lung cancer; a study from the TRICL
consortium. Maria Teresa Landi, Yufei Wang, James D. Mckay,
Thorunn Rafnar, Zhaoming Wang, Maria Timofeeva, Peter
Broderick, Kari Stefansson, Angela Risch, Stephen J. Chanock,
David C. Christiani, Rayjean J. Hung, Paul Brennan, Richard S.
Houlston, Christopher I. Amos.
943
A comprehensive examination of breast cancer risk
loci in African American women. Ye Feng, Gary K. Chen, Daniel
O. Stram, Robert C. Millikan, Christine B. Ambrosone, Esther M.
John, Leslie Bernstein, Wei Zheng, Andrew F. Olshan, Jennifer J.
Hu, Regina G. Ziegler, Sarah Nyante, Elisa V. Bandera, Sue A.
Ingles, Michael F. Press, Sandra L. Deming, Jorge L. RodriguezGil, Julie R. Palmer, Olufunmilayo I. Olopade, Dezheng Huo,
Clement A. Adebamowo, Temidayo Ogundiran, Alex Stram, Karen
Park, Kristin A. Rand, Stephen J. Chanock, Loic L. Marchand,
Laurence N. Kolonel, David V. Conti, Douglas Easton, Brian E.
Henderson, Christopher A. Haiman.
944
Translational implications of the 19q12 bladder cancer
GWAS signal for aggressive bladder cancer. Yi-Ping Fu, Indu
Kohaar, Lee Moore, Petra Lenz, Jonine D. Figueroa, Wei Tang,
Patricia Porter-Gill, Stephen Chanock, Stephen M. Hewitt, Debra T.
Silverman, Nathaniel Rothman, NCI-GWAS Bladder Cancer
Consortium, Ludmila Prokunina-Olsson.
945
Genetic association study of the mitochondrial genome
and colorectal cancer risk: The Multiethnic Cohort. Iona C.
Cheng, Christian Caberto, Kenneth Beckman, Annette Lum-Jones,
Christopher Haiman, Loic Le Marchand, Daniel Stram, Richa
Saxena.
4:50
946
Exome genotyping array identifies rare and lowfrequency variants that may be associated with ovarian
cancer risk. Jennifer Permuth-Wey, Y. Ann Chen, Zhihua Chen,
Andrew Berchuck, Georgia Chenevix-Trench, Jennifer Doherty,
Simon Gayther, Ellen L. Goode, Edwin Iversen, Alvaro N. Monteiro,
Leigh Pearce, Paul D. Pharoah, Catherine M. Phelan, Ailith Pirie,
Susan Ramus, Mary Ann Rossing, Joellen M. Schildkraut, Thomas
A. Sellers, on behalf of the Ovarian Cancer Association
Consortium.
5:05
Discussion
267
MINISYMPOSIA
Sunday, 3:15 p.m.-5:15 p.m.
Understanding Mechanisms of
Resistance to Targeted Agents in
Patients
Cancer Metabolism: New Pathways and
Progress Toward Therapy
Chairpersons: Philippe L Bedard and
Andrew I. Minchinton
3:15
Introduction
3:20
954
Integrated genomic analysis by whole exome and
transcriptome sequencing of tumor samples from EGFRmutant non-small-cell lung cancer patients with acquired
resistance to erlotinib. Petros Giannikopoulos, John St. John,
Nicholas Hahner, Joel S. Parker, Niki Karachaliou, Carlota Costa,
Oscar Westesson, Urvish Parikh, Catherine K. Foo, Aleah F.
Cauhlin, Maria D. Lozano, Santiago Viteri, Jose L. Perez-Gracia,
Alessandra Curioni, Eloisa Jantus-Lewintre, Carlos Camps, Alain
Vergenegre, Radj Gervais, Anne Wellde, Jonathan Barry, George
W. Wellde, Rodolfo Bordoni, Rolf Stahel, Andres F. Cardona Zorilla,
William R. Polkinghorn, Jonathan Weissman, Trever G. Bivona,
Rafael Rosell.
Chairpersons: Matthew G. Vander Heiden and
David M. Sabatini
3:15
Introduction
3:20
961
6-phosphogluconate dehydrogenase links oxidative
PPP, lipogenesis and tumor growth by inhibiting LKB1-AMPK
signaling. Changliang Shan, Shannon E. Elf, Ting-Lei Gu, Hanna
J. Khoury, Titus Boggon, Sumin Kang, Jing Chen.
3:35
962
Identification of a PFKFB3 inhibitor suitable for phase I
trial testing that synergizes with the B-Raf inhibitor
vemurafenib. Julie O’Neal, Gilles Tapolsky, Brian Clem, Sucheta
Telang, Jason Chesney.
3:50
963
IDH2(R140Q) knock-in mouse recapitulating human
type II D-2-hydroxyglutaric aciduria. Fang Wang, Jeremy
Travins, Zhizhong Lin, Lee Silverman, Yue Chen, Yuxuan Lu, Hua
Yang, Michael Su, Yong Cang, Kate Ellwood-Yen, Shengfang Jin.
3:35
955
Transformation from NSCLC to SCLC in EGFR mutant
lung cancers with acquired resistance to EGFR inhibitors.
Matthew J. Niederst, Lecia V. Sequist, Elizabeth L. Lockerman,
Angel R. Garcia, Carlotta Costa, Farhiya Mohamoud, Darrell R.
Borger, Toshi Shioda, Gad Getz, Anthony J. Iafrate, Mari MinoKenudson, Jeffrey A. Engelman.
4:05
964
Inhibiting glycolysis with an LDHA inhibitor: A new
solution to an old problem. Thomas O’Brien, Hans Purkey, Anna
Hitz, Dave Peterson, Aaron Boudreau, Christopher Delnagro, Mandy
Kwong, Rebecca Hong, Min Gao, Jodi Pang, Alex Vanderbilt,
Simon Williams, Laurent Salphati, Deepak Sampath, Georgia
Hatzivassiliou, Marie Evangelista.
3:50
956
Elucidating the mechanisms of acquired resistance in
lung adenocarcinomas. Sandra Ortiz-Cuarán, Lynnette
Fernandez-Cuesta, Marc Bos, Lukas Heukamp, Christine M. Lovly,
Martin Peifer, Masyar Gardizi, Matthias Scheffler, Ilona Dahmen,
Christian Müller, Katharina König, Kerstin Albus, Alexandra Florin,
Sascha Ansén, Reinhard Buettner, Jürgen Wolf, William Pao,
Roman K. Thomas.
4:20
965
An oncogenic metabolic switch mediates resistance to
NOTCH1 inhibition in T-ALL. Daniel Herranz, Alberto AmbesiImpiombato1, Jessica Sudderth, Marta Sánchez-Martín, Valeria
Tosello, Luyao Xu, Mireia Castillo, Carlos Cordon-Cardo, Andrew L.
Kung, Ralph J. DeBerardinis, Adolfo Ferrando.
4:35
966
Novel pharmacodynamic assays to measure
glutaminase inhibition following oral administration of CB839. Andy L. MacKinnon, Mark K. Bennett, Matthew I. Gross, Julie
R. Janes, Evan R. Lewis, Mirna L. Rodriguez, Peter J. Shwonek,
Wang Taotao, Jinfu Yang, Frances Zhao, Francesco Parlati.
4:50
Discussion
4:05
957
The ALK inhibitor LDK378 overcomes crizotinib
resistance in non-small cell lung cancer. Luc Friboulet, Nanxin
Li, Ryohei Katayama, Christian C. Lee, Justin F. Gainor, Adam S.
Crystal, Pierre-Yves Michellys, Mark M. Awad, Noriko Yanagitani,
Sungjoon Kim, AnneMarie Pferdekamper, Jie Li, Shailaja
Kasibhatla, Frank Sun, Xiuying Sun, Su Hua, Peter McNamara,
Sidra Mahmood, Elizabeth L. Lockerman, Naoya Fujita, Makoto
Nishio, Jennifer L. Harris, Alice T. Shaw, Jeffrey A. Engelman.
4:20
958
Activation of COL11A1 by anticancer drugs through
IGF-1R/PI3K pathway confers chemoresistance in ovarian
cancer via activating NF-␬B-mediated Twist1 expression. YiHui Wu, Yu-Fang Huang, Cheng-Yang Chou.
4:35
959
FAS mutations induce therapeutic resistance in nonHodgkin lymphomas. Nathalie Johnson, Denis Gaucher, Ryan
Morin, Randy Gascoyne, Joseph Connors, Marco Marra, Jerry
Pelletier, Hawley Rigsby, Koren Mann.
4:50
960
Targeting Egr-1 is an effective strategy for overcoming
kinase inhibitor resistance in CML. Mary E. Irwin, Roxsan
Manshouri, Blake Johnson, Hesham M. Amin, Joya Chandra.
5:05
Discussion
268
MINISYMPOSIA
Sunday, 3:15 p.m.-5:15 p.m.
Cell Signaling in Cancer
Modulation of MicroRNA Expression
Chairpersons: Murray Korc and Rachel Schiff
Chairpersons: Philip N. Tsichlis and Curtis C. Harris
3:15
Introduction
3:15
Introduction
3:20
967
A novel regulator of Wnt-signaling in colorectal
cancer. Johannes Betge, Oksana Voloshanenko, Gerrit Erdmann,
Kubilay Demir, Matthias P. Ebert, Michael Boutros.
3:20
974
Targeting the tumor microenvironment with antimiRs
that exploit oncomiR addiction in lymphoma. Christopher
J. Cheng, Don M. Engelman, Mark Saltzman, Frank J. Slack.
3:35
968 ␤-catenin plays an important role in lung tumor
development induced by EGFR mutations. Sohei Nakayama,
Natasha J. Sng, Julian Carretero, Robert Welner, Yuichiro Hayashi,
Mihoko Yamamoto, Tan J. Alistair, Norihiro Yamaguchi, Hiroyuki
Yasuda, Li Danan, Kenzo Soejima, Soo A. Ross, Costa B. Daniel,
Kwok-Kin Wong, Susumu S. Kobayashi.
3:35
975
MicroRNA-155 In chronic lymphocytic leukemia
influences B-cell receptor signaling. Liguang Chen, Bing Cui,
Suping Zhang, Marek Mraz, Jessie-F. Fecteau, Jian Yu, Ling
Zhang, Lei Bao, Laura Rassenti, Karen Messer, Carlo Croce,
Thomas Kipps.
3:50
3:50
969
TGF-beta cross-talks with the EGF receptor family to
promote proliferation of pancreatic cancer cells with
dysfunctional RB. Jesse Gore, Samantha L. Deitz, Julie L. Wilson,
Murray Korc.
4:05
970
Mass spectrometry analysis of PIK3CA mutant
mammary epithelial cells identifies EGFR as a paracrine
effector of PI3K in basal-like breast cancer. Christian D. Young,
Lisa J. Zimmerman, Michael L. Gatza, Meghan M. Morrison,
Corbin A. Whitwell, Neil E. Bhola, Ariella B. Hanker, Thomas
Stricker, Premal Patel, Dana M. Brantley-Sieders, Charles M.
Perou, Ben H. Park, Daniel C. Liebler, Rebecca S. Cook, Carlos L.
Arteaga.
976
Junctional adhesion molecule-A (JAM-A) expression is
downmodulated by miR-21 during colorectal cancer
progression. Andrea Lampis, Claudio Murgia, Viola Paulus-Hock,
Matteo Fassan, Joanne Edwards, Paul Horgan, Owen Sansom,
Luigi Terracciano, Michael Karin, Carlo Croce, Chiara Braconi,
Nicola Valeri.
4:05
977
Characterizing the regulation and function of miR-155
in hypoxia biology. Jennifer Czochor, Peter M. Glazer.
4:20
978
microRNA-211 modulates energy metabolism in human
melanoma cells by destabilizing HIF1-␣ and downregulating
PDK4. Joseph Mazar, Adam Richardson, Feng Qi, Bongyong Lee,
Angeles Duran, Subramaniam Govindarajan, John Shelley,
Laurence M. Brill, Jian-Liang Li, Xianlin Han, Jorge Moscat, Ranjan
J. Perera.
4:35
979
microRNA-mediated leukemia-initiating cell activity.
Chinavenmeni S. Velu, Aditya Chaubey, James D. Phelan, Sara
Meyer, Shane R. Horman, Mark Wunderlich, Monica L. Guzman,
Anil G. Jegga, Nancy J. Zeleznik-Le, Jianjun Chen, James C.
Mulloy, Jose A. Cancelas, Craig T. Jordan, Bruce J. Aronow, Guido
Marcucci, Balkrishen Bhat, Brian Gebelein, H. L. Grimes.
4:50
980
Small molecule inhibitor of miR-155, SMM155I, inhibits
epithelial-mesenchymal transition and tumor growth in cancer
cells overexpressing miR-155. Cheng-Xiong Xu, William Kong,
Donghwa Kim, Edward Richards, Fei Yan, Yueling Li, Domenico
Coppola, Jin Q. Cheng.
5:05
Discussion
4:20
4:35
4:50
5:05
971
Phosphatase PTP4A3 is critical for cell growth of
triple-negative breast cancer. Petra den Hollander, Anna
Tismelzon, Jonathan Shepherd, Kathryn R. Rawls, Jamal L. Hill,
Abhijit Mazumdar, Susan G. Hilsenbeck, Gordon B. Mills, Powel H.
Brown.
972
B-cell maturation antigen (BCMA) activation in human
multiple myeloma cells promotes myeloma cell growth and
survival in the bone marrow microenvironment via
upregulated MCL-1 and NF␬B signaling. Yu-Tzu Tai, Chirag
Acharya, Mike Y. Zhong, Michele Cea, Antonia Cagnetta, Paul
Richardson, Nikhil C. Munshi, Kenneth C. Anderson.
973
Tumor-associated fibroblasts induce long-term
changes in breast cancer invasion, cancer stem cell
populations, and metastasis through modulation of the Tiam1ostepontin pathway. Kun Xu, Xuejun Tian, Stephen P. Naber, Sun
Oh, Charlotte Kuperwasser, Rachel J. Buchsbaum.
Discussion
269
MINISYMPOSIA
Sunday, 3:15 p.m.-5:15 p.m.
Tumor Biology 9
Molecular Profiling to Elucidate Tumor
Heterogeneity and Clonal Evolution
Molecular Regulation of Tumor
Metastasis
Chairpersons: Jonathan J. Keats and Marco Gerlinger
Chairpersons: Bruce R. Zetter and Frank J. Rauscher
3:15
Introduction
3:15
Introduction
3:20
982
Analysis of clonal evolution of leukemia in vivo
following novel targeted treatments. Naga Poojitha Ojamies,
Mika Kontro, Henrik Edgren, Samuli Eldfors, Pekka Ellonen, Tea
Pemovska, Langstrom Sonja, Henrikki Almusa, Maija Lepisto, Tero
Aittokallio, Krister Wennerberg, Caroline Heckman, Kimmo Porkka,
Olli Kallioniemi.
3:20
988
A mouse model gene expression database reveals
E2Fs as key regulators of breast cancer metastasis. Daniel
Hollern, John Rennhack, Eran Andrechek.
3:35
989
NEDD9 expression promotes epithelial ovarian cancer
growth and dissemination. Rashid Gabbasov, Laura E. Bickel,
Shane W. O’Brien, Samuel Litwin, Sachiko Seo, Erica A. Golemis,
Denise C. Connolly.
3:50
990
Metastasis suppressor CD82/KAI1 expression is
dependent on functional SWI/SNF ARID1A/B. Rusheeswar
Challa, Yutaka Shoji, Kelly A. Conrads, Brian L. Hood, Guisong
Wang, Kathleen M. Darcy, Chad A. Hamilton, George L. Maxwell,
Thomas P. Conrads, John I. Risinger.
4:05
991
Brain metastasis depends on tumor cell initiated
coagulation. Laurie J. Gay, John Day, Sarah LeBoeuf, Melissa
Ritland, Zaverio Ruggeri, Wolfram Ruf, Brunhilde H. Felding.
4:20
992
LIMD2 is a small LIM-only protein overexpressed in
metastatic lesions which regulates cell motility and tumor
progression by directly binding to and activating the integrinlinked-kinase. Hongzhuang Peng, Mehdi Taleb Zadeh Farrooji,
Michael J. Osborne, Jeremy W. Prokop, Paul C. McDonald,
Jayashree Karar, Zhaoyuan Hou, Mei He, Electron Kebebew,
Torben Orntoft, Meenhard Herlyn, Andrew J. Caton, William
Fredericks, Bruce Malkowicz, Christopher S. Paterno, Alexandra S.
Carolin, David W. Speicher, Emmanuel Skordalakes, Qihong
Huang, Shoukat S. Dedhar, Katherine L. Borden, Frank J.
Rauscher.
4:35
993
Whole exome sequencing of CTCs as a window into
metastatic cancer. Viktor A. Adalsteinsson, Jens G. Lohr, Kristian
Cibulskis, Atish D. Choudhury, Mara Rosenberg, Peter CruzGordillo, Joshua Francis, ChengZhong Zhang, Alexander K. Shalek,
Rahul Satija, John T. Trombetta, Diana Lu, Naren Tallapragada,
Narmin T. Tahirova, Sora Kim, Brendan Blumenstiel, Carrie
Sougnez, Daniel Auclair, Eliezer M. Van Allen, Mari Nakabayashi,
Rosina T. Lis, Gwo-Shu M. Lee, Tiantian Li, Matthew S. Chabot,
Mary-Ellen Taplin, Thomas E. Clancy, Massimo Loda, Aviv Regev,
Matthew Meyerson, William C. Hahn, Philip W. Kantoff, Todd R.
Golub, Gad Getz, Jesse S. Boehm, J C. Love.
4:50
994
Integrated embryonic transcriptome analyses identify
key melanoma metastasis regulator . Pravin J. Mishra, Theresa
Guo, Raza Zaidi, Sean Davis, Aleksandra Michalowski, Helen
Michael, William Reinhold, Heinz Arnheiter, Paul Meltzer, Glenn
Merlino.
5:05
Discussion
3:35
3:50
983
Intratumor heterogeneity in non-small cell lung cancer
inferred by multi-region exome sequencing. Elza De Bruin,
Nicholas McGranahan, Lucy Yates, Mariam Jamal-Hanjani, Max
Salm, Richard Mitter, Seema Shafi, Nirupa Murugaesu, Andrew
Rowan, Marco Gerlinger, David Wedge, Stuart Horswell, Ignacio
Varela, Warren Tom, Chaitali Parikh, Timothy Harkins, Clarence
Lee, Nik Matthews, Aengus Stewart, Peter Campbell, Charles
Swanton.
984
Alteration of the p53 pathway is associated with
subclonal tumor progression in glioblastoma. Hoon Kim, Siyuan
Zheng, Seyed S. Amini, Selene M. Virk, Tom Mikkelsen, Daniel J.
Brat, Jonna Grimsby, Carrie Sougnez, Andrew E. Sloan, Mark L.
Cohen, Erwin G. Van Meir, Lisa Scarpace, The Cancer Genome
Research Network, Peter W. Laird, John N. Weinstein, Eric Lander,
Stacey Gabriel, Gad Getz, Matthew Meyerson, Lynda Chin, Jill S.
Barnholtz-Sloan, Roel G. Verhaak.
4:05
985
The mutational landscape of LN metastasis and
recurrence in HNSCC. Matthew L. Hedberg, Gerald Goh, Maria
Freilino, Yan Zeng, Vivian W. Lui, Roy S. Herbst, Richard P. Lifton,
Jennifer R. Grandis.
4:20
986
Unraveling breast cancer progression through
geographical and temporal sequencing. Christine Desmedt,
David Brown, Borbala Szekely, Dominiek Smeets, Marcell A.
Szasz, Pierre-Yves Adnet, Françoise Rothé, Zsofia I. Nagy, Zsofia
Farago, Anna-Maria Tokes, Dimitrios Zardavas, Gabriele Zoppoli,
Michail Ignatiadis, Lajos Pusztai, Martine Piccart, Denis Larsimont,
Diether Lambrechts, Janina Kulka, Christos Sotiriou.
4:35
987
Comprehensive characterization of urothelial bladder
cancer: a TCGA Project update. John N. Weinstein, Jaegil Kim,
Chad J. Creighton, Rehan Akbani, Katherine A. Hoadley, William Y.
Kim, Margaret B. Morgan, Toshinori Hinoue, Andrew Cherniack,
Xiaoping Su, Andrew J. Mungall, Michael C. Ryan, Jonathan E.
Rosenberg, Dean F. Bajorin, Bogdan Czerniak, Donna Hansel,
Victor E. Reuter, Brian D. Robinson, Hikmat A. Al-Ahmadie, Jeffrey
S. Damrauer, Wei Zhang, Yuexin Liu, Dmitry Gordenin, Joshua M.
Stuart, Nikolaus Schultz, Gordon Robertson, Raju Kucherlapati,
Peter W. Laird, Gordon B. Mills, David J. Kwiatkowski, Seth P.
Lerner, representing TCGA’s Bladder Cancer Working Group.
4:50
270
Discussion
MINISYMPOSIA
Sunday, 3:15 p.m.-5:15 p.m.
Tumor Biology 10
Pediatric Cancers 1
Chairpersons: Charles G. Mullighan and
Lionel M. Chow
3:15
Introduction
3:20
995
Loss of ATRX decreases survival and improves
response to DNA damaging agents in a novel mouse model of
glioblastoma. Carl Koschmann, Alexandra Calinescu, Marta
Dzaman, Rosie Lemons, Daniel Thomas, Maria G. Castro, Pedro R.
Lowenstein.
3:35
996
Metastasis and tumor recurrence from rare SOX9positive cells in Group 4 medulloblastoma. Vasil Savov,
Grammatiki Fotaki, Marc Remke, Adrian M. Dubuc, Vijay
Ramaswamy, Matko Čančer, Holger Weishaupt, Michael D. Taylor,
Fredrik J. Swartling.
3:50
997
Targeting the Jak/Stat signaling pathway is highly
effective in xenograft models of early T cell precursor (ETP)
acute lymphoblastic leukemia (ALL). Shannon L. Maude,
Sibasish Dolai, Cristina Delagdo-Martin, Tiffaney Vincent, Alissa
Robbins, Arthavan Selvanathan, Theresa Ryan, Stephen P. Hunger,
Mignon L. Loh, Charles G. Mullighan, Brent L. Wood, Michelle L.
Hermiston, Stephan A. Grupp, Richard B. Lock, David T. Teachey.
4:05
998
Rise and fall of subclones from diagnosis to relapse in
pediatric B-acute lymphoblastic leukemia (B-ALL): A report
from the children’s oncology group (COG) - Target - St. Jude
Pediatric Cancer Genome Project. Xiaotu Ma, Mignon L. Loh,
Michael Rusch, Michael Edmonson, Richard C. Harvey, David A.
Wheeler, Oliver A. Hampton, John Easton, Donald Yergeau, Bhavin
Vadodaria, Gang Wu, William L. Carroll, I-Ming Chen, Daniela S.
Gerhard, Julie M. Gastier-Foster, Mary V. Relling, Malcolm A.
Smith, Meenakshi Devidas, Jaime M. Guidry Auvil, James R.
Downing, Cheryl L. Willman, Charles G. Mullighan, Stephen P.
Hunger, Jinghui Zhang.
4:20
999
The genomic landscape of pediatric Ewing sarcoma.
Brian Crompton, Chip Stewart, Amaro Taylor-Weiner, Gabriela
Alexa, Kyle Kurek, Monica Calicchio, Adam Kiezun, Scott Carter,
Sachet Shukla, Swapnil Mehta, Aaron Thorner, Carmen de Torres,
Cinzia Lavarino, Mariona Sunol, Aaron McKenna, Andrey
Sivachenko, Kristian Cibulskis, Michael Lawrence, Lauren
Ambrogio, Daniel Auclair, Ivan Rosshandler, Angela Schwarz-Cruz
y Celis, Miguel Rivera, Carlos Rodriguez-Galindo, Mark Fleming,
Todd Golub, Gad Getz, Jaume Mora, Kimberly Stegmaier.
4:35
1000
Combination CDK4/6 and ALK inhibition demonstrates
on-target synergy against neuroblastoma. Andrew C. Wood,
Kateryna Krytska, Hannah Ryles, Renata Sano, Nanxin Li, Frederick
King, Timothy Smith, Tove Tuntland, Sunkyu Kim, Giordano
Caponigro, You Qun He, Harris Jennifer, Yael Mosse.
4:50
1001
CD146 is a novel marker of highly tumorigenic
populations and a therapeutic target in malignant rhabdoid
tumor. Seishiro Nodomi, Katsutsugu Umeda, Satoshi Saida,
Yasumichi Kuwahara, Takayuki Hamabata, Tomoo Daifu, Itaru
Kato, Hidefumi Hiramatsu, Ken-ichiro Watanabe, Souichi Adachi,
Eiichi Konishi, Hajime Hosoi, Toshio Heike.
5:05
Discussion
271
MEET AND GREET
Sunday, 3:30 p.m.-4:30 p.m.
Meet the Mentor: Undergraduate Focus
Organized by the Science Education Committee
Ernest T. Hawk, MD, MPH
Vice President and Division Head
Division of Cancer Prevention & Population Sciences
Boone Pickens Distinguished Chair for Early Prevention of Cancer
The University of Texas MD Anderson Cancer Center
Houston, TX
Ernest T. Hawk, MD, MPH, is vice president and division head for Cancer Prevention and
Population Sciences at The University of Texas MD Anderson Cancer Center. Prior to his
appointment at MD Anderson in December 2007, Dr. Hawk held several positions at the National
Cancer Institute in Bethesda, MD. He most recently served as director of the Office of Centers,
Training and Resources. His other NCI posts included chief and medical officer in the
Gastrointestinal and Other Cancers Research Group, medical officer in the Chemoprevention
Branch, and chair of the Translational Research Working Group.
Dr. Hawk has been involved in a wide range of preclinical and clinical chemoprevention research,
including studies of nonsteroidal anti-inflammatory drugs, COX-2 inhibitors, and agent
combinations in high-risk cohorts. In addition, he is interested in improving the participation of
minority and underserved populations in clinical research, and in the integration of risk
assessment, behavioral science, and preventive strategies in clinical trials. He has earned
numerous awards for his work, including the NCI Research Award for Distinguished Achievement
in Cancer Prevention.
A native of Detroit, Dr. Hawk earned his bachelor’s and medical degrees at Wayne State University
and his master of public health degree at Johns Hopkins University. He completed an internal
medicine internship and residency at Emory University, a medical oncology clinical fellowship at
the University of California, San Francisco, and a cancer prevention fellowship at NCI.
Dr. Hawk has published more than 170 articles, abstracts, and book chapters, is the senior deputy
editor for Cancer Prevention Research, serves on the editorial board of Cancer Medicine, and an
ad hoc reviewer for numerous peer-reviewed journals, including JNCI, NEJM, Lancet and Lancet
Oncology.
272
SPECIAL SESSION
Sunday, 3:45 p.m.-5:15 p.m.
Room 6E, San Diego Convention Center
Funding Opportunities in Europe for Creative Minds From Anywhere
in the World
Launched in 2007, the European Research Council is already shaping Europe’s research scene
and is highly regarded by the international research community, establishing itself as a world-class
research funding agency. This investigator-driven, pioneering frontier research funded is now
starting to bear fruit.
Horizon 2020 (H2020), the new European Union framework Program for research and innovation
runs from 2014-2020. With a budget of €77 billion, Horizon 2020 is a key component of Europe’s
strategy to create economic growth and to reinforce its global competitiveness. The European
Research Council (ERC) is part of H2020’s first pillar of “Excellent Science” and has a budget of
over €13 billion, an approximate 75% increase compared to the previous framework program. This
substantial budget increase will allow the ERC to continue its mission – finding and funding the
very best researchers with the most creative ideas.
Through highly competitive competitions for attractive grants, the ERC promotes junior and
established researchers to pursue their work in Europe in any field of research and regardless of
their nationality. Encouraging international scientific cooperation, the ERC supports top researchers
from anywhere in the world, including the U.S. Since 2007, more than 3,860 projects have been
selected for funding from more than 43,000 applications, including several Nobel Prize winners.
The workshop will explain the ERC’s funding schemes as well as provide answers to practical
questions such as:
• How does the ERC support research careers?
• What are their main features?
• What are the main changes for the ERC with respect to the new Horizon 2020 framework?
• What are the selection criteria and how long is the selection process?
• How does the application process work?
• How many researchers are funded each year?
• What are the chances of success?
In addition, ERC Grantees will be present to share their experiences with these funding initiatives
and will answer questions from the audience.
Molecular mechanisms controlling normal and neoplastic breast stem cells,
metastasis, and resistance
Mohamed Bentires-Alj, Friedrich Miescher Institute for Biomedical Research, Basel,
Switzerland
Increasing the sensitivity of tumors to anticancer drugs
E. G. Elisabeth De Vries, University Medical Center Groningen, Groningen,
The Netherlands
Early detection of dormant tumor cells
Klaus Pantel, University Medical Center Hamburg, Hamburg, Germany
273
Sunday, 4:00 p.m.-5:00 p.m.
Meet the Pancreatic Cancer Research Icon:
Margaret A. Tempero, MD
This interactive and informal session is an opportunity to chat with a senior pancreatic cancer
physician-scientist and learn how she charted a successful career in this field. Meet Dr. Margaret
A. Tempero, Director of the University of California, San Francisco (UCSF) Pancreas Center,
Rombauer Family Distinguished Professor in Pancreas Cancer Clinical and Translational Science
at the UCSF Helen Diller Family Comprehensive Cancer Center, Professor of Medicine in the
Division of Hematology and Oncology, Department of Medicine at UCSF, and member of the
Pancreatic Cancer Action Network Scientific Advisory Board. Learn about the opportunities that
exist in the pancreatic cancer research field and broaden your professional network. Suggestions
and tips for career directions will be provided. Topics to be addressed relate to postdoctoral
development, starting your own laboratory, choosing a mentor, grantsmanship, networking,
publications, collaborations, biospecimen access, little known professional opportunities, etc. This
session will take place in the AACR Amphitheatre located in AACRcentral.
274
Sunday, 4:15 p.m.-4:45 p.m.
Meet the Research Icon:
Carol L. Prives, PhD
Formerly known as Meet the Research Pioneer, these informal sessions, organized by the
Associate Member Council, provide early-career scientists with the opportunity to hear from an
esteemed senior researcher in a small-group setting to learn about the speaker’s professional and
personal experiences as well as key decisions that shaped their career path. Carol L. Prives, PhD,
is a Professor in the Department of Biological Sciences at Columbia University. Dr. Prives’
research primarily involves the structure and function of the p53 tumor suppressor protein; how
p53 regulates transcription of its target genes, how the p53/Mdm2 circuit is regulated, how cells
transmit signals from genotoxic stress to regulate p53 and its homologues p63 and p73, the roles
of the p63 and p73 genes and how their protein products are regulated, how p53 promotes
apoptosis, and how we can use information derived from the basic research on this protein to
develop p53-based cancer therapeutics. This session is open to all graduate students, medical
students, residents, and clinical and postdoctoral fellows and will take place in the Associate
Member Resource and Career Center located in AACRcentral. #AACR14 #AACRicon
275
PEZCOLLER FOUNDATION-AACR LECTURE
Sunday, 4:30 p.m.-5:30 p.m.
Seventeenth Annual Pezcoller Foundation-AACR International Award for
Cancer Research
Stem Cells in Silence, Action, and Cancer
Elaine Fuchs, PhD
Howard Hughes Medical Investigator
Rebecca C. Lancefield Professor
Head of Laboratory of Mammalian Cell Biology and Development
The Rockefeller University, New York, NY
The Pezcoller Foundation-AACR International Award was
established in 1997 to recognize a scientist who has
made a major scientific discovery in basic cancer
research, or who has made significant contributions to
translational cancer research; who continues to be active
in cancer research, and has a record of recent and
noteworthy publications; and whose ongoing work holds
promise for continued substantive contributions to
progress in the field of cancer.
Dr. Elaine Fuchs is honored for her many contributions to
the biology and molecular mechanisms underlying
development and differentiation of the epidermis and its
stem cells. Her research has greatly advanced our
understanding of epithelial biology and its cancers, and
provides a foundation for developing reagents for cancer
diagnosis and treatment. Dr. Fuchs illuminated how skin
stem cells receive environmental signals, change gene
expression and remodel cellular interactions to make
epidermis and its appendages, and how processes of
stem cell activation are deregulated in its cancers. Her
studies have shaped our understanding of skin and its
associated diseases, in particular cancers and other
hyperproliferative disorders.
Dr. Fuchs constructed a framework for understanding
how stem cells develop into epithelial tissues and
exploited it to uncover links between aberrations in stem
cells activation and cancer. She used molecular and
genetic approaches to pioneer “reverse genetics,” the
reverse of positional-cloning. Her transcriptional interests
led to her discovery that Lef1 functions in the decision of
skin stem cells to make HFs not epidermis. In elucidating
how skin SC populations become activated to make
tissues, Dr. Fuchs’ research demonstrated that defects in
the activation step contribute to cancers. Her
discoveries now makes possible in months what was
previously thought possible only in lower eukaryotes or
276
cell culture. Its implications for cancer therapeutics are
wide-ranging.
Dr. Fuchs received her doctorate from Princeton
University, and completed postdoctoral training at
Massachusetts Institute of Technology, before becoming
Assistant Professor of Biochemistry at the University of
Chicago. She served as Associate Professor and
Professor at the University of Chicago in the
departments of Biochemistry and Molecular Biology and
Molecular Genetics and Cell Biology. She was also
named an Investigator of the Howard Hughes Medical
Institute, and is currently at Rockefeller University as
Professor and Head of the Laboratory of Mammalian Cell
Biology and Development.
Copious accolades have been awarded to Dr. Fuchs,
including the Searle Scholar Award (1981-83), the
Presidential Young Investigator Award (1984-89), the
Richard Lounsbery Award from the National Academy of
Sciences (2001), the Dickson Prize in Medicine (2004),
the National Medal of Science (2009), L’Oreal UNESCO
Award for Women in Science (2010), the Albany Prize in
Medicine (2011), the Passano Award (2011), March of
Dimes Prize in Developmental Biology (2012), and the
Pasarow Award for Cancer Research (2013). She is a
member of the National Academy of Sciences, Institutes
of Medicine, the American Philosophical Society, and a
Foreign member of EMBO.
PRESIDENTIAL ADDRESS
Sunday, 5:30 p.m.-6:30 p.m.
Overcoming Cancer Drug Resistance
Charles L. Sawyers, MD
Chairperson, Human Oncology and Pathogenesis Program, and
Member, Memorial Sloan-Kettering Cancer Center; Professor,
Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, NY;
Investigator, Howard Hughes Medical Institute
AACR President, 2013-2014
As a physician scientist and leader in the development of
targeted therapies for cancer, Dr. Sawyers investigates
the signaling pathways that drive the growth and drug
resistance of cancer cells. He and his colleagues played
a critical role in developing the molecularly targeted
cancer drug, Gleevec (imatinib), for the treatment of
chronic myeloid leukemia. Dr. Sawyers’ research into
treatments for cancer that becomes resistant to
established therapies led to the development of Sprycel
for patients with Gleevec-resistant chronic myeloid
leukemia and Xtandi for metastatic prostate cancer that
has become resistant to Taxotere.
Dr. Sawyers has continued to expand his pursuit of novel
anticancer drugs by collaborating with structural
biologists to ascertain how potential drugs may fit within
a potential therapeutic target. This research technique
has since been expanded alongside recent efforts to
sequence and map resistance-enhancing genetic
mutations to understand how drugs must be
manipulated to allow for efficacy even in patients
harboring specific genetic abnormalities.
The many awards and honors that Dr. Sawyers has
received include the 2013 Breakthrough Prize in Life
Sciences, election to membership in the National
Academy of Sciences (2012), the 2009 Lasker-Debakey
Clinical Medical Research Award, the 2009 Dorothy P.
Landon-AACR Prize for Translational Cancer Research,
election as a Member of the Institute of Medicine (2008),
the 2007 Emil J. Freireich Award for Clinical Research
from the University of Texas MD Anderson Cancer
Center, the 2005 David A. Karnofsky Memorial Award
and Lecture from the American Society for Clinical
Oncology, the 2005 AACR-Richard and Hinda Rosenthal
Award, the 2003 Freedom-to-Discover Research Award
in Cancer from Bristol-Meyers Squibb, the 2001 Doris
Duke Distinguished Clinical Scientist Award, and the
2000 Stohlman Scholar Award from the Leukemia and
Lymphoma Society.
Through his dedication to improving precision medicine
and patient care, Dr. Sawyers continues to positively
influence the cancer research field. He has also been a
strong advocate for biomedical research and has served
on National Academy of Science and Institute of
Medicine panels that have made recommendations to
national leaders on topics such as biomarker use as well
as clinical trial design and implementation.
Dr. Sawyers is a graduate of Princeton University and
received his MD from the Johns Hopkins University
School of Medicine in 1985. He served on the AACR
Board of Directors (2003-2006), as President-Elect
(2012-2013), and as President (2013-2014).
277
MEG TOWN MEETING
Sunday, 6:00 p.m.-7:30 p.m.
Marina Ballroom F, South Tower, San Diego Marriott Marquis & Marina
Molecular Epidemiology (MEG) Town Meeting and
Networking Reception
The Town Hall Meeting will include a discussion on “Roadmaps to Transdisciplinary Success:
Progress and Potholes,” featuring Kathryn H. Schmitz, PhD, MPH, Department of Biostatistics and
Epidemiology, Perelman School of Medicine, University of Pennsylvania; and Raymond C. Bergan,
MD, Director of Experimental Therapeutics, Robert H. Lurie Cancer Center of Northwestern
University; Co-Director, Center for Molecular Innovation and Drug Discovery (CMIDD); and
Professor, Department of Medicine, Division of Hematology/Oncology, Northwestern University.
Come learn about this and other important MEG initiatives; meet members of the working group
and steering committee and the newest MEG Scholar-in-Training Award recipients, in addition to
learning more about joining the MEG Working Group. A networking reception will follow.
6:00 p.m.
Chairperson: Opening Remarks
Johanna W. Lampe, Fred Hutchinson Cancer Research Center, Seattle, WA
6:10 p.m.
Chairperson-Elect: Remarks
Susan M. Gapstur, American Cancer Society, Atlanta, GA
6:20 p.m.
TREC-ing into transdisciplinarity: A traveler’s observations on what to pack,
how to prepare, highlights, and surprises
Kathryn H. Schmitz, University of Pennsylvania, Philadelphia, PA
6:40 p.m.
Therapeutically targeting carcinogenesis
Raymond C. Bergan, Northwestern University Lurie Comprehensive Cancer Center,
Chicago, IL
7:00 p.m.
Closing Remarks
Susan M. Gapstur, American Cancer Society, Atlanta, GA
278
PCWG TOWN MEETING
Sunday, 6:30 p.m.-8:30 p.m.
Marina Ballroom D, South Tower, San Diego Marriott Marquis & Marina
Pediatric Cancer Working Group Town Hall Meeting and
Chairperson: Lee J. Helman, National Cancer Institute, Bethesda, MD
Members of the Pediatric Cancer Working Group (PCWG) and those interested in pediatric
oncology are invited to attend this special evening session. The meeting will consist of a
summary of AACR’s pediatric cancer-related programs and activities, networking reception, and
announcement of the 2014-2015 PCWG Chairperson-Elect.
279
TME TOWN MEETING
Sunday, 6:30 p.m.-8:30 p.m.
Marina Ballroom G, South Tower, San Diego Marriott Marquis & Marina
Tumor Microenvironment (TME) Town Meeting and
This is an opportunity for all interested to hear an update from our colleagues on “Modeling the
Microenvironment.” Dr. Kenneth J. Pienta, Johns Hopkins University, will speak on “Of niche
construction and ecological inheritance: Applying the science of ecology to cancer”; Dr. Katarzyna
A. Rejniak, Moffitt Cancer Center and Research Institute, will speak on “M for microenvironment
modeling: Mathematics, morphology, mechanics and mice”; and Dr. Raghu Kalluri, The University
of Texas MD Anderson Cancer Center, will speak on “Functional auditing of tissue
microenvironment in pancreas cancer.”
Come learn about these and other important TME initiatives, meet members of the working group
and steering committee, in addition to taking advantage of the opportunity to join the TME
Working Group. A networking reception will follow.
6:30 a.m.
Chairperson: Opening remarks
Mary Helen Barcellos-Hoff, New York University, New York, NY
6:45 a.m.
Chairperson-Elect: Remarks
Raghu Kalluri, The University of Texas MD Anderson Cancer Center, Houston, TX
7:00 p.m.
Of niche construction and ecological inheritance: Applying the science of
ecology to cancer
Kenneth J. Pienta, Johns Hopkins University School of Medicine, Baltimore, MD
7:20 p.m.
M for microenvironment modeling: Mathematics, morphology,
mechanics, and mice
Katarzyna A. Rejniak, H. Lee Moffitt Cancer Center and Research Institute,
Tampa, FL
7:40 p.m.
Functional auditing of tissue microenvironment in pancreas cancer
8:00 p.m.
Closing Remarks
280
ANNUAL RECEPTION
Sunday, 9:00 p.m.-12:00 a.m.
Marriott Hall, San Diego Marriott Marquis & Marina
All Annual Meeting registrants are invited to attend the Annual Reception on Sunday evening,
April 6, from 9:00 p.m. to 12:00 a.m. at the San Diego Marriott Marquis & Marina, Marriott Hall.
Complimentary light refreshments will be served, and a live band will provide music for dancing.
On Sunday evening, shuttle buses will run between all AACR hotels where busing is provided
during the day and the San Diego Marriott Marquis. Shuttle schedules will be posted in each hotel.
Each registrant will receive a voucher for a complimentary beverage at the Annual Reception with
his/her registration materials.
281
NOTES
282
283
NOTES
284

Detailed Schedule - Sunday, April 6

Transcription

Similar documents

Installation of Scrolling Ceiling

Installation of Scrolling Banner CNFS00 1

Layout 1 (Page 1) - Rescue Task Force

AMPULLA OF VATER STAGING FORM

sistema cetys universidad - Imperial Valley Renewable Energy Summit

The Chaparral of California In much of California, botanical activity

Leaving Cert Craft Exam-Poster Question By Ruth Graydon

Exsanguination - Northern Health

angionesesis emt metastasis

tumor marker`s